id sid tid token lemma pos dpc-6646 1 1 dermatology dermatology NOUN dpc-6646 1 2 : : PUNCT dpc-6646 1 3 practical practical ADJ dpc-6646 1 4 and and CCONJ dpc-6646 1 5 conceptual conceptual ADJ dpc-6646 1 6 original original ADJ dpc-6646 1 7 article article NOUN dpc-6646 1 8 | | ADV dpc-6646 1 9 dermatol dermatol ADJ dpc-6646 1 10 pract pract NOUN dpc-6646 1 11 concept concept NOUN dpc-6646 1 12 . . PUNCT dpc-6646 2 1 2025;15(4):6646 2025;15(4):6646 NUM dpc-6646 2 2 1 1 NUM dpc-6646 2 3 long long ADJ dpc-6646 2 4 - - PUNCT dpc-6646 2 5 term term NOUN dpc-6646 2 6 persistence persistence NOUN dpc-6646 2 7 with with ADP dpc-6646 2 8 guselkumab guselkumab NOUN dpc-6646 2 9 : : PUNCT dpc-6646 2 10 a a DET dpc-6646 2 11 5 5 NUM dpc-6646 2 12 - - PUNCT dpc-6646 2 13 year year NOUN dpc-6646 2 14 multicenter multicenter NOUN dpc-6646 2 15 retrospective retrospective ADJ dpc-6646 2 16 study study NOUN dpc-6646 2 17 across across ADP dpc-6646 2 18 14 14 NUM dpc-6646 2 19 dermatology dermatology NOUN dpc-6646 2 20 centers center NOUN dpc-6646 2 21 in in ADP dpc-6646 2 22 italy italy PROPN dpc-6646 2 23 bernardini bernardini PROPN dpc-6646 2 24 nicoletta1 nicoletta1 PROPN dpc-6646 2 25 , , PUNCT dpc-6646 2 26 caldarola caldarola PROPN dpc-6646 2 27 giacomo2 giacomo2 PROPN dpc-6646 2 28 , , PUNCT dpc-6646 2 29 richetta richetta VERB dpc-6646 2 30 antonio antonio PROPN dpc-6646 2 31 giovanni3 giovanni3 PROPN dpc-6646 2 32 , , PUNCT dpc-6646 2 33 esposito esposito PROPN dpc-6646 2 34 maria4 maria4 PROPN dpc-6646 2 35 , , PUNCT dpc-6646 2 36 trovato trovato PROPN dpc-6646 2 37 federica5 federica5 PROPN dpc-6646 2 38 , , PUNCT dpc-6646 2 39 amerio amerio ADP dpc-6646 2 40 paolo6 paolo6 PROPN dpc-6646 2 41 , , PUNCT dpc-6646 2 42 morea morea PROPN dpc-6646 2 43 edvige6 edvige6 PROPN dpc-6646 2 44 , , PUNCT dpc-6646 2 45 bonifati bonifati PROPN dpc-6646 2 46 claudio7 claudio7 PROPN dpc-6646 2 47 , , PUNCT dpc-6646 2 48 graceffa graceffa PROPN dpc-6646 2 49 dario8 dario8 PROPN dpc-6646 2 50 , , PUNCT dpc-6646 2 51 bruni bruni PROPN dpc-6646 2 52 pier pier PROPN dpc-6646 2 53 luigi9 luigi9 PROPN dpc-6646 2 54 , , PUNCT dpc-6646 2 55 giordano giordano PROPN dpc-6646 2 56 domenico10 domenico10 PROPN dpc-6646 2 57 , , PUNCT dpc-6646 2 58 persechino persechino NOUN dpc-6646 2 59 severino10 severino10 NOUN dpc-6646 2 60 , , PUNCT dpc-6646 2 61 mazzotta mazzotta NOUN dpc-6646 2 62 annamaria11 annamaria11 NOUN dpc-6646 2 63 , , PUNCT dpc-6646 2 64 moretta moretta ADJ dpc-6646 2 65 gaia5 gaia5 NOUN dpc-6646 2 66 , , PUNCT dpc-6646 2 67 pagnanelli pagnanelli PROPN dpc-6646 2 68 gianluca5 gianluca5 PROPN dpc-6646 2 69 , , PUNCT dpc-6646 2 70 pallotta pallotta NOUN dpc-6646 2 71 sabatino5 sabatino5 PROPN dpc-6646 2 72 , , PUNCT dpc-6646 2 73 annedda annedda PROPN dpc-6646 2 74 jasmine12 jasmine12 PROPN dpc-6646 2 75 , , PUNCT dpc-6646 2 76 mugheddu mugheddu ADJ dpc-6646 2 77 cristina12 cristina12 NOUN dpc-6646 2 78 , , PUNCT dpc-6646 2 79 miraglia miraglia PROPN dpc-6646 2 80 emanuele13 emanuele13 NOUN dpc-6646 2 81 , , PUNCT dpc-6646 2 82 panasiti panasiti NOUN dpc-6646 2 83 vincenzo14 vincenzo14 NOUN dpc-6646 2 84 , , PUNCT dpc-6646 2 85 molinelli molinelli NOUN dpc-6646 2 86 elisa15 elisa15 NOUN dpc-6646 2 87 , , PUNCT dpc-6646 2 88 simonetti simonetti PROPN dpc-6646 2 89 oriana15 oriana15 NOUN dpc-6646 2 90 , , PUNCT dpc-6646 2 91 fargnoli fargnoli PROPN dpc-6646 2 92 maria maria PROPN dpc-6646 2 93 concetta4 concetta4 PROPN dpc-6646 2 94 , , PUNCT dpc-6646 2 95 peris peris PROPN dpc-6646 2 96 ketty2 ketty2 PROPN dpc-6646 2 97 , , PUNCT dpc-6646 2 98 pellacani pellacani PROPN dpc-6646 2 99 giovanni3 giovanni3 PROPN dpc-6646 2 100 , , PUNCT dpc-6646 2 101 potenza potenza PROPN dpc-6646 2 102 concetta1 concetta1 PROPN dpc-6646 2 103 , , PUNCT dpc-6646 2 104 dattola dattola PROPN dpc-6646 2 105 annunziata3 annunziata3 NOUN dpc-6646 2 106 1 1 NUM dpc-6646 2 107 dermatology dermatology NOUN dpc-6646 2 108 unit unit NOUN dpc-6646 2 109 , , PUNCT dpc-6646 2 110 a. a. PROPN dpc-6646 2 111 fiorini fiorini PROPN dpc-6646 2 112 hospital hospital PROPN dpc-6646 2 113 , , PUNCT dpc-6646 2 114 sapienza sapienza PROPN dpc-6646 2 115 university university PROPN dpc-6646 2 116 of of ADP dpc-6646 2 117 rome rome PROPN dpc-6646 2 118 – – PUNCT dpc-6646 2 119 polo polo NOUN dpc-6646 2 120 pontino pontino NOUN dpc-6646 2 121 , , PUNCT dpc-6646 2 122 terracina terracina PROPN dpc-6646 2 123 , , PUNCT dpc-6646 2 124 italy italy PROPN dpc-6646 2 125 2 2 NUM dpc-6646 2 126 section section NOUN dpc-6646 2 127 of of ADP dpc-6646 2 128 dermatology dermatology NOUN dpc-6646 2 129 , , PUNCT dpc-6646 2 130 department department NOUN dpc-6646 2 131 of of ADP dpc-6646 2 132 translational translational ADJ dpc-6646 2 133 medicine medicine NOUN dpc-6646 2 134 and and CCONJ dpc-6646 2 135 surgery surgery NOUN dpc-6646 2 136 , , PUNCT dpc-6646 2 137 catholic catholic PROPN dpc-6646 2 138 university university PROPN dpc-6646 2 139 of of ADP dpc-6646 2 140 the the DET dpc-6646 2 141 s. s. PROPN dpc-6646 2 142 heart heart PROPN dpc-6646 2 143 , , PUNCT dpc-6646 2 144 rome rome PROPN dpc-6646 2 145 , , PUNCT dpc-6646 2 146 italy italy PROPN dpc-6646 2 147 3 3 NUM dpc-6646 2 148 department department PROPN dpc-6646 2 149 of of ADP dpc-6646 2 150 internal internal ADJ dpc-6646 2 151 medicine medicine NOUN dpc-6646 2 152 and and CCONJ dpc-6646 2 153 medical medical ADJ dpc-6646 2 154 specialties specialty NOUN dpc-6646 2 155 , , PUNCT dpc-6646 2 156 sapienza sapienza PROPN dpc-6646 2 157 university university PROPN dpc-6646 2 158 of of ADP dpc-6646 2 159 rome rome PROPN dpc-6646 2 160 , , PUNCT dpc-6646 2 161 policlinico policlinico NOUN dpc-6646 2 162 umberto umberto NOUN dpc-6646 3 1 i i PRON dpc-6646 3 2 , , PUNCT dpc-6646 3 3 rome rome PROPN dpc-6646 3 4 , , PUNCT dpc-6646 3 5 italy italy PROPN dpc-6646 3 6 4 4 NUM dpc-6646 3 7 unit unit NOUN dpc-6646 3 8 of of ADP dpc-6646 3 9 general general ADJ dpc-6646 3 10 and and CCONJ dpc-6646 3 11 oncologic oncologic ADJ dpc-6646 3 12 dermatology dermatology NOUN dpc-6646 3 13 , , PUNCT dpc-6646 3 14 san san PROPN dpc-6646 3 15 salvatore salvatore PROPN dpc-6646 3 16 hospital hospital PROPN dpc-6646 3 17 , , PUNCT dpc-6646 3 18 l’aquila l’aquila PROPN dpc-6646 3 19 , , PUNCT dpc-6646 3 20 italy italy PROPN dpc-6646 3 21 5 5 NUM dpc-6646 3 22 idi idi PROPN dpc-6646 3 23 - - PUNCT dpc-6646 3 24 irccs irccs PROPN dpc-6646 3 25 , , PUNCT dpc-6646 3 26 luigi luigi PROPN dpc-6646 3 27 maria maria PROPN dpc-6646 3 28 monti monti PROPN dpc-6646 3 29 foundation foundation PROPN dpc-6646 3 30 , , PUNCT dpc-6646 3 31 rome rome PROPN dpc-6646 3 32 , , PUNCT dpc-6646 3 33 italy italy PROPN dpc-6646 3 34 6 6 NUM dpc-6646 3 35 dermatology dermatology NOUN dpc-6646 3 36 unit unit NOUN dpc-6646 3 37 , , PUNCT dpc-6646 3 38 local local ADJ dpc-6646 3 39 health health NOUN dpc-6646 3 40 authority authority NOUN dpc-6646 3 41 asl2 asl2 PROPN dpc-6646 3 42 abruzzo abruzzo PROPN dpc-6646 3 43 , , PUNCT dpc-6646 3 44 chieti chieti PROPN dpc-6646 3 45 , , PUNCT dpc-6646 3 46 italy italy PROPN dpc-6646 3 47 7 7 NUM dpc-6646 3 48 clinical clinical ADJ dpc-6646 3 49 dermatology dermatology NOUN dpc-6646 3 50 – – PUNCT dpc-6646 3 51 psoriasis psoriasis NOUN dpc-6646 3 52 center center NOUN dpc-6646 3 53 , , PUNCT dpc-6646 3 54 san san PROPN dpc-6646 3 55 gallicano gallicano PROPN dpc-6646 3 56 dermatological dermatological PROPN dpc-6646 3 57 institute institute NOUN dpc-6646 3 58 ( ( PUNCT dpc-6646 3 59 irccs irccs PROPN dpc-6646 3 60 ) ) PUNCT dpc-6646 3 61 , , PUNCT dpc-6646 3 62 rome rome PROPN dpc-6646 3 63 , , PUNCT dpc-6646 3 64 italy italy PROPN dpc-6646 3 65 8 8 NUM dpc-6646 3 66 ifo ifo PROPN dpc-6646 3 67 - - PUNCT dpc-6646 3 68 san san PROPN dpc-6646 3 69 gallicano gallicano ADJ dpc-6646 3 70 hospital hospital NOUN dpc-6646 3 71 , , PUNCT dpc-6646 3 72 rome rome PROPN dpc-6646 3 73 , , PUNCT dpc-6646 3 74 italy italy PROPN dpc-6646 3 75 9 9 NUM dpc-6646 3 76 dermatology dermatology NOUN dpc-6646 3 77 clinic clinic NOUN dpc-6646 3 78 , , PUNCT dpc-6646 3 79 terni terni PROPN dpc-6646 3 80 , , PUNCT dpc-6646 3 81 italy italy PROPN dpc-6646 3 82 10 10 NUM dpc-6646 3 83 sant sant NOUN dpc-6646 3 84 ’ ' PUNCT dpc-6646 3 85 andrea andrea PROPN dpc-6646 3 86 hospital hospital PROPN dpc-6646 3 87 , , PUNCT dpc-6646 3 88 department department NOUN dpc-6646 3 89 of of ADP dpc-6646 3 90 neurosciences neuroscience NOUN dpc-6646 3 91 , , PUNCT dpc-6646 3 92 mental mental ADJ dpc-6646 3 93 health health NOUN dpc-6646 3 94 and and CCONJ dpc-6646 3 95 sensory sensory ADJ dpc-6646 3 96 organs organ NOUN dpc-6646 3 97 ( ( PUNCT dpc-6646 3 98 nesmos nesmos ADJ dpc-6646 3 99 ) ) PUNCT dpc-6646 3 100 , , PUNCT dpc-6646 3 101 sapienza sapienza PROPN dpc-6646 3 102 university university PROPN dpc-6646 3 103 of of ADP dpc-6646 3 104 rome rome PROPN dpc-6646 3 105 , , PUNCT dpc-6646 3 106 rome rome PROPN dpc-6646 3 107 , , PUNCT dpc-6646 3 108 italy italy PROPN dpc-6646 3 109 11 11 NUM dpc-6646 3 110 dermatology dermatology NOUN dpc-6646 3 111 unit unit NOUN dpc-6646 3 112 , , PUNCT dpc-6646 3 113 san san PROPN dpc-6646 3 114 camillo camillo PROPN dpc-6646 3 115 forlanini forlanini PROPN dpc-6646 3 116 hospital hospital PROPN dpc-6646 3 117 , , PUNCT dpc-6646 3 118 rome rome PROPN dpc-6646 3 119 , , PUNCT dpc-6646 3 120 italy italy PROPN dpc-6646 3 121 12 12 NUM dpc-6646 3 122 department department NOUN dpc-6646 3 123 of of ADP dpc-6646 3 124 medical medical ADJ dpc-6646 3 125 sciences sciences PROPN dpc-6646 3 126 and and CCONJ dpc-6646 3 127 public public ADJ dpc-6646 3 128 health health NOUN dpc-6646 3 129 , , PUNCT dpc-6646 3 130 dermatology dermatology NOUN dpc-6646 3 131 clinic clinic NOUN dpc-6646 3 132 , , PUNCT dpc-6646 3 133 university university PROPN dpc-6646 3 134 of of ADP dpc-6646 3 135 cagliari cagliari PROPN dpc-6646 3 136 , , PUNCT dpc-6646 3 137 cagliari cagliari PROPN dpc-6646 3 138 , , PUNCT dpc-6646 3 139 italy italy PROPN dpc-6646 3 140 13 13 NUM dpc-6646 3 141 san san PROPN dpc-6646 3 142 sebastiano sebastiano PROPN dpc-6646 3 143 hospital hospital PROPN dpc-6646 3 144 , , PUNCT dpc-6646 3 145 frascati frascati PROPN dpc-6646 3 146 , , PUNCT dpc-6646 3 147 italy italy PROPN dpc-6646 3 148 14 14 NUM dpc-6646 3 149 dermatology dermatology NOUN dpc-6646 3 150 unit unit NOUN dpc-6646 3 151 , , PUNCT dpc-6646 3 152 campus campus NOUN dpc-6646 3 153 bio bio PROPN dpc-6646 3 154 - - ADJ dpc-6646 3 155 medico medico PROPN dpc-6646 3 156 university university NOUN dpc-6646 3 157 hospital hospital NOUN dpc-6646 3 158 , , PUNCT dpc-6646 3 159 rome rome PROPN dpc-6646 3 160 , , PUNCT dpc-6646 3 161 italy italy PROPN dpc-6646 3 162 15 15 NUM dpc-6646 3 163 dermatology dermatology NOUN dpc-6646 3 164 clinic clinic NOUN dpc-6646 3 165 , , PUNCT dpc-6646 3 166 azienda azienda PROPN dpc-6646 3 167 ospedaliero ospedaliero PROPN dpc-6646 3 168 - - PUNCT dpc-6646 3 169 universitaria universitaria PROPN dpc-6646 3 170 ospedali ospedali PROPN dpc-6646 3 171 riuniti riuniti PROPN dpc-6646 3 172 , , PUNCT dpc-6646 3 173 ancona ancona PROPN dpc-6646 3 174 , , PUNCT dpc-6646 3 175 italy italy PROPN dpc-6646 3 176 key key ADJ dpc-6646 3 177 words word NOUN dpc-6646 3 178 : : PUNCT dpc-6646 3 179 psoriasis psoriasis NOUN dpc-6646 3 180 , , PUNCT dpc-6646 3 181 guselkumab guselkumab NOUN dpc-6646 3 182 , , PUNCT dpc-6646 3 183 drug drug NOUN dpc-6646 3 184 survival survival NOUN dpc-6646 3 185 , , PUNCT dpc-6646 3 186 real real ADJ dpc-6646 3 187 - - PUNCT dpc-6646 3 188 world world NOUN dpc-6646 3 189 evidence evidence NOUN dpc-6646 3 190 , , PUNCT dpc-6646 3 191 biologic biologic NOUN dpc-6646 3 192 therapy therapy NOUN dpc-6646 3 193 citation citation NOUN dpc-6646 3 194 : : PUNCT dpc-6646 3 195 bernardini bernardini PROPN dpc-6646 3 196 n n CCONJ dpc-6646 3 197 , , PUNCT dpc-6646 3 198 caldarola caldarola PROPN dpc-6646 3 199 g g PROPN dpc-6646 3 200 , , PUNCT dpc-6646 3 201 richetta richetta PROPN dpc-6646 3 202 ag ag PROPN dpc-6646 3 203 , , PUNCT dpc-6646 3 204 et et PROPN dpc-6646 3 205 al al PROPN dpc-6646 3 206 . . PUNCT dpc-6646 4 1 long long ADJ dpc-6646 4 2 - - PUNCT dpc-6646 4 3 term term NOUN dpc-6646 4 4 persistence persistence NOUN dpc-6646 4 5 with with ADP dpc-6646 4 6 guselkumab guselkumab NOUN dpc-6646 4 7 : : PUNCT dpc-6646 4 8 a a DET dpc-6646 4 9 5 5 NUM dpc-6646 4 10 - - PUNCT dpc-6646 4 11 year year NOUN dpc-6646 4 12 multicenter multicenter NOUN dpc-6646 4 13 retrospective retrospective ADJ dpc-6646 4 14 study study NOUN dpc-6646 4 15 across across ADP dpc-6646 4 16 14 14 NUM dpc-6646 4 17 dermatology dermatology NOUN dpc-6646 4 18 centers center NOUN dpc-6646 4 19 in in ADP dpc-6646 4 20 italy italy PROPN dpc-6646 4 21 . . PUNCT dpc-6646 5 1 dermatol dermatol NOUN dpc-6646 5 2 pract pract PROPN dpc-6646 5 3 concept concept NOUN dpc-6646 5 4 . . PUNCT dpc-6646 6 1 2025;15(4):6646 2025;15(4):6646 PROPN dpc-6646 6 2 . . PUNCT dpc-6646 7 1 doi doi NOUN dpc-6646 7 2 : : PUNCT dpc-6646 7 3 https://doi.org/10.5826/dpc.1504a6646 https://doi.org/10.5826/dpc.1504a6646 NOUN dpc-6646 7 4 accepted accept VERB dpc-6646 7 5 : : PUNCT dpc-6646 7 6 october october PROPN dpc-6646 7 7 8 8 NUM dpc-6646 7 8 , , PUNCT dpc-6646 7 9 2025 2025 NUM dpc-6646 7 10 ; ; PUNCT dpc-6646 7 11 published publish VERB dpc-6646 7 12 : : PUNCT dpc-6646 8 1 october october PROPN dpc-6646 8 2 2025 2025 NUM dpc-6646 8 3 copyright copyright NOUN dpc-6646 8 4 : : PUNCT dpc-6646 8 5 © © PROPN dpc-6646 8 6 2025 2025 NUM dpc-6646 8 7 bernardini bernardini X dpc-6646 8 8 et et PROPN dpc-6646 8 9 al al PROPN dpc-6646 8 10 . . PUNCT dpc-6646 9 1 this this PRON dpc-6646 9 2 is be AUX dpc-6646 9 3 an an DET dpc-6646 9 4 open open ADJ dpc-6646 9 5 - - PUNCT dpc-6646 9 6 access access NOUN dpc-6646 9 7 article article NOUN dpc-6646 9 8 distributed distribute VERB dpc-6646 9 9 under under ADP dpc-6646 9 10 the the DET dpc-6646 9 11 terms term NOUN dpc-6646 9 12 of of ADP dpc-6646 9 13 the the DET dpc-6646 9 14 creative creative ADJ dpc-6646 9 15 commons common NOUN dpc-6646 9 16 attributionnoncommercial attributionnoncommercial ADJ dpc-6646 9 17 license license NOUN dpc-6646 9 18 ( ( PUNCT dpc-6646 9 19 by by ADP dpc-6646 9 20 - - PUNCT dpc-6646 9 21 nc-4.0 nc-4.0 NOUN dpc-6646 9 22 ) ) PUNCT dpc-6646 9 23 , , PUNCT dpc-6646 9 24 https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ PROPN dpc-6646 9 25 , , PUNCT dpc-6646 9 26 which which PRON dpc-6646 9 27 permits permit VERB dpc-6646 9 28 unrestricted unrestricted ADJ dpc-6646 9 29 noncommercial noncommercial ADJ dpc-6646 9 30 use use NOUN dpc-6646 9 31 , , PUNCT dpc-6646 9 32 distribution distribution NOUN dpc-6646 9 33 , , PUNCT dpc-6646 9 34 and and CCONJ dpc-6646 9 35 reproduction reproduction NOUN dpc-6646 9 36 in in ADP dpc-6646 9 37 any any DET dpc-6646 9 38 medium medium NOUN dpc-6646 9 39 , , PUNCT dpc-6646 9 40 provided provide VERB dpc-6646 9 41 the the DET dpc-6646 9 42 original original ADJ dpc-6646 9 43 authors author NOUN dpc-6646 9 44 and and CCONJ dpc-6646 9 45 source source NOUN dpc-6646 9 46 are be AUX dpc-6646 9 47 credited credit VERB dpc-6646 9 48 . . PUNCT dpc-6646 10 1 funding funding NOUN dpc-6646 10 2 : : PUNCT dpc-6646 10 3 none none NOUN dpc-6646 10 4 . . PUNCT dpc-6646 11 1 competing compete VERB dpc-6646 11 2 interests interest NOUN dpc-6646 11 3 : : PUNCT dpc-6646 11 4 none none NOUN dpc-6646 11 5 . . PUNCT dpc-6646 12 1 authorship authorship NOUN dpc-6646 12 2 : : PUNCT dpc-6646 12 3 annunziata annunziata PROPN dpc-6646 12 4 dattola dattola PROPN dpc-6646 12 5 , , PUNCT dpc-6646 12 6 nicoletta nicoletta PROPN dpc-6646 12 7 bernardini bernardini PROPN dpc-6646 12 8 , , PUNCT dpc-6646 12 9 giacomo giacomo PROPN dpc-6646 12 10 caldarola caldarola PROPN dpc-6646 12 11 , , PUNCT dpc-6646 12 12 concetta concetta PROPN dpc-6646 12 13 potenza potenza PROPN dpc-6646 12 14 , , PUNCT dpc-6646 12 15 giovanni giovanni PROPN dpc-6646 12 16 pellacani pellacani PROPN dpc-6646 12 17 , , PUNCT dpc-6646 12 18 and and CCONJ dpc-6646 12 19 antonio antonio PROPN dpc-6646 12 20 giovanni giovanni PROPN dpc-6646 12 21 richetta richetta PROPN dpc-6646 12 22 have have AUX dpc-6646 12 23 made make VERB dpc-6646 12 24 substantial substantial ADJ dpc-6646 12 25 contributions contribution NOUN dpc-6646 12 26 to to ADP dpc-6646 12 27 the the DET dpc-6646 12 28 conception conception NOUN dpc-6646 12 29 , , PUNCT dpc-6646 12 30 the the DET dpc-6646 12 31 design design NOUN dpc-6646 12 32 of of ADP dpc-6646 12 33 the the DET dpc-6646 12 34 manuscript manuscript NOUN dpc-6646 12 35 , , PUNCT dpc-6646 12 36 the the DET dpc-6646 12 37 analysis analysis NOUN dpc-6646 12 38 and and CCONJ dpc-6646 12 39 interpretation interpretation NOUN dpc-6646 12 40 of of ADP dpc-6646 12 41 the the DET dpc-6646 12 42 data datum NOUN dpc-6646 12 43 , , PUNCT dpc-6646 12 44 and and CCONJ dpc-6646 12 45 drafting draft VERB dpc-6646 12 46 the the DET dpc-6646 12 47 manuscript manuscript NOUN dpc-6646 12 48 . . PUNCT dpc-6646 13 1 all all DET dpc-6646 13 2 authors author NOUN dpc-6646 13 3 contributed contribute VERB dpc-6646 13 4 to to ADP dpc-6646 13 5 drafting draft VERB dpc-6646 13 6 the the DET dpc-6646 13 7 manuscript manuscript NOUN dpc-6646 13 8 and and CCONJ dpc-6646 13 9 read read VERB dpc-6646 13 10 and and CCONJ dpc-6646 13 11 approved approve VERB dpc-6646 13 12 the the DET dpc-6646 13 13 final final ADJ dpc-6646 13 14 version version NOUN dpc-6646 13 15 of of ADP dpc-6646 13 16 the the DET dpc-6646 13 17 manuscript manuscript NOUN dpc-6646 13 18 . . PUNCT dpc-6646 14 1 2 2 NUM dpc-6646 14 2 original original ADJ dpc-6646 14 3 article article NOUN dpc-6646 14 4 | | ADV dpc-6646 14 5 dermatol dermatol ADJ dpc-6646 14 6 pract pract NOUN dpc-6646 14 7 concept concept NOUN dpc-6646 14 8 . . PUNCT dpc-6646 15 1 2025;15(4):6646 2025;15(4):6646 NUM dpc-6646 15 2 introduction introduction NOUN dpc-6646 15 3 psoriasis psoriasis NOUN dpc-6646 15 4 is be AUX dpc-6646 15 5 a a DET dpc-6646 15 6 chronic chronic ADJ dpc-6646 15 7 systemic systemic ADJ dpc-6646 15 8 inflammatory inflammatory ADJ dpc-6646 15 9 condition condition NOUN dpc-6646 15 10 that that PRON dpc-6646 15 11 affects affect VERB dpc-6646 15 12 both both DET dpc-6646 15 13 the the DET dpc-6646 15 14 skin skin NOUN dpc-6646 15 15 and and CCONJ dpc-6646 15 16 multiple multiple ADJ dpc-6646 15 17 organ organ NOUN dpc-6646 15 18 systems system NOUN dpc-6646 15 19 and and CCONJ dpc-6646 15 20 is be AUX dpc-6646 15 21 frequently frequently ADV dpc-6646 15 22 associated associate VERB dpc-6646 15 23 with with ADP dpc-6646 15 24 comorbidities comorbiditie NOUN dpc-6646 15 25 such such ADJ dpc-6646 15 26 as as ADP dpc-6646 15 27 metabolic metabolic NOUN dpc-6646 15 28 syndrome syndrome NOUN dpc-6646 15 29 , , PUNCT dpc-6646 15 30 cardiovascular cardiovascular ADJ dpc-6646 15 31 disease disease NOUN dpc-6646 15 32 , , PUNCT dpc-6646 15 33 and and CCONJ dpc-6646 15 34 inflammatory inflammatory ADJ dpc-6646 15 35 bowel bowel NOUN dpc-6646 15 36 disorders disorder NOUN dpc-6646 15 37 [ [ X dpc-6646 15 38 1 1 NUM dpc-6646 15 39 - - SYM dpc-6646 15 40 4 4 NUM dpc-6646 15 41 ] ] PUNCT dpc-6646 15 42 . . PUNCT dpc-6646 16 1 the the DET dpc-6646 16 2 pathogenesis pathogenesis NOUN dpc-6646 16 3 of of ADP dpc-6646 16 4 psoriasis psoriasis NOUN dpc-6646 16 5 involves involve VERB dpc-6646 16 6 complex complex ADJ dpc-6646 16 7 interactions interaction NOUN dpc-6646 16 8 between between ADP dpc-6646 16 9 genetic genetic ADJ dpc-6646 16 10 predispositions predisposition NOUN dpc-6646 16 11 and and CCONJ dpc-6646 16 12 environmental environmental ADJ dpc-6646 16 13 triggers trigger NOUN dpc-6646 16 14 , , PUNCT dpc-6646 16 15 leading lead VERB dpc-6646 16 16 to to ADP dpc-6646 16 17 an an DET dpc-6646 16 18 inflammatory inflammatory ADJ dpc-6646 16 19 response response NOUN dpc-6646 16 20 mediated mediate VERB dpc-6646 16 21 by by ADP dpc-6646 16 22 dendritic dendritic ADJ dpc-6646 16 23 cells cell NOUN dpc-6646 16 24 , , PUNCT dpc-6646 16 25 t t NOUN dpc-6646 16 26 cells cell NOUN dpc-6646 16 27 , , PUNCT dpc-6646 16 28 keratinocytes keratinocyte NOUN dpc-6646 16 29 , , PUNCT dpc-6646 16 30 and and CCONJ dpc-6646 16 31 cytokines cytokine VERB dpc-6646 16 32 such such ADJ dpc-6646 16 33 as as ADP dpc-6646 16 34 tnfα tnfα NOUN dpc-6646 16 35 and and CCONJ dpc-6646 16 36 the the DET dpc-6646 16 37 il-23 il-23 NOUN dpc-6646 16 38 / / SYM dpc-6646 16 39 il-17 il-17 NUM dpc-6646 16 40 pathways pathway NOUN dpc-6646 16 41 [ [ X dpc-6646 16 42 1,5 1,5 NUM dpc-6646 16 43 ] ] PUNCT dpc-6646 16 44 . . PUNCT dpc-6646 17 1 this this DET dpc-6646 17 2 inflammatory inflammatory ADJ dpc-6646 17 3 cascade cascade NOUN dpc-6646 17 4 not not PART dpc-6646 17 5 only only ADV dpc-6646 17 6 affects affect VERB dpc-6646 17 7 the the DET dpc-6646 17 8 skin skin NOUN dpc-6646 17 9 , , PUNCT dpc-6646 17 10 causing cause VERB dpc-6646 17 11 characteristic characteristic ADJ dpc-6646 17 12 erythematous erythematous ADJ dpc-6646 17 13 , , PUNCT dpc-6646 17 14 indurated indurate VERB dpc-6646 17 15 , , PUNCT dpc-6646 17 16 and and CCONJ dpc-6646 17 17 scaly scaly NOUN dpc-6646 17 18 plaques plaque NOUN dpc-6646 17 19 , , PUNCT dpc-6646 17 20 but but CCONJ dpc-6646 17 21 also also ADV dpc-6646 17 22 contributes contribute VERB dpc-6646 17 23 to to ADP dpc-6646 17 24 systemic systemic ADJ dpc-6646 17 25 inflammation inflammation NOUN dpc-6646 17 26 , , PUNCT dpc-6646 17 27 which which PRON dpc-6646 17 28 is be AUX dpc-6646 17 29 implicated implicate VERB dpc-6646 17 30 in in ADP dpc-6646 17 31 the the DET dpc-6646 17 32 development development NOUN dpc-6646 17 33 of of ADP dpc-6646 17 34 the the DET dpc-6646 17 35 above above ADV dpc-6646 17 36 - - PUNCT dpc-6646 17 37 mentioned mention VERB dpc-6646 17 38 comorbidities comorbiditie NOUN dpc-6646 17 39 [ [ X dpc-6646 17 40 1,2 1,2 NUM dpc-6646 17 41 ] ] PUNCT dpc-6646 17 42 . . PUNCT dpc-6646 18 1 moderate moderate ADJ dpc-6646 18 2 - - PUNCT dpc-6646 18 3 to to ADP dpc-6646 18 4 - - PUNCT dpc-6646 18 5 severe severe ADJ dpc-6646 18 6 psoriasis psoriasis NOUN dpc-6646 18 7 significantly significantly ADV dpc-6646 18 8 impacts impact VERB dpc-6646 18 9 patients patient NOUN dpc-6646 18 10 ’ ' PUNCT dpc-6646 18 11 quality quality NOUN dpc-6646 18 12 of of ADP dpc-6646 18 13 life life NOUN dpc-6646 18 14 and and CCONJ dpc-6646 18 15 creates create VERB dpc-6646 18 16 a a DET dpc-6646 18 17 substantial substantial ADJ dpc-6646 18 18 long long ADJ dpc-6646 18 19 - - PUNCT dpc-6646 18 20 term term NOUN dpc-6646 18 21 disease disease NOUN dpc-6646 18 22 burden burden NOUN dpc-6646 18 23 , , PUNCT dpc-6646 18 24 necessitating necessitate VERB dpc-6646 18 25 ongoing ongoing ADJ dpc-6646 18 26 disease disease NOUN dpc-6646 18 27 management management NOUN dpc-6646 18 28 . . PUNCT dpc-6646 19 1 the the DET dpc-6646 19 2 chronic chronic ADJ dpc-6646 19 3 nature nature NOUN dpc-6646 19 4 of of ADP dpc-6646 19 5 psoriasis psoriasis NOUN dpc-6646 19 6 leads lead VERB dpc-6646 19 7 to to ADP dpc-6646 19 8 considerable considerable ADJ dpc-6646 19 9 physical physical ADJ dpc-6646 19 10 , , PUNCT dpc-6646 19 11 social social ADJ dpc-6646 19 12 , , PUNCT dpc-6646 19 13 and and CCONJ dpc-6646 19 14 psychological psychological ADJ dpc-6646 19 15 impairments impairment NOUN dpc-6646 19 16 , , PUNCT dpc-6646 19 17 affecting affect VERB dpc-6646 19 18 not not PART dpc-6646 19 19 only only ADV dpc-6646 19 20 patients patient NOUN dpc-6646 19 21 but but CCONJ dpc-6646 19 22 also also ADV dpc-6646 19 23 their their PRON dpc-6646 19 24 families family NOUN dpc-6646 19 25 [ [ X dpc-6646 19 26 6,7 6,7 NUM dpc-6646 19 27 ] ] PUNCT dpc-6646 19 28 . . PUNCT dpc-6646 20 1 the the DET dpc-6646 20 2 introduction introduction NOUN dpc-6646 20 3 of of ADP dpc-6646 20 4 biologics biologic NOUN dpc-6646 20 5 targeting target VERB dpc-6646 20 6 interleukin interleukin NOUN dpc-6646 20 7 pathways pathway NOUN dpc-6646 20 8 ( ( PUNCT dpc-6646 20 9 il-12/23 il-12/23 PROPN dpc-6646 20 10 , , PUNCT dpc-6646 20 11 il-17 il-17 ADV dpc-6646 20 12 , , PUNCT dpc-6646 20 13 il-23 il-23 NOUN dpc-6646 20 14 ) ) PUNCT dpc-6646 20 15 has have AUX dpc-6646 20 16 revolutionized revolutionize VERB dpc-6646 20 17 the the DET dpc-6646 20 18 management management NOUN dpc-6646 20 19 of of ADP dpc-6646 20 20 psoriasis psoriasis NOUN dpc-6646 20 21 and and CCONJ dpc-6646 20 22 psoriatic psoriatic ADJ dpc-6646 20 23 arthritis arthritis NOUN dpc-6646 20 24 . . PUNCT dpc-6646 21 1 il-12/23 il-12/23 ADJ dpc-6646 21 2 inhibitors inhibitor NOUN dpc-6646 21 3 like like ADP dpc-6646 21 4 ustekinumab ustekinumab NOUN dpc-6646 21 5 , , PUNCT dpc-6646 21 6 and and CCONJ dpc-6646 21 7 il-23 il-23 NOUN dpc-6646 21 8 inhibitors inhibitor NOUN dpc-6646 21 9 such such ADJ dpc-6646 21 10 as as ADP dpc-6646 21 11 guselkumab guselkumab NOUN dpc-6646 21 12 , , PUNCT dpc-6646 21 13 tildrakizumab tildrakizumab NOUN dpc-6646 21 14 , , PUNCT dpc-6646 21 15 and and CCONJ dpc-6646 21 16 risankizumab risankizumab NOUN dpc-6646 21 17 have have AUX dpc-6646 21 18 demonstrated demonstrate VERB dpc-6646 21 19 varying vary VERB dpc-6646 21 20 levels level NOUN dpc-6646 21 21 of of ADP dpc-6646 21 22 treatment treatment NOUN dpc-6646 21 23 persistence persistence NOUN dpc-6646 21 24 , , PUNCT dpc-6646 21 25 which which PRON dpc-6646 21 26 is be AUX dpc-6646 21 27 an an DET dpc-6646 21 28 essential essential ADJ dpc-6646 21 29 measure measure NOUN dpc-6646 21 30 of of ADP dpc-6646 21 31 long long ADJ dpc-6646 21 32 - - PUNCT dpc-6646 21 33 term term NOUN dpc-6646 21 34 efficacy efficacy NOUN dpc-6646 21 35 and and CCONJ dpc-6646 21 36 safety safety NOUN dpc-6646 21 37 and and CCONJ dpc-6646 21 38 an an DET dpc-6646 21 39 essential essential ADJ dpc-6646 21 40 feature feature NOUN dpc-6646 21 41 leading lead VERB dpc-6646 21 42 to to ADP dpc-6646 21 43 patient patient ADJ dpc-6646 21 44 satisfaction satisfaction NOUN dpc-6646 21 45 in in ADP dpc-6646 21 46 real real ADJ dpc-6646 21 47 - - PUNCT dpc-6646 21 48 world world NOUN dpc-6646 21 49 settings setting NOUN dpc-6646 21 50 [ [ X dpc-6646 21 51 8 8 NUM dpc-6646 21 52 ] ] PUNCT dpc-6646 21 53 . . PUNCT dpc-6646 22 1 guselkumab guselkumab NOUN dpc-6646 22 2 has have AUX dpc-6646 22 3 demonstrated demonstrate VERB dpc-6646 22 4 high high ADJ dpc-6646 22 5 drug drug NOUN dpc-6646 22 6 survival survival NOUN dpc-6646 22 7 rates rate NOUN dpc-6646 22 8 in in ADP dpc-6646 22 9 the the DET dpc-6646 22 10 treatment treatment NOUN dpc-6646 22 11 of of ADP dpc-6646 22 12 moderate moderate ADJ dpc-6646 22 13 - - PUNCT dpc-6646 22 14 to to ADP dpc-6646 22 15 - - PUNCT dpc-6646 22 16 severe severe ADJ dpc-6646 22 17 psoriasis psoriasis NOUN dpc-6646 22 18 across across ADP dpc-6646 22 19 various various ADJ dpc-6646 22 20 real real ADJ dpc-6646 22 21 - - PUNCT dpc-6646 22 22 world world NOUN dpc-6646 22 23 studies study NOUN dpc-6646 22 24 [ [ X dpc-6646 22 25 9 9 NUM dpc-6646 22 26 - - SYM dpc-6646 22 27 13 13 NUM dpc-6646 22 28 ] ] PUNCT dpc-6646 22 29 . . PUNCT dpc-6646 23 1 however however ADV dpc-6646 23 2 , , PUNCT dpc-6646 23 3 real real ADJ dpc-6646 23 4 - - PUNCT dpc-6646 23 5 life life NOUN dpc-6646 23 6 evidence evidence NOUN dpc-6646 23 7 regarding regard VERB dpc-6646 23 8 guselkumab guselkumab NOUN dpc-6646 23 9 persistence persistence NOUN dpc-6646 23 10 over over ADP dpc-6646 23 11 extended extended ADJ dpc-6646 23 12 follow follow NOUN dpc-6646 23 13 - - PUNCT dpc-6646 23 14 up up NOUN dpc-6646 23 15 and and CCONJ dpc-6646 23 16 the the DET dpc-6646 23 17 factors factor NOUN dpc-6646 23 18 influencing influence VERB dpc-6646 23 19 it it PRON dpc-6646 23 20 remains remain VERB dpc-6646 23 21 limited limited ADJ dpc-6646 23 22 . . PUNCT dpc-6646 24 1 the the DET dpc-6646 24 2 aim aim NOUN dpc-6646 24 3 of of ADP dpc-6646 24 4 this this DET dpc-6646 24 5 work work NOUN dpc-6646 24 6 was be AUX dpc-6646 24 7 to to PART dpc-6646 24 8 retrospectively retrospectively ADV dpc-6646 24 9 assess assess VERB dpc-6646 24 10 the the DET dpc-6646 24 11 longterm longterm ADJ dpc-6646 24 12 persistence persistence NOUN dpc-6646 24 13 of of ADP dpc-6646 24 14 guselkumab guselkumab NOUN dpc-6646 24 15 in in ADP dpc-6646 24 16 a a DET dpc-6646 24 17 cohort cohort NOUN dpc-6646 24 18 of of ADP dpc-6646 24 19 patients patient NOUN dpc-6646 24 20 with with ADP dpc-6646 24 21 psoriasis psoriasis NOUN dpc-6646 24 22 as as ADV dpc-6646 24 23 well well ADV dpc-6646 24 24 as as ADP dpc-6646 24 25 to to PART dpc-6646 24 26 explore explore VERB dpc-6646 24 27 the the DET dpc-6646 24 28 associations association NOUN dpc-6646 24 29 between between ADP dpc-6646 24 30 persistence persistence NOUN dpc-6646 24 31 and and CCONJ dpc-6646 24 32 key key ADJ dpc-6646 24 33 variables variable NOUN dpc-6646 24 34 such such ADJ dpc-6646 24 35 as as ADP dpc-6646 24 36 bmi bmi NOUN dpc-6646 24 37 , , PUNCT dpc-6646 24 38 pasi pasi NOUN dpc-6646 24 39 , , PUNCT dpc-6646 24 40 previous previous ADJ dpc-6646 24 41 biologic biologic NOUN dpc-6646 24 42 treatments treatment NOUN dpc-6646 24 43 , , PUNCT dpc-6646 24 44 and and CCONJ dpc-6646 24 45 the the DET dpc-6646 24 46 involvement involvement NOUN dpc-6646 24 47 of of ADP dpc-6646 24 48 difficult difficult ADJ dpc-6646 24 49 - - PUNCT dpc-6646 24 50 to to ADP dpc-6646 24 51 - - PUNCT dpc-6646 24 52 treat treat NOUN dpc-6646 24 53 areas area NOUN dpc-6646 24 54 . . PUNCT dpc-6646 25 1 materials material NOUN dpc-6646 25 2 and and CCONJ dpc-6646 25 3 methods method NOUN dpc-6646 25 4 study study NOUN dpc-6646 25 5 design design NOUN dpc-6646 25 6 and and CCONJ dpc-6646 25 7 population population NOUN dpc-6646 25 8 this this DET dpc-6646 25 9 multicenter multicenter ADJ dpc-6646 25 10 retrospective retrospective ADJ dpc-6646 25 11 observational observational ADJ dpc-6646 25 12 study study NOUN dpc-6646 25 13 was be AUX dpc-6646 25 14 conducted conduct VERB dpc-6646 25 15 across across ADP dpc-6646 25 16 14 14 NUM dpc-6646 25 17 dermatology dermatology NOUN dpc-6646 25 18 centers center NOUN dpc-6646 25 19 in in ADP dpc-6646 25 20 italy italy PROPN dpc-6646 25 21 ( ( PUNCT dpc-6646 25 22 listed list VERB dpc-6646 25 23 in in ADP dpc-6646 25 24 table table NOUN dpc-6646 25 25 s1 s1 NOUN dpc-6646 25 26 ) ) PUNCT dpc-6646 25 27 . . PUNCT dpc-6646 26 1 it it PRON dpc-6646 26 2 included include VERB dpc-6646 26 3 adult adult NOUN dpc-6646 26 4 patients patient NOUN dpc-6646 26 5 ( ( PUNCT dpc-6646 26 6 aged aged ADJ dpc-6646 26 7 18 18 NUM dpc-6646 26 8 years year NOUN dpc-6646 26 9 or or CCONJ dpc-6646 26 10 older old ADJ dpc-6646 26 11 ) ) PUNCT dpc-6646 26 12 with with ADP dpc-6646 26 13 moderate moderate ADJ dpc-6646 26 14 - - PUNCT dpc-6646 26 15 to to ADP dpc-6646 26 16 - - PUNCT dpc-6646 26 17 severe severe ADJ dpc-6646 26 18 plaque plaque NOUN dpc-6646 26 19 psoriasis psoriasis NOUN dpc-6646 26 20 who who PRON dpc-6646 26 21 initiated initiate VERB dpc-6646 26 22 guselkumab guselkumab NOUN dpc-6646 26 23 treatment treatment NOUN dpc-6646 26 24 as as ADP dpc-6646 26 25 a a DET dpc-6646 26 26 part part NOUN dpc-6646 26 27 of of ADP dpc-6646 26 28 routine routine ADJ dpc-6646 26 29 clinical clinical ADJ dpc-6646 26 30 practice practice NOUN dpc-6646 26 31 . . PUNCT dpc-6646 27 1 corresponding correspond VERB dpc-6646 27 2 author author NOUN dpc-6646 27 3 : : PUNCT dpc-6646 27 4 annunziata annunziata PROPN dpc-6646 27 5 dattola dattola PROPN dpc-6646 27 6 , , PUNCT dpc-6646 27 7 dermatology dermatology NOUN dpc-6646 27 8 unit unit NOUN dpc-6646 27 9 , , PUNCT dpc-6646 27 10 department department NOUN dpc-6646 27 11 of of ADP dpc-6646 27 12 clinical clinical ADJ dpc-6646 27 13 internal internal ADJ dpc-6646 27 14 , , PUNCT dpc-6646 27 15 anesthesiological anesthesiological ADJ dpc-6646 27 16 and and CCONJ dpc-6646 27 17 cardiovascular cardiovascular ADJ dpc-6646 27 18 sciences science NOUN dpc-6646 27 19 , , PUNCT dpc-6646 27 20 sapienza sapienza PROPN dpc-6646 27 21 university university NOUN dpc-6646 27 22 , , PUNCT dpc-6646 27 23 viale viale NOUN dpc-6646 27 24 del del PROPN dpc-6646 27 25 policlinico policlinico NOUN dpc-6646 27 26 155 155 NUM dpc-6646 27 27 , , PUNCT dpc-6646 27 28 00185 00185 NUM dpc-6646 27 29 , , PUNCT dpc-6646 27 30 rome rome PROPN dpc-6646 27 31 , , PUNCT dpc-6646 27 32 italy italy PROPN dpc-6646 27 33 . . PUNCT dpc-6646 28 1 orcid orcid PROPN dpc-6646 29 1 i i PRON dpc-6646 29 2 d d NOUN dpc-6646 29 3 : : PUNCT dpc-6646 29 4 0000 0000 NUM dpc-6646 29 5 - - PUNCT dpc-6646 29 6 0001 0001 NUM dpc-6646 29 7 - - PUNCT dpc-6646 29 8 9504 9504 NUM dpc-6646 29 9 - - SYM dpc-6646 29 10 5882 5882 NUM dpc-6646 29 11 . . PUNCT dpc-6646 30 1 email email NOUN dpc-6646 30 2 : : PUNCT dpc-6646 30 3 nancydattola@ nancydattola@ X dpc-6646 30 4 gmail.com gmail.com X dpc-6646 30 5 introduction introduction NOUN dpc-6646 30 6 : : PUNCT dpc-6646 30 7 psoriasis psoriasis NOUN dpc-6646 30 8 is be AUX dpc-6646 30 9 a a DET dpc-6646 30 10 chronic chronic ADJ dpc-6646 30 11 systemic systemic ADJ dpc-6646 30 12 inflammatory inflammatory ADJ dpc-6646 30 13 disease disease NOUN dpc-6646 30 14 that that PRON dpc-6646 30 15 requires require VERB dpc-6646 30 16 long long ADJ dpc-6646 30 17 - - PUNCT dpc-6646 30 18 term term NOUN dpc-6646 30 19 treatment treatment NOUN dpc-6646 30 20 strategies strategy NOUN dpc-6646 30 21 to to PART dpc-6646 30 22 maintain maintain VERB dpc-6646 30 23 sustained sustained ADJ dpc-6646 30 24 disease disease NOUN dpc-6646 30 25 control control NOUN dpc-6646 30 26 . . PUNCT dpc-6646 31 1 treatment treatment NOUN dpc-6646 31 2 persistence persistence NOUN dpc-6646 31 3 is be AUX dpc-6646 31 4 an an DET dpc-6646 31 5 important important ADJ dpc-6646 31 6 real real ADJ dpc-6646 31 7 - - PUNCT dpc-6646 31 8 world world NOUN dpc-6646 31 9 indicator indicator NOUN dpc-6646 31 10 of of ADP dpc-6646 31 11 therapeutic therapeutic ADJ dpc-6646 31 12 effectiveness effectiveness NOUN dpc-6646 31 13 and and CCONJ dpc-6646 31 14 tolerability tolerability NOUN dpc-6646 31 15 . . PUNCT dpc-6646 32 1 guselkumab guselkumab NOUN dpc-6646 32 2 , , PUNCT dpc-6646 32 3 an an DET dpc-6646 32 4 il-23 il-23 NOUN dpc-6646 32 5 inhibitor inhibitor NOUN dpc-6646 32 6 , , PUNCT dpc-6646 32 7 has have AUX dpc-6646 32 8 shown show VERB dpc-6646 32 9 favorable favorable ADJ dpc-6646 32 10 persistence persistence NOUN dpc-6646 32 11 in in ADP dpc-6646 32 12 several several ADJ dpc-6646 32 13 studies study NOUN dpc-6646 32 14 , , PUNCT dpc-6646 32 15 but but CCONJ dpc-6646 32 16 extended extended ADJ dpc-6646 32 17 long long ADJ dpc-6646 32 18 - - PUNCT dpc-6646 32 19 term term NOUN dpc-6646 32 20 data datum NOUN dpc-6646 32 21 remain remain VERB dpc-6646 32 22 limited limited ADJ dpc-6646 32 23 . . PUNCT dpc-6646 33 1 objectives objective NOUN dpc-6646 33 2 : : PUNCT dpc-6646 33 3 to to PART dpc-6646 33 4 assess assess VERB dpc-6646 33 5 3and 3and NUM dpc-6646 33 6 5 5 NUM dpc-6646 33 7 - - PUNCT dpc-6646 33 8 year year NOUN dpc-6646 33 9 drug drug NOUN dpc-6646 33 10 survival survival NOUN dpc-6646 33 11 rates rate NOUN dpc-6646 33 12 of of ADP dpc-6646 33 13 guselkumab guselkumab NOUN dpc-6646 33 14 in in ADP dpc-6646 33 15 patients patient NOUN dpc-6646 33 16 with with ADP dpc-6646 33 17 moderate moderate ADJ dpc-6646 33 18 - - PUNCT dpc-6646 33 19 to to ADP dpc-6646 33 20 severe severe ADJ dpc-6646 33 21 plaque plaque NOUN dpc-6646 33 22 psoriasis psoriasis NOUN dpc-6646 33 23 and and CCONJ dpc-6646 33 24 to to PART dpc-6646 33 25 examine examine VERB dpc-6646 33 26 the the DET dpc-6646 33 27 relationship relationship NOUN dpc-6646 33 28 between between ADP dpc-6646 33 29 persistence persistence NOUN dpc-6646 33 30 and and CCONJ dpc-6646 33 31 clinical clinical ADJ dpc-6646 33 32 variables variable NOUN dpc-6646 33 33 such such ADJ dpc-6646 33 34 as as ADP dpc-6646 33 35 pasi pasi NOUN dpc-6646 33 36 , , PUNCT dpc-6646 33 37 bmi bmi PROPN dpc-6646 33 38 , , PUNCT dpc-6646 33 39 prior prior ADJ dpc-6646 33 40 biologic biologic ADJ dpc-6646 33 41 exposure exposure NOUN dpc-6646 33 42 , , PUNCT dpc-6646 33 43 and and CCONJ dpc-6646 33 44 involvement involvement NOUN dpc-6646 33 45 of of ADP dpc-6646 33 46 difficult difficult ADJ dpc-6646 33 47 - - PUNCT dpc-6646 33 48 to to ADP dpc-6646 33 49 - - PUNCT dpc-6646 33 50 treat treat NOUN dpc-6646 33 51 areas area NOUN dpc-6646 33 52 . . PUNCT dpc-6646 34 1 methods method NOUN dpc-6646 34 2 : : PUNCT dpc-6646 34 3 this this PRON dpc-6646 34 4 was be AUX dpc-6646 34 5 a a DET dpc-6646 34 6 multicenter multicenter ADJ dpc-6646 34 7 retrospective retrospective ADJ dpc-6646 34 8 observational observational ADJ dpc-6646 34 9 study study NOUN dpc-6646 34 10 conducted conduct VERB dpc-6646 34 11 across across ADP dpc-6646 34 12 14 14 NUM dpc-6646 34 13 dermatology dermatology NOUN dpc-6646 34 14 centers center NOUN dpc-6646 34 15 in in ADP dpc-6646 34 16 italy italy PROPN dpc-6646 34 17 . . PUNCT dpc-6646 35 1 adult adult NOUN dpc-6646 35 2 patients patient NOUN dpc-6646 35 3 with with ADP dpc-6646 35 4 moderate moderate ADJ dpc-6646 35 5 - - PUNCT dpc-6646 35 6 to to ADP dpc-6646 35 7 - - PUNCT dpc-6646 35 8 severe severe ADJ dpc-6646 35 9 plaque plaque NOUN dpc-6646 35 10 psoriasis psoriasis NOUN dpc-6646 35 11 who who PRON dpc-6646 35 12 started start VERB dpc-6646 35 13 guselkumab guselkumab NOUN dpc-6646 35 14 were be AUX dpc-6646 35 15 included include VERB dpc-6646 35 16 . . PUNCT dpc-6646 36 1 data datum NOUN dpc-6646 36 2 collected collect VERB dpc-6646 36 3 included include VERB dpc-6646 36 4 demographics demographic NOUN dpc-6646 36 5 , , PUNCT dpc-6646 36 6 clinical clinical ADJ dpc-6646 36 7 history history NOUN dpc-6646 36 8 , , PUNCT dpc-6646 36 9 disease disease NOUN dpc-6646 36 10 severity severity NOUN dpc-6646 36 11 , , PUNCT dpc-6646 36 12 comorbidities comorbiditie NOUN dpc-6646 36 13 , , PUNCT dpc-6646 36 14 and and CCONJ dpc-6646 36 15 treatment treatment NOUN dpc-6646 36 16 details detail NOUN dpc-6646 36 17 . . PUNCT dpc-6646 37 1 drug drug NOUN dpc-6646 37 2 survival survival NOUN dpc-6646 37 3 was be AUX dpc-6646 37 4 analyzed analyze VERB dpc-6646 37 5 using use VERB dpc-6646 37 6 kaplan kaplan PROPN dpc-6646 37 7 – – PUNCT dpc-6646 37 8 meier meier PROPN dpc-6646 37 9 curves curve NOUN dpc-6646 37 10 and and CCONJ dpc-6646 37 11 cox cox PROPN dpc-6646 37 12 proportional proportional ADJ dpc-6646 37 13 hazards hazard NOUN dpc-6646 37 14 models model NOUN dpc-6646 37 15 . . PUNCT dpc-6646 38 1 results result NOUN dpc-6646 38 2 : : PUNCT dpc-6646 38 3 a a DET dpc-6646 38 4 total total NOUN dpc-6646 38 5 of of ADP dpc-6646 38 6 247 247 NUM dpc-6646 38 7 patients patient NOUN dpc-6646 38 8 were be AUX dpc-6646 38 9 included include VERB dpc-6646 38 10 . . PUNCT dpc-6646 39 1 at at ADP dpc-6646 39 2 three three NUM dpc-6646 39 3 years year NOUN dpc-6646 39 4 , , PUNCT dpc-6646 39 5 80.2 80.2 NUM dpc-6646 39 6 % % NOUN dpc-6646 39 7 of of ADP dpc-6646 39 8 patients patient NOUN dpc-6646 39 9 remained remain VERB dpc-6646 39 10 on on ADP dpc-6646 39 11 guselkumab guselkumab NOUN dpc-6646 39 12 , , PUNCT dpc-6646 39 13 and and CCONJ dpc-6646 39 14 at at ADP dpc-6646 39 15 five five NUM dpc-6646 39 16 years year NOUN dpc-6646 39 17 , , PUNCT dpc-6646 39 18 72.8 72.8 NUM dpc-6646 39 19 % % NOUN dpc-6646 39 20 continued continued ADJ dpc-6646 39 21 treatment treatment NOUN dpc-6646 39 22 . . PUNCT dpc-6646 40 1 persistence persistence NOUN dpc-6646 40 2 was be AUX dpc-6646 40 3 not not PART dpc-6646 40 4 significantly significantly ADV dpc-6646 40 5 influenced influence VERB dpc-6646 40 6 by by ADP dpc-6646 40 7 bmi bmi PROPN dpc-6646 40 8 , , PUNCT dpc-6646 40 9 pasi pasi NOUN dpc-6646 40 10 , , PUNCT dpc-6646 40 11 or or CCONJ dpc-6646 40 12 age age NOUN dpc-6646 40 13 . . PUNCT dpc-6646 41 1 however however ADV dpc-6646 41 2 , , PUNCT dpc-6646 41 3 prior prior ADJ dpc-6646 41 4 biologics biologic NOUN dpc-6646 41 5 exposure exposure NOUN dpc-6646 41 6 was be AUX dpc-6646 41 7 associated associate VERB dpc-6646 41 8 with with ADP dpc-6646 41 9 a a DET dpc-6646 41 10 higher high ADJ dpc-6646 41 11 risk risk NOUN dpc-6646 41 12 of of ADP dpc-6646 41 13 discontinuation discontinuation NOUN dpc-6646 41 14 ( ( PUNCT dpc-6646 41 15 hazard hazard NOUN dpc-6646 41 16 ratio ratio NOUN dpc-6646 41 17 ( ( PUNCT dpc-6646 41 18 hr hr NOUN dpc-6646 41 19 ): ): PUNCT dpc-6646 41 20 1.84 1.84 NUM dpc-6646 41 21 ; ; PUNCT dpc-6646 41 22 p=0.0208 p=0.0208 NUM dpc-6646 41 23 ) ) PUNCT dpc-6646 41 24 , , PUNCT dpc-6646 41 25 especially especially ADV dpc-6646 41 26 in in ADP dpc-6646 41 27 those those PRON dpc-6646 41 28 previously previously ADV dpc-6646 41 29 treated treat VERB dpc-6646 41 30 with with ADP dpc-6646 41 31 il-17 il-17 NUM dpc-6646 41 32 inhibitors inhibitor NOUN dpc-6646 41 33 ( ( PUNCT dpc-6646 41 34 hr:2.14 hr:2.14 NOUN dpc-6646 41 35 ; ; PUNCT dpc-6646 41 36 p=0.0150 p=0.0150 NUM dpc-6646 41 37 ) ) PUNCT dpc-6646 41 38 . . PUNCT dpc-6646 42 1 the the DET dpc-6646 42 2 involvement involvement NOUN dpc-6646 42 3 of of ADP dpc-6646 42 4 difficult difficult ADJ dpc-6646 42 5 - - PUNCT dpc-6646 42 6 to to ADP dpc-6646 42 7 - - PUNCT dpc-6646 42 8 treat treat NOUN dpc-6646 42 9 areas area NOUN dpc-6646 42 10 did do AUX dpc-6646 42 11 not not PART dpc-6646 42 12 significantly significantly ADV dpc-6646 42 13 affect affect VERB dpc-6646 42 14 persistence persistence NOUN dpc-6646 42 15 , , PUNCT dpc-6646 42 16 although although SCONJ dpc-6646 42 17 a a DET dpc-6646 42 18 trend trend NOUN dpc-6646 42 19 toward toward ADP dpc-6646 42 20 reduced reduce VERB dpc-6646 42 21 discontinuation discontinuation NOUN dpc-6646 42 22 was be AUX dpc-6646 42 23 observed observe VERB dpc-6646 42 24 in in ADP dpc-6646 42 25 patients patient NOUN dpc-6646 42 26 with with ADP dpc-6646 42 27 genital genital ADJ dpc-6646 42 28 involvement involvement NOUN dpc-6646 42 29 ( ( PUNCT dpc-6646 42 30 p=0.0539 p=0.0539 NOUN dpc-6646 42 31 ) ) PUNCT dpc-6646 42 32 . . PUNCT dpc-6646 43 1 conclusions conclusion NOUN dpc-6646 43 2 : : PUNCT dpc-6646 43 3 guselkumab guselkumab NOUN dpc-6646 43 4 demonstrated demonstrate VERB dpc-6646 43 5 high high ADJ dpc-6646 43 6 long long ADJ dpc-6646 43 7 - - PUNCT dpc-6646 43 8 term term NOUN dpc-6646 43 9 persistence persistence NOUN dpc-6646 43 10 in in ADP dpc-6646 43 11 real real ADJ dpc-6646 43 12 - - PUNCT dpc-6646 43 13 world world NOUN dpc-6646 43 14 clinical clinical ADJ dpc-6646 43 15 practice practice NOUN dpc-6646 43 16 . . PUNCT dpc-6646 44 1 drug drug NOUN dpc-6646 44 2 survival survival NOUN dpc-6646 44 3 remained remain VERB dpc-6646 44 4 consistently consistently ADV dpc-6646 44 5 high high ADJ dpc-6646 44 6 across across ADP dpc-6646 44 7 various various ADJ dpc-6646 44 8 subgroups subgroup NOUN dpc-6646 44 9 , , PUNCT dpc-6646 44 10 with with ADP dpc-6646 44 11 prior prior ADJ dpc-6646 44 12 il-17 il-17 NUM dpc-6646 44 13 inhibitor inhibitor NOUN dpc-6646 44 14 exposure exposure NOUN dpc-6646 44 15 being be AUX dpc-6646 44 16 the the DET dpc-6646 44 17 main main ADJ dpc-6646 44 18 predictor predictor NOUN dpc-6646 44 19 of of ADP dpc-6646 44 20 decreased decrease VERB dpc-6646 44 21 persistence persistence NOUN dpc-6646 44 22 . . PUNCT dpc-6646 45 1 abstract abstract ADJ dpc-6646 45 2 original original ADJ dpc-6646 45 3 article article NOUN dpc-6646 45 4 | | ADV dpc-6646 45 5 dermatol dermatol ADJ dpc-6646 45 6 pract pract NOUN dpc-6646 45 7 concept concept NOUN dpc-6646 45 8 . . PUNCT dpc-6646 46 1 2025;15(4):6646 2025;15(4):6646 NUM dpc-6646 46 2 3 3 NUM dpc-6646 46 3 both both DET dpc-6646 46 4 bio bio NOUN dpc-6646 46 5 - - ADJ dpc-6646 46 6 naïve naïve ADJ dpc-6646 46 7 and and CCONJ dpc-6646 46 8 bio bio ADJ dpc-6646 46 9 - - ADJ dpc-6646 46 10 experienced experienced ADJ dpc-6646 46 11 patients patient NOUN dpc-6646 46 12 were be AUX dpc-6646 46 13 eligible eligible ADJ dpc-6646 46 14 . . PUNCT dpc-6646 47 1 clinical clinical ADJ dpc-6646 47 2 data datum NOUN dpc-6646 47 3 were be AUX dpc-6646 47 4 collected collect VERB dpc-6646 47 5 retrospectively retrospectively ADV dpc-6646 47 6 from from ADP dpc-6646 47 7 medical medical ADJ dpc-6646 47 8 records record NOUN dpc-6646 47 9 , , PUNCT dpc-6646 47 10 starting start VERB dpc-6646 47 11 from from ADP dpc-6646 47 12 the the DET dpc-6646 47 13 initiation initiation NOUN dpc-6646 47 14 of of ADP dpc-6646 47 15 treatment treatment NOUN dpc-6646 47 16 . . PUNCT dpc-6646 48 1 follow follow VERB dpc-6646 48 2 - - PUNCT dpc-6646 48 3 up up NOUN dpc-6646 48 4 was be AUX dpc-6646 48 5 assessed assess VERB dpc-6646 48 6 at at ADP dpc-6646 48 7 three three NUM dpc-6646 48 8 years year NOUN dpc-6646 48 9 ( ( PUNCT dpc-6646 48 10 primary primary ADJ dpc-6646 48 11 endpoint endpoint NOUN dpc-6646 48 12 ) ) PUNCT dpc-6646 48 13 and and CCONJ dpc-6646 48 14 five five NUM dpc-6646 48 15 years year NOUN dpc-6646 48 16 ( ( PUNCT dpc-6646 48 17 secondary secondary ADJ dpc-6646 48 18 endpoint endpoint NOUN dpc-6646 48 19 ) ) PUNCT dpc-6646 48 20 , , PUNCT dpc-6646 48 21 as as SCONJ dpc-6646 48 22 specified specify VERB dpc-6646 48 23 in in ADP dpc-6646 48 24 the the DET dpc-6646 48 25 study study NOUN dpc-6646 48 26 protocol protocol NOUN dpc-6646 48 27 . . PUNCT dpc-6646 49 1 data datum NOUN dpc-6646 49 2 collection collection NOUN dpc-6646 49 3 collected collect VERB dpc-6646 49 4 variables variable NOUN dpc-6646 49 5 included include VERB dpc-6646 49 6 demographic demographic ADJ dpc-6646 49 7 ( ( PUNCT dpc-6646 49 8 age age NOUN dpc-6646 49 9 , , PUNCT dpc-6646 49 10 sex sex NOUN dpc-6646 49 11 ) ) PUNCT dpc-6646 49 12 and and CCONJ dpc-6646 49 13 anthropometric anthropometric ADJ dpc-6646 49 14 variables variable NOUN dpc-6646 49 15 ( ( PUNCT dpc-6646 49 16 weight weight NOUN dpc-6646 49 17 , , PUNCT dpc-6646 49 18 height height NOUN dpc-6646 49 19 , , PUNCT dpc-6646 49 20 bmi bmi PROPN dpc-6646 49 21 ) ) PUNCT dpc-6646 49 22 , , PUNCT dpc-6646 49 23 clinical clinical ADJ dpc-6646 49 24 history history NOUN dpc-6646 49 25 ( ( PUNCT dpc-6646 49 26 age age NOUN dpc-6646 49 27 at at ADP dpc-6646 49 28 disease disease NOUN dpc-6646 49 29 onset onset VERB dpc-6646 49 30 , , PUNCT dpc-6646 49 31 disease disease NOUN dpc-6646 49 32 duration duration NOUN dpc-6646 49 33 , , PUNCT dpc-6646 49 34 family family NOUN dpc-6646 49 35 history history NOUN dpc-6646 49 36 ) ) PUNCT dpc-6646 49 37 , , PUNCT dpc-6646 49 38 comorbidities comorbiditie NOUN dpc-6646 49 39 ( ( PUNCT dpc-6646 49 40 especially especially ADV dpc-6646 49 41 cardiometabolic cardiometabolic NOUN dpc-6646 49 42 and and CCONJ dpc-6646 49 43 gastrointestinal gastrointestinal ADJ dpc-6646 49 44 ) ) PUNCT dpc-6646 49 45 , , PUNCT dpc-6646 49 46 and and CCONJ dpc-6646 49 47 previous previous ADJ dpc-6646 49 48 biologic biologic NOUN dpc-6646 49 49 therapies therapy NOUN dpc-6646 49 50 . . PUNCT dpc-6646 50 1 psoriasis psoriasis NOUN dpc-6646 50 2 characteristics characteristic NOUN dpc-6646 50 3 included include VERB dpc-6646 50 4 baseline baseline ADJ dpc-6646 50 5 pasi pasi NOUN dpc-6646 50 6 scores score NOUN dpc-6646 50 7 and and CCONJ dpc-6646 50 8 involvement involvement NOUN dpc-6646 50 9 of of ADP dpc-6646 50 10 difficult difficult ADJ dpc-6646 50 11 - - PUNCT dpc-6646 50 12 to to ADP dpc-6646 50 13 - - PUNCT dpc-6646 50 14 treat treat NOUN dpc-6646 50 15 areas area NOUN dpc-6646 50 16 ( ( PUNCT dpc-6646 50 17 scalp scalp NOUN dpc-6646 50 18 , , PUNCT dpc-6646 50 19 nails nail NOUN dpc-6646 50 20 , , PUNCT dpc-6646 50 21 genital genital ADJ dpc-6646 50 22 , , PUNCT dpc-6646 50 23 and and CCONJ dpc-6646 50 24 pretibial pretibial ADJ dpc-6646 50 25 regions region NOUN dpc-6646 50 26 ) ) PUNCT dpc-6646 50 27 . . PUNCT dpc-6646 51 1 data datum NOUN dpc-6646 51 2 on on ADP dpc-6646 51 3 treatment treatment NOUN dpc-6646 51 4 discontinuation discontinuation NOUN dpc-6646 51 5 , , PUNCT dpc-6646 51 6 including include VERB dpc-6646 51 7 timing timing NOUN dpc-6646 51 8 and and CCONJ dpc-6646 51 9 documented document VERB dpc-6646 51 10 reasons reason NOUN dpc-6646 51 11 , , PUNCT dpc-6646 51 12 were be AUX dpc-6646 51 13 also also ADV dpc-6646 51 14 collected collect VERB dpc-6646 51 15 . . PUNCT dpc-6646 52 1 outcome outcome NOUN dpc-6646 52 2 measures measure NOUN dpc-6646 52 3 the the DET dpc-6646 52 4 primary primary ADJ dpc-6646 52 5 endpoint endpoint NOUN dpc-6646 52 6 was be AUX dpc-6646 52 7 the the DET dpc-6646 52 8 survival survival NOUN dpc-6646 52 9 of of ADP dpc-6646 52 10 the the DET dpc-6646 52 11 drug drug NOUN dpc-6646 52 12 guselkumab guselkumab NOUN dpc-6646 52 13 , , PUNCT dpc-6646 52 14 defined define VERB dpc-6646 52 15 as as ADP dpc-6646 52 16 persistence persistence NOUN dpc-6646 52 17 in in ADP dpc-6646 52 18 treatment treatment NOUN dpc-6646 52 19 over over ADP dpc-6646 52 20 time time NOUN dpc-6646 52 21 , , PUNCT dpc-6646 52 22 evaluated evaluate VERB dpc-6646 52 23 for for ADP dpc-6646 52 24 up up ADP dpc-6646 52 25 to to PART dpc-6646 52 26 three three NUM dpc-6646 52 27 years year NOUN dpc-6646 52 28 after after ADP dpc-6646 52 29 treatment treatment NOUN dpc-6646 52 30 initiation initiation NOUN dpc-6646 52 31 . . PUNCT dpc-6646 53 1 secondary secondary ADJ dpc-6646 53 2 endpoints endpoint NOUN dpc-6646 53 3 included include VERB dpc-6646 53 4 evaluating evaluate VERB dpc-6646 53 5 the the DET dpc-6646 53 6 drug drug NOUN dpc-6646 53 7 survival survival NOUN dpc-6646 53 8 with with ADP dpc-6646 53 9 guselkumab guselkumab NOUN dpc-6646 53 10 for for ADP dpc-6646 53 11 up up ADP dpc-6646 53 12 to to PART dpc-6646 53 13 five five NUM dpc-6646 53 14 years year NOUN dpc-6646 53 15 after after ADP dpc-6646 53 16 treatment treatment NOUN dpc-6646 53 17 initiation initiation NOUN dpc-6646 53 18 , , PUNCT dpc-6646 53 19 based base VERB dpc-6646 53 20 on on ADP dpc-6646 53 21 baseline baseline NOUN dpc-6646 53 22 pasi pasi NOUN dpc-6646 53 23 , , PUNCT dpc-6646 53 24 bmi bmi PROPN dpc-6646 53 25 , , PUNCT dpc-6646 53 26 prior prior ADJ dpc-6646 53 27 biologics biologic NOUN dpc-6646 53 28 exposure exposure NOUN dpc-6646 53 29 ( ( PUNCT dpc-6646 53 30 overall overall ADJ dpc-6646 53 31 and and CCONJ dpc-6646 53 32 by by ADP dpc-6646 53 33 drug drug NOUN dpc-6646 53 34 class class NOUN dpc-6646 53 35 ) ) PUNCT dpc-6646 53 36 , , PUNCT dpc-6646 53 37 and and CCONJ dpc-6646 53 38 involvement involvement NOUN dpc-6646 53 39 of of ADP dpc-6646 53 40 difficult difficult ADJ dpc-6646 53 41 - - PUNCT dpc-6646 53 42 to to AUX dpc-6646 53 43 - - PUNCT dpc-6646 53 44 treat treat VERB dpc-6646 53 45 anatomical anatomical ADJ dpc-6646 53 46 sites site NOUN dpc-6646 53 47 . . PUNCT dpc-6646 54 1 statistical statistical ADJ dpc-6646 54 2 analysis analysis NOUN dpc-6646 54 3 descriptive descriptive ADJ dpc-6646 54 4 statistics statistic NOUN dpc-6646 54 5 were be AUX dpc-6646 54 6 used use VERB dpc-6646 54 7 to to PART dpc-6646 54 8 summarize summarize VERB dpc-6646 54 9 baseline baseline NOUN dpc-6646 54 10 characteristics characteristic NOUN dpc-6646 54 11 . . PUNCT dpc-6646 55 1 continuous continuous ADJ dpc-6646 55 2 variables variable NOUN dpc-6646 55 3 are be AUX dpc-6646 55 4 reported report VERB dpc-6646 55 5 as as ADP dpc-6646 55 6 means mean NOUN dpc-6646 55 7 and and CCONJ dpc-6646 55 8 standard standard ADJ dpc-6646 55 9 deviations deviation NOUN dpc-6646 55 10 ( ( PUNCT dpc-6646 55 11 sd sd NOUN dpc-6646 55 12 ) ) PUNCT dpc-6646 55 13 , , PUNCT dpc-6646 55 14 and and CCONJ dpc-6646 55 15 categorical categorical ADJ dpc-6646 55 16 variables variable NOUN dpc-6646 55 17 as as ADP dpc-6646 55 18 counts count NOUN dpc-6646 55 19 and and CCONJ dpc-6646 55 20 percentages percentage NOUN dpc-6646 55 21 . . PUNCT dpc-6646 56 1 kaplan kaplan PROPN dpc-6646 56 2 – – PUNCT dpc-6646 56 3 meier meier PROPN dpc-6646 56 4 curves curve NOUN dpc-6646 56 5 were be AUX dpc-6646 56 6 used use VERB dpc-6646 56 7 to to PART dpc-6646 56 8 assess assess VERB dpc-6646 56 9 drug drug NOUN dpc-6646 56 10 survival survival NOUN dpc-6646 56 11 over over ADP dpc-6646 56 12 time time NOUN dpc-6646 56 13 . . PUNCT dpc-6646 57 1 factors factor NOUN dpc-6646 57 2 associated associate VERB dpc-6646 57 3 with with ADP dpc-6646 57 4 treatment treatment NOUN dpc-6646 57 5 discontinuation discontinuation NOUN dpc-6646 57 6 were be AUX dpc-6646 57 7 evaluated evaluate VERB dpc-6646 57 8 using use VERB dpc-6646 57 9 multivariate multivariate NOUN dpc-6646 57 10 cox cox PROPN dpc-6646 57 11 proportional proportional ADJ dpc-6646 57 12 hazards hazard NOUN dpc-6646 57 13 models model NOUN dpc-6646 57 14 , , PUNCT dpc-6646 57 15 including include VERB dpc-6646 57 16 age age NOUN dpc-6646 57 17 , , PUNCT dpc-6646 57 18 sex sex NOUN dpc-6646 57 19 , , PUNCT dpc-6646 57 20 bmi bmi NOUN dpc-6646 57 21 , , PUNCT dpc-6646 57 22 pasi pasi NOUN dpc-6646 57 23 , , PUNCT dpc-6646 57 24 bio bio NOUN dpc-6646 57 25 - - NOUN dpc-6646 57 26 experience experience NOUN dpc-6646 57 27 , , PUNCT dpc-6646 57 28 prior prior ADJ dpc-6646 57 29 biologics biologic NOUN dpc-6646 57 30 exposure exposure NOUN dpc-6646 57 31 ( ( PUNCT dpc-6646 57 32 overall overall ADJ dpc-6646 57 33 and and CCONJ dpc-6646 57 34 by by ADP dpc-6646 57 35 drug drug NOUN dpc-6646 57 36 class class NOUN dpc-6646 57 37 ) ) PUNCT dpc-6646 57 38 , , PUNCT dpc-6646 57 39 and and CCONJ dpc-6646 57 40 site site NOUN dpc-6646 57 41 - - PUNCT dpc-6646 57 42 specific specific ADJ dpc-6646 57 43 involvement involvement NOUN dpc-6646 57 44 . . PUNCT dpc-6646 58 1 a a DET dpc-6646 58 2 p p NOUN dpc-6646 58 3 - - PUNCT dpc-6646 58 4 value value NOUN dpc-6646 58 5 of of ADP dpc-6646 58 6 < < NOUN dpc-6646 58 7 0.05 0.05 NUM dpc-6646 58 8 was be AUX dpc-6646 58 9 considered consider VERB dpc-6646 58 10 statistically statistically ADV dpc-6646 58 11 significant significant ADJ dpc-6646 58 12 . . PUNCT dpc-6646 59 1 analyses analysis NOUN dpc-6646 59 2 were be AUX dpc-6646 59 3 performed perform VERB dpc-6646 59 4 using use VERB dpc-6646 59 5 r r NOUN dpc-6646 59 6 ( ( PUNCT dpc-6646 59 7 version version NOUN dpc-6646 59 8 4.0.5 4.0.5 NUM dpc-6646 59 9 ) ) PUNCT dpc-6646 59 10 and and CCONJ dpc-6646 59 11 graphpad graphpad NOUN dpc-6646 59 12 prism prism NOUN dpc-6646 59 13 4.0 4.0 NUM dpc-6646 59 14 ( ( PUNCT dpc-6646 59 15 graphpad graphpad PROPN dpc-6646 59 16 software software PROPN dpc-6646 59 17 inc inc PROPN dpc-6646 59 18 . . PROPN dpc-6646 59 19 , , PUNCT dpc-6646 59 20 la la PROPN dpc-6646 59 21 jolla jolla PROPN dpc-6646 59 22 , , PUNCT dpc-6646 59 23 ca ca PROPN dpc-6646 59 24 , , PUNCT dpc-6646 59 25 usa usa PROPN dpc-6646 59 26 ) ) PUNCT dpc-6646 59 27 . . PUNCT dpc-6646 60 1 ethics ethic NOUN dpc-6646 60 2 statement statement VERB dpc-6646 60 3 the the DET dpc-6646 60 4 study study NOUN dpc-6646 60 5 was be AUX dpc-6646 60 6 conducted conduct VERB dpc-6646 60 7 in in ADP dpc-6646 60 8 accordance accordance NOUN dpc-6646 60 9 with with ADP dpc-6646 60 10 the the DET dpc-6646 60 11 principles principle NOUN dpc-6646 60 12 outlined outline VERB dpc-6646 60 13 in in ADP dpc-6646 60 14 the the DET dpc-6646 60 15 declaration declaration NOUN dpc-6646 60 16 of of ADP dpc-6646 60 17 helsinki helsinki PROPN dpc-6646 60 18 . . PUNCT dpc-6646 61 1 the the DET dpc-6646 61 2 ethics ethic NOUN dpc-6646 61 3 committees committee NOUN dpc-6646 61 4 of of ADP dpc-6646 61 5 the the DET dpc-6646 61 6 participating participate VERB dpc-6646 61 7 centers center NOUN dpc-6646 61 8 waived waive VERB dpc-6646 61 9 the the DET dpc-6646 61 10 requirement requirement NOUN dpc-6646 61 11 for for ADP dpc-6646 61 12 formal formal ADJ dpc-6646 61 13 approval approval NOUN dpc-6646 61 14 and and CCONJ dpc-6646 61 15 informed informed ADJ dpc-6646 61 16 consent consent NOUN dpc-6646 61 17 as as SCONJ dpc-6646 61 18 the the DET dpc-6646 61 19 study study NOUN dpc-6646 61 20 was be AUX dpc-6646 61 21 non non ADJ dpc-6646 61 22 - - ADJ dpc-6646 61 23 interventional interventional ADJ dpc-6646 61 24 and and CCONJ dpc-6646 61 25 based base VERB dpc-6646 61 26 on on ADP dpc-6646 61 27 retrospective retrospective ADJ dpc-6646 61 28 , , PUNCT dpc-6646 61 29 anonymized anonymize VERB dpc-6646 61 30 data datum NOUN dpc-6646 61 31 collection collection NOUN dpc-6646 61 32 . . PUNCT dpc-6646 62 1 results result VERB dpc-6646 62 2 patients patient NOUN dpc-6646 62 3 ’ ' PUNCT dpc-6646 62 4 baseline baseline PROPN dpc-6646 62 5 characteristics characteristic NOUN dpc-6646 62 6 a a DET dpc-6646 62 7 total total NOUN dpc-6646 62 8 of of ADP dpc-6646 62 9 247 247 NUM dpc-6646 62 10 patients patient NOUN dpc-6646 62 11 with with ADP dpc-6646 62 12 moderate moderate ADJ dpc-6646 62 13 - - PUNCT dpc-6646 62 14 to to ADP dpc-6646 62 15 - - PUNCT dpc-6646 62 16 severe severe ADJ dpc-6646 62 17 plaque plaque NOUN dpc-6646 62 18 psoriasis psoriasis NOUN dpc-6646 62 19 who who PRON dpc-6646 62 20 received receive VERB dpc-6646 62 21 guselkumab guselkumab NOUN dpc-6646 62 22 treatment treatment NOUN dpc-6646 62 23 were be AUX dpc-6646 62 24 included include VERB dpc-6646 62 25 in in ADP dpc-6646 62 26 the the DET dpc-6646 62 27 analysis analysis NOUN dpc-6646 62 28 . . PUNCT dpc-6646 63 1 the the DET dpc-6646 63 2 mean mean ADJ dpc-6646 63 3 age age NOUN dpc-6646 63 4 was be AUX dpc-6646 63 5 53.2 53.2 NUM dpc-6646 63 6 years year NOUN dpc-6646 63 7 ( ( PUNCT dpc-6646 63 8 sd sd NOUN dpc-6646 63 9 : : PUNCT dpc-6646 63 10 13.9 13.9 NUM dpc-6646 63 11 ) ) PUNCT dpc-6646 63 12 , , PUNCT dpc-6646 63 13 with with ADP dpc-6646 63 14 a a DET dpc-6646 63 15 slight slight ADJ dpc-6646 63 16 predominance predominance NOUN dpc-6646 63 17 of of ADP dpc-6646 63 18 males male NOUN dpc-6646 63 19 ( ( PUNCT dpc-6646 63 20 57.5 57.5 NUM dpc-6646 63 21 % % NOUN dpc-6646 63 22 ) ) PUNCT dpc-6646 63 23 . . PUNCT dpc-6646 64 1 the the DET dpc-6646 64 2 average average ADJ dpc-6646 64 3 weight weight NOUN dpc-6646 64 4 was be AUX dpc-6646 64 5 78.8 78.8 NUM dpc-6646 64 6 kg kg NOUN dpc-6646 64 7 ( ( PUNCT dpc-6646 64 8 sd sd NOUN dpc-6646 64 9 : : PUNCT dpc-6646 64 10 15.2 15.2 NUM dpc-6646 64 11 ) ) PUNCT dpc-6646 64 12 , , PUNCT dpc-6646 64 13 and and CCONJ dpc-6646 64 14 mean mean VERB dpc-6646 64 15 bmi bmi PROPN dpc-6646 64 16 was be AUX dpc-6646 64 17 27.2 27.2 NUM dpc-6646 64 18 kg kg NOUN dpc-6646 64 19 / / SYM dpc-6646 64 20 m² m² PROPN dpc-6646 64 21 ( ( PUNCT dpc-6646 64 22 sd sd NOUN dpc-6646 64 23 : : PUNCT dpc-6646 64 24 4.9 4.9 NUM dpc-6646 64 25 ) ) PUNCT dpc-6646 64 26 . . PUNCT dpc-6646 65 1 according accord VERB dpc-6646 65 2 to to ADP dpc-6646 65 3 bmi bmi PROPN dpc-6646 65 4 classification classification NOUN dpc-6646 65 5 , , PUNCT dpc-6646 65 6 1.2 1.2 NUM dpc-6646 65 7 % % NOUN dpc-6646 65 8 of of ADP dpc-6646 65 9 patients patient NOUN dpc-6646 65 10 were be AUX dpc-6646 65 11 underweight underweight ADJ dpc-6646 65 12 , , PUNCT dpc-6646 65 13 32.8 32.8 NUM dpc-6646 65 14 % % NOUN dpc-6646 65 15 had have VERB dpc-6646 65 16 normal normal ADJ dpc-6646 65 17 weight weight NOUN dpc-6646 65 18 , , PUNCT dpc-6646 65 19 39.3 39.3 NUM dpc-6646 65 20 % % NOUN dpc-6646 65 21 were be AUX dpc-6646 65 22 overweight overweight ADJ dpc-6646 65 23 , , PUNCT dpc-6646 65 24 and and CCONJ dpc-6646 65 25 23.1 23.1 NUM dpc-6646 65 26 % % NOUN dpc-6646 65 27 were be AUX dpc-6646 65 28 classified classify VERB dpc-6646 65 29 as as ADP dpc-6646 65 30 obese obese ADJ dpc-6646 65 31 . . PUNCT dpc-6646 66 1 the the DET dpc-6646 66 2 mean mean PROPN dpc-6646 66 3 pasi pasi PROPN dpc-6646 66 4 index index NOUN dpc-6646 66 5 was be AUX dpc-6646 66 6 14.51 14.51 NUM dpc-6646 66 7 ( ( PUNCT dpc-6646 66 8 sd sd NOUN dpc-6646 66 9 : : PUNCT dpc-6646 66 10 8.76 8.76 NUM dpc-6646 66 11 ) ) PUNCT dpc-6646 66 12 . . PUNCT dpc-6646 67 1 approximately approximately ADV dpc-6646 67 2 half half NOUN dpc-6646 67 3 of of ADP dpc-6646 67 4 the the DET dpc-6646 67 5 cohort cohort NOUN dpc-6646 67 6 ( ( PUNCT dpc-6646 67 7 53 53 NUM dpc-6646 67 8 % % NOUN dpc-6646 67 9 ) ) PUNCT dpc-6646 67 10 had have VERB dpc-6646 67 11 prior prior ADJ dpc-6646 67 12 exposure exposure NOUN dpc-6646 67 13 to to ADP dpc-6646 67 14 biologic biologic NOUN dpc-6646 67 15 therapies therapy NOUN dpc-6646 67 16 . . PUNCT dpc-6646 68 1 other other ADJ dpc-6646 68 2 baseline baseline ADJ dpc-6646 68 3 characteristics characteristic NOUN dpc-6646 68 4 of of ADP dpc-6646 68 5 the the DET dpc-6646 68 6 study study NOUN dpc-6646 68 7 population population NOUN dpc-6646 68 8 are be AUX dpc-6646 68 9 detailed detail VERB dpc-6646 68 10 in in ADP dpc-6646 68 11 table table NOUN dpc-6646 68 12 1 1 NUM dpc-6646 68 13 . . PUNCT dpc-6646 69 1 overall overall ADJ dpc-6646 69 2 drug drug NOUN dpc-6646 69 3 survival survival NOUN dpc-6646 69 4 a a DET dpc-6646 69 5 total total NOUN dpc-6646 69 6 of of ADP dpc-6646 69 7 247 247 NUM dpc-6646 69 8 patients patient NOUN dpc-6646 69 9 treated treat VERB dpc-6646 69 10 with with ADP dpc-6646 69 11 guselkumab guselkumab NOUN dpc-6646 69 12 were be AUX dpc-6646 69 13 included include VERB dpc-6646 69 14 in in ADP dpc-6646 69 15 the the DET dpc-6646 69 16 persistence persistence NOUN dpc-6646 69 17 analysis analysis NOUN dpc-6646 69 18 . . PUNCT dpc-6646 70 1 as as SCONJ dpc-6646 70 2 shown show VERB dpc-6646 70 3 in in ADP dpc-6646 70 4 figure figure NOUN dpc-6646 70 5 1 1 NUM dpc-6646 70 6 , , PUNCT dpc-6646 70 7 at at ADP dpc-6646 70 8 three three NUM dpc-6646 70 9 years year NOUN dpc-6646 70 10 , , PUNCT dpc-6646 70 11 198 198 NUM dpc-6646 70 12 of of ADP dpc-6646 70 13 the the DET dpc-6646 70 14 247 247 NUM dpc-6646 70 15 patients patient NOUN dpc-6646 70 16 ( ( PUNCT dpc-6646 70 17 80.2 80.2 NUM dpc-6646 70 18 % % NOUN dpc-6646 70 19 ) ) PUNCT dpc-6646 70 20 were be AUX dpc-6646 70 21 still still ADV dpc-6646 70 22 receiving receive VERB dpc-6646 70 23 treatment treatment NOUN dpc-6646 70 24 , , PUNCT dpc-6646 70 25 while while SCONJ dpc-6646 70 26 49 49 NUM dpc-6646 70 27 patients patient NOUN dpc-6646 70 28 ( ( PUNCT dpc-6646 70 29 19.8 19.8 NUM dpc-6646 70 30 % % NOUN dpc-6646 70 31 ) ) PUNCT dpc-6646 70 32 had have AUX dpc-6646 70 33 discontinued discontinue VERB dpc-6646 70 34 . . PUNCT dpc-6646 71 1 at at ADP dpc-6646 71 2 five five NUM dpc-6646 71 3 years year NOUN dpc-6646 71 4 , , PUNCT dpc-6646 71 5 67 67 NUM dpc-6646 71 6 patients patient NOUN dpc-6646 71 7 ( ( PUNCT dpc-6646 71 8 27.1 27.1 NUM dpc-6646 71 9 % % NOUN dpc-6646 71 10 ) ) PUNCT dpc-6646 71 11 had have AUX dpc-6646 71 12 discontinued discontinue VERB dpc-6646 71 13 treatment treatment NOUN dpc-6646 71 14 for for ADP dpc-6646 71 15 various various ADJ dpc-6646 71 16 reasons reason NOUN dpc-6646 71 17 , , PUNCT dpc-6646 71 18 while while SCONJ dpc-6646 71 19 180 180 NUM dpc-6646 71 20 patients patient NOUN dpc-6646 71 21 ( ( PUNCT dpc-6646 71 22 72.8 72.8 NUM dpc-6646 71 23 % % NOUN dpc-6646 71 24 ) ) PUNCT dpc-6646 71 25 continued continue VERB dpc-6646 71 26 the the DET dpc-6646 71 27 therapy therapy NOUN dpc-6646 71 28 . . PUNCT dpc-6646 72 1 drug drug NOUN dpc-6646 72 2 survival survival NOUN dpc-6646 72 3 based base VERB dpc-6646 72 4 on on ADP dpc-6646 72 5 bmi bmi NOUN dpc-6646 72 6 treatment treatment NOUN dpc-6646 72 7 persistence persistence NOUN dpc-6646 72 8 with with ADP dpc-6646 72 9 guselkumab guselkumab NOUN dpc-6646 72 10 was be AUX dpc-6646 72 11 analyzed analyze VERB dpc-6646 72 12 according accord VERB dpc-6646 72 13 to to ADP dpc-6646 72 14 baseline baseline NOUN dpc-6646 72 15 weight weight NOUN dpc-6646 72 16 , , PUNCT dpc-6646 72 17 stratifying stratify VERB dpc-6646 72 18 patients patient NOUN dpc-6646 72 19 into into ADP dpc-6646 72 20 two two NUM dpc-6646 72 21 groups group NOUN dpc-6646 72 22 : : PUNCT dpc-6646 72 23 ≤90 ≤90 PROPN dpc-6646 72 24 kg kg INTJ dpc-6646 72 25 and and CCONJ dpc-6646 72 26 > > X dpc-6646 72 27 90 90 NUM dpc-6646 72 28 kg kg NOUN dpc-6646 72 29 , , PUNCT dpc-6646 72 30 as as SCONJ dpc-6646 72 31 shown show VERB dpc-6646 72 32 in in ADP dpc-6646 72 33 figure figure NOUN dpc-6646 72 34 2a 2a NUM dpc-6646 72 35 . . PUNCT dpc-6646 73 1 at at ADP dpc-6646 73 2 12 12 NUM dpc-6646 73 3 months month NOUN dpc-6646 73 4 , , PUNCT dpc-6646 73 5 the the DET dpc-6646 73 6 persistence persistence NOUN dpc-6646 73 7 rates rate NOUN dpc-6646 73 8 were be AUX dpc-6646 73 9 97.0 97.0 NUM dpc-6646 73 10 % % NOUN dpc-6646 73 11 for for ADP dpc-6646 73 12 patients patient NOUN dpc-6646 73 13 weighing weigh VERB dpc-6646 73 14 ≤90 ≤90 PROPN dpc-6646 73 15 kg kg NOUN dpc-6646 73 16 and and CCONJ dpc-6646 73 17 95.0 95.0 NUM dpc-6646 73 18 % % NOUN dpc-6646 73 19 for for ADP dpc-6646 73 20 those those PRON dpc-6646 73 21 > > SYM dpc-6646 73 22 90 90 NUM dpc-6646 73 23 kg kg NOUN dpc-6646 73 24 ( ( PUNCT dpc-6646 73 25 p=0.556 p=0.556 NOUN dpc-6646 73 26 ) ) PUNCT dpc-6646 73 27 . . PUNCT dpc-6646 74 1 at at ADP dpc-6646 74 2 24 24 NUM dpc-6646 74 3 months month NOUN dpc-6646 74 4 , , PUNCT dpc-6646 74 5 persistence persistence NOUN dpc-6646 74 6 declined decline VERB dpc-6646 74 7 slightly slightly ADV dpc-6646 74 8 to to ADP dpc-6646 74 9 92.0 92.0 NUM dpc-6646 74 10 % % NOUN dpc-6646 74 11 and and CCONJ dpc-6646 74 12 89.0 89.0 NUM dpc-6646 74 13 % % NOUN dpc-6646 74 14 , , PUNCT dpc-6646 74 15 respectively respectively ADV dpc-6646 74 16 ( ( PUNCT dpc-6646 74 17 p=0.244 p=0.244 NOUN dpc-6646 74 18 ) ) PUNCT dpc-6646 74 19 . . PUNCT dpc-6646 75 1 at at ADP dpc-6646 75 2 36 36 NUM dpc-6646 75 3 months month NOUN dpc-6646 75 4 , , PUNCT dpc-6646 75 5 the the DET dpc-6646 75 6 rates rate NOUN dpc-6646 75 7 were be AUX dpc-6646 75 8 88.0 88.0 NUM dpc-6646 75 9 % % NOUN dpc-6646 75 10 and and CCONJ dpc-6646 75 11 82.0 82.0 NUM dpc-6646 75 12 % % NOUN dpc-6646 75 13 ( ( PUNCT dpc-6646 75 14 p=0.656 p=0.656 NOUN dpc-6646 75 15 ) ) PUNCT dpc-6646 75 16 , , PUNCT dpc-6646 75 17 followed follow VERB dpc-6646 75 18 by by ADP dpc-6646 75 19 84.0 84.0 NUM dpc-6646 75 20 % % NOUN dpc-6646 75 21 and and CCONJ dpc-6646 75 22 75.0 75.0 NUM dpc-6646 75 23 % % NOUN dpc-6646 75 24 at at ADP dpc-6646 75 25 48 48 NUM dpc-6646 75 26 months month NOUN dpc-6646 75 27 ( ( PUNCT dpc-6646 75 28 p=0.999 p=0.999 NOUN dpc-6646 75 29 ) ) PUNCT dpc-6646 75 30 and and CCONJ dpc-6646 75 31 80.0 80.0 NUM dpc-6646 75 32 % % NOUN dpc-6646 75 33 and and CCONJ dpc-6646 75 34 70.0 70.0 NUM dpc-6646 75 35 % % NOUN dpc-6646 75 36 at at ADP dpc-6646 75 37 60 60 NUM dpc-6646 75 38 months month NOUN dpc-6646 75 39 ( ( PUNCT dpc-6646 75 40 p=0.998 p=0.998 NOUN dpc-6646 75 41 ) ) PUNCT dpc-6646 75 42 . . PUNCT dpc-6646 76 1 no no DET dpc-6646 76 2 statistically statistically ADV dpc-6646 76 3 significant significant ADJ dpc-6646 76 4 difference difference NOUN dpc-6646 76 5 was be AUX dpc-6646 76 6 observed observe VERB dpc-6646 76 7 . . PUNCT dpc-6646 77 1 treatment treatment NOUN dpc-6646 77 2 persistence persistence NOUN dpc-6646 77 3 with with ADP dpc-6646 77 4 guselkumab guselkumab NOUN dpc-6646 77 5 was be AUX dpc-6646 77 6 also also ADV dpc-6646 77 7 evaluated evaluate VERB dpc-6646 77 8 according accord VERB dpc-6646 77 9 to to ADP dpc-6646 77 10 baseline baseline PROPN dpc-6646 77 11 body body NOUN dpc-6646 77 12 mass mass NOUN dpc-6646 77 13 index index NOUN dpc-6646 77 14 ( ( PUNCT dpc-6646 77 15 bmi bmi PROPN dpc-6646 77 16 ) ) PUNCT dpc-6646 77 17 , , PUNCT dpc-6646 77 18 as as SCONJ dpc-6646 77 19 shown show VERB dpc-6646 77 20 in in ADP dpc-6646 77 21 figure figure NOUN dpc-6646 77 22 2b 2b NOUN dpc-6646 77 23 . . PUNCT dpc-6646 78 1 patients patient NOUN dpc-6646 78 2 were be AUX dpc-6646 78 3 categorized categorize VERB dpc-6646 78 4 into into ADP dpc-6646 78 5 three three NUM dpc-6646 78 6 groups group NOUN dpc-6646 78 7 : : PUNCT dpc-6646 78 8 bmi bmi PROPN dpc-6646 78 9 < < X dpc-6646 78 10 20 20 NUM dpc-6646 78 11 , , PUNCT dpc-6646 78 12 bmi bmi NOUN dpc-6646 78 13 21–30 21–30 NUM dpc-6646 78 14 , , PUNCT dpc-6646 78 15 and and CCONJ dpc-6646 78 16 bmi bmi X dpc-6646 78 17 > > PROPN dpc-6646 78 18 30 30 NUM dpc-6646 78 19 . . PUNCT dpc-6646 79 1 at at ADP dpc-6646 79 2 12 12 NUM dpc-6646 79 3 months month NOUN dpc-6646 79 4 , , PUNCT dpc-6646 79 5 persistence persistence NOUN dpc-6646 79 6 rates rate NOUN dpc-6646 79 7 were be AUX dpc-6646 79 8 95.0 95.0 NUM dpc-6646 79 9 % % NOUN dpc-6646 79 10 in in ADP dpc-6646 79 11 the the DET dpc-6646 79 12 bmi bmi NOUN dpc-6646 79 13 < < X dpc-6646 79 14 20 20 NUM dpc-6646 79 15 group group NOUN dpc-6646 79 16 , , PUNCT dpc-6646 79 17 96.0 96.0 NUM dpc-6646 79 18 % % NOUN dpc-6646 79 19 in in ADP dpc-6646 79 20 the the DET dpc-6646 79 21 bmi bmi NOUN dpc-6646 79 22 21–30 21–30 NUM dpc-6646 79 23 group group NOUN dpc-6646 79 24 , , PUNCT dpc-6646 79 25 and and CCONJ dpc-6646 79 26 94.0 94.0 NUM dpc-6646 79 27 % % NOUN dpc-6646 79 28 in in ADP dpc-6646 79 29 the the DET dpc-6646 79 30 bmi bmi NOUN dpc-6646 79 31 > > SYM dpc-6646 79 32 30 30 NUM dpc-6646 79 33 group group NOUN dpc-6646 79 34 . . PUNCT dpc-6646 80 1 the the DET dpc-6646 80 2 differences difference NOUN dpc-6646 80 3 between between ADP dpc-6646 80 4 groups group NOUN dpc-6646 80 5 at at ADP dpc-6646 80 6 this this DET dpc-6646 80 7 time time NOUN dpc-6646 80 8 point point NOUN dpc-6646 80 9 were be AUX dpc-6646 80 10 not not PART dpc-6646 80 11 statistically statistically ADV dpc-6646 80 12 significant significant ADJ dpc-6646 80 13 ( ( PUNCT dpc-6646 80 14 bmi bmi NOUN dpc-6646 80 15 21–30 21–30 NUM dpc-6646 80 16 vs vs ADP dpc-6646 80 17 < < X dpc-6646 80 18 20 20 NUM dpc-6646 80 19 : : PUNCT dpc-6646 80 20 p=0.098 p=0.098 NOUN dpc-6646 80 21 ; ; PUNCT dpc-6646 80 22 bmi bmi X dpc-6646 80 23 > > X dpc-6646 80 24 30 30 NUM dpc-6646 80 25 vs vs ADP dpc-6646 80 26 21–30 21–30 NUM dpc-6646 80 27 : : PUNCT dpc-6646 80 28 p=0.098 p=0.098 NOUN dpc-6646 80 29 ) ) PUNCT dpc-6646 80 30 . . PUNCT dpc-6646 81 1 over over ADP dpc-6646 81 2 time time NOUN dpc-6646 81 3 , , PUNCT dpc-6646 81 4 persistence persistence NOUN dpc-6646 81 5 rates rate NOUN dpc-6646 81 6 declined decline VERB dpc-6646 81 7 gradually gradually ADV dpc-6646 81 8 across across ADP dpc-6646 81 9 all all DET dpc-6646 81 10 bmi bmi NOUN dpc-6646 81 11 categories category NOUN dpc-6646 81 12 . . PUNCT dpc-6646 82 1 at at ADP dpc-6646 82 2 24 24 NUM dpc-6646 82 3 months month NOUN dpc-6646 82 4 , , PUNCT dpc-6646 82 5 persistence persistence NOUN dpc-6646 82 6 was be AUX dpc-6646 82 7 91.0 91.0 NUM dpc-6646 82 8 % % NOUN dpc-6646 82 9 in in ADP dpc-6646 82 10 both both CCONJ dpc-6646 82 11 the the DET dpc-6646 82 12 < < NOUN dpc-6646 82 13 20 20 NUM dpc-6646 82 14 and and CCONJ dpc-6646 82 15 21–30 21–30 NUM dpc-6646 82 16 bmi bmi NOUN dpc-6646 82 17 groups group NOUN dpc-6646 82 18 , , PUNCT dpc-6646 82 19 and and CCONJ dpc-6646 82 20 87.0 87.0 NUM dpc-6646 82 21 % % NOUN dpc-6646 82 22 in in ADP dpc-6646 82 23 the the DET dpc-6646 82 24 > > SYM dpc-6646 82 25 30 30 NUM dpc-6646 82 26 group group NOUN dpc-6646 82 27 . . PUNCT dpc-6646 83 1 at at ADP dpc-6646 83 2 36 36 NUM dpc-6646 83 3 months month NOUN dpc-6646 83 4 , , PUNCT dpc-6646 83 5 persistence persistence NOUN dpc-6646 83 6 reached reach VERB dpc-6646 83 7 85.0 85.0 NUM dpc-6646 83 8 % % NOUN dpc-6646 83 9 , , PUNCT dpc-6646 83 10 87.0 87.0 NUM dpc-6646 83 11 % % NOUN dpc-6646 83 12 , , PUNCT dpc-6646 83 13 and and CCONJ dpc-6646 83 14 80.0 80.0 NUM dpc-6646 83 15 % % NOUN dpc-6646 83 16 , , PUNCT dpc-6646 83 17 respectively respectively ADV dpc-6646 83 18 , , PUNCT dpc-6646 83 19 with with ADP dpc-6646 83 20 no no DET dpc-6646 83 21 statistically statistically ADV dpc-6646 83 22 significant significant ADJ dpc-6646 83 23 difference difference NOUN dpc-6646 83 24 observed observe VERB dpc-6646 83 25 ( ( PUNCT dpc-6646 83 26 e.g. e.g. ADV dpc-6646 83 27 , , PUNCT dpc-6646 83 28 p=1.000 p=1.000 PRON dpc-6646 83 29 for for ADP dpc-6646 83 30 < < X dpc-6646 83 31 20 20 NUM dpc-6646 83 32 vs vs ADP dpc-6646 83 33 21–30 21–30 NUM dpc-6646 83 34 ; ; PUNCT dpc-6646 83 35 p=0.9731 p=0.9731 NOUN dpc-6646 83 36 for for ADP dpc-6646 83 37 > > PROPN dpc-6646 83 38 30 30 NUM dpc-6646 83 39 vs vs ADP dpc-6646 83 40 21–30 21–30 NUM dpc-6646 83 41 ) ) PUNCT dpc-6646 83 42 . . PUNCT dpc-6646 84 1 4 4 NUM dpc-6646 84 2 original original ADJ dpc-6646 84 3 article article NOUN dpc-6646 84 4 | | ADV dpc-6646 84 5 dermatol dermatol ADJ dpc-6646 84 6 pract pract NOUN dpc-6646 84 7 concept concept NOUN dpc-6646 84 8 . . PUNCT dpc-6646 85 1 2025;15(4):6646 2025;15(4):6646 NUM dpc-6646 85 2 figure figure NOUN dpc-6646 85 3 1 1 NUM dpc-6646 85 4 . . PUNCT dpc-6646 86 1 kaplan kaplan PROPN dpc-6646 86 2 - - PUNCT dpc-6646 86 3 meier meier PROPN dpc-6646 86 4 curve curve NOUN dpc-6646 86 5 showing show VERB dpc-6646 86 6 treatment treatment NOUN dpc-6646 86 7 persistence persistence NOUN dpc-6646 86 8 with with ADP dpc-6646 86 9 guselkumab guselkumab NOUN dpc-6646 86 10 in in ADP dpc-6646 86 11 the the DET dpc-6646 86 12 overall overall ADJ dpc-6646 86 13 study study NOUN dpc-6646 86 14 population population NOUN dpc-6646 86 15 ( ( PUNCT dpc-6646 86 16 n=247 n=247 PROPN dpc-6646 86 17 ) ) PUNCT dpc-6646 86 18 . . PUNCT dpc-6646 87 1 the the DET dpc-6646 87 2 analysis analysis NOUN dpc-6646 87 3 includes include VERB dpc-6646 87 4 all all DET dpc-6646 87 5 reasons reason NOUN dpc-6646 87 6 for for ADP dpc-6646 87 7 discontinuation discontinuation NOUN dpc-6646 87 8 , , PUNCT dpc-6646 87 9 both both CCONJ dpc-6646 87 10 clinical clinical ADJ dpc-6646 87 11 and and CCONJ dpc-6646 87 12 non non ADJ dpc-6646 87 13 - - ADJ dpc-6646 87 14 clinical clinical ADJ dpc-6646 87 15 . . PUNCT dpc-6646 88 1 at at ADP dpc-6646 88 2 three three NUM dpc-6646 88 3 years year NOUN dpc-6646 88 4 , , PUNCT dpc-6646 88 5 198 198 NUM dpc-6646 88 6 patients patient NOUN dpc-6646 88 7 ( ( PUNCT dpc-6646 88 8 80.2 80.2 NUM dpc-6646 88 9 % % NOUN dpc-6646 88 10 ) ) PUNCT dpc-6646 88 11 remained remain VERB dpc-6646 88 12 on on ADP dpc-6646 88 13 treatment treatment NOUN dpc-6646 88 14 ; ; PUNCT dpc-6646 88 15 at at ADP dpc-6646 88 16 five five NUM dpc-6646 88 17 years year NOUN dpc-6646 88 18 , , PUNCT dpc-6646 88 19 180 180 NUM dpc-6646 88 20 patients patient NOUN dpc-6646 88 21 ( ( PUNCT dpc-6646 88 22 72.8 72.8 NUM dpc-6646 88 23 % % NOUN dpc-6646 88 24 ) ) PUNCT dpc-6646 88 25 continued continued ADJ dpc-6646 88 26 therapy therapy NOUN dpc-6646 88 27 , , PUNCT dpc-6646 88 28 while while SCONJ dpc-6646 88 29 67 67 NUM dpc-6646 88 30 patients patient NOUN dpc-6646 88 31 ( ( PUNCT dpc-6646 88 32 27.1 27.1 NUM dpc-6646 88 33 % % NOUN dpc-6646 88 34 ) ) PUNCT dpc-6646 88 35 had have AUX dpc-6646 88 36 discontinued discontinue VERB dpc-6646 88 37 . . PUNCT dpc-6646 89 1 table table NOUN dpc-6646 89 2 1 1 NUM dpc-6646 89 3 . . PUNCT dpc-6646 90 1 patients patient NOUN dpc-6646 90 2 ’ ' PUNCT dpc-6646 90 3 baseline baseline PROPN dpc-6646 90 4 characteristics characteristic NOUN dpc-6646 90 5 . . PUNCT dpc-6646 91 1 characteristic characteristic ADJ dpc-6646 91 2 count count NOUN dpc-6646 91 3 % % NOUN dpc-6646 91 4 mean mean NOUN dpc-6646 91 5 ± ± NOUN dpc-6646 91 6 sd sd ADP dpc-6646 91 7 age age NOUN dpc-6646 91 8 ( ( PUNCT dpc-6646 91 9 years year NOUN dpc-6646 91 10 ) ) PUNCT dpc-6646 91 11         SPACE dpc-6646 91 12 53.2 53.2 NUM dpc-6646 91 13 ± ± NUM dpc-6646 91 14 13.9 13.9 NUM dpc-6646 91 15 sex sex NOUN dpc-6646 91 16 : : PUNCT dpc-6646 91 17 male male NOUN dpc-6646 91 18 142.0 142.0 NUM dpc-6646 91 19 57.5 57.5 NUM dpc-6646 91 20     SPACE dpc-6646 91 21 weight weight NOUN dpc-6646 91 22 ( ( PUNCT dpc-6646 91 23 kg kg NOUN dpc-6646 91 24 ) ) PUNCT dpc-6646 91 25         SPACE dpc-6646 91 26 78.8 78.8 NUM dpc-6646 91 27 ± ± NUM dpc-6646 91 28 15.2 15.2 NUM dpc-6646 91 29 bmi bmi NOUN dpc-6646 91 30 ( ( PUNCT dpc-6646 91 31 kg kg NOUN dpc-6646 91 32 / / SYM dpc-6646 91 33 m² m² PROPN dpc-6646 91 34 ) ) PUNCT dpc-6646 91 35         SPACE dpc-6646 91 36 27.2 27.2 NUM dpc-6646 91 37 ± ± NUM dpc-6646 91 38 4.9 4.9 NUM dpc-6646 91 39 bmi bmi NOUN dpc-6646 91 40 underweight underweight NOUN dpc-6646 91 41 3.0 3.0 NUM dpc-6646 91 42 1.2 1.2 NUM dpc-6646 91 43     SPACE dpc-6646 91 44 bmi bmi VERB dpc-6646 91 45 normal normal ADJ dpc-6646 91 46 weight weight NOUN dpc-6646 91 47 81.0 81.0 NUM dpc-6646 91 48 32.8 32.8 NUM dpc-6646 91 49     SPACE dpc-6646 91 50 bmi bmi NOUN dpc-6646 91 51 overweight overweight VERB dpc-6646 91 52 97.0 97.0 NUM dpc-6646 91 53 39.3 39.3 NUM dpc-6646 91 54     SPACE dpc-6646 91 55 bmi bmi NOUN dpc-6646 91 56 obese obese ADP dpc-6646 91 57 57.0 57.0 NUM dpc-6646 91 58 23.1 23.1 NUM dpc-6646 91 59     SPACE dpc-6646 91 60 pasi pasi NOUN dpc-6646 91 61     SPACE dpc-6646 91 62 14.51 14.51 NUM dpc-6646 91 63 ± ± NUM dpc-6646 91 64 8.76 8.76 NUM dpc-6646 91 65 bio bio NOUN dpc-6646 91 66 - - ADJ dpc-6646 91 67 experienced experienced ADJ dpc-6646 91 68 : : PUNCT dpc-6646 91 69 yes yes INTJ dpc-6646 91 70 131.0 131.0 NUM dpc-6646 91 71 53.0 53.0 NUM dpc-6646 91 72     SPACE dpc-6646 91 73 cardiometabolic cardiometabolic NOUN dpc-6646 91 74 comorbidities comorbiditie VERB dpc-6646 91 75 76.0 76.0 NUM dpc-6646 91 76 30.8 30.8 NUM dpc-6646 91 77     SPACE dpc-6646 91 78 gastrointestinal gastrointestinal ADJ dpc-6646 91 79 comorbidities comorbiditie NOUN dpc-6646 91 80 : : PUNCT dpc-6646 91 81 4.0 4.0 NUM dpc-6646 91 82 1.6 1.6 NUM dpc-6646 91 83     SPACE dpc-6646 91 84 nail nail NOUN dpc-6646 91 85 involvement involvement NOUN dpc-6646 91 86 : : PUNCT dpc-6646 91 87 70.0 70.0 NUM dpc-6646 91 88 28.3 28.3 NUM dpc-6646 91 89     SPACE dpc-6646 91 90 scalp scalp NOUN dpc-6646 91 91 involvement involvement NOUN dpc-6646 91 92 : : PUNCT dpc-6646 91 93 144.0 144.0 NUM dpc-6646 91 94 58.3 58.3 NUM dpc-6646 91 95     SPACE dpc-6646 91 96 genital genital ADJ dpc-6646 91 97 involvement involvement NOUN dpc-6646 91 98 : : PUNCT dpc-6646 91 99 66.0 66.0 NUM dpc-6646 91 100 26.7 26.7 NUM dpc-6646 91 101     SPACE dpc-6646 91 102 pretibial pretibial ADJ dpc-6646 91 103 involvement involvement NOUN dpc-6646 91 104 : : PUNCT dpc-6646 91 105 134.0 134.0 NUM dpc-6646 91 106 54.3 54.3 NUM dpc-6646 91 107     SPACE dpc-6646 91 108 by by ADP dpc-6646 91 109 48 48 NUM dpc-6646 91 110 months month NOUN dpc-6646 91 111 , , PUNCT dpc-6646 91 112 rates rate NOUN dpc-6646 91 113 were be AUX dpc-6646 91 114 78.0 78.0 NUM dpc-6646 91 115 % % NOUN dpc-6646 91 116 , , PUNCT dpc-6646 91 117 83.0 83.0 NUM dpc-6646 91 118 % % NOUN dpc-6646 91 119 , , PUNCT dpc-6646 91 120 and and CCONJ dpc-6646 91 121 72.0 72.0 NUM dpc-6646 91 122 % % NOUN dpc-6646 91 123 , , PUNCT dpc-6646 91 124 respectively respectively ADV dpc-6646 91 125 , , PUNCT dpc-6646 91 126 and and CCONJ dpc-6646 91 127 at at ADP dpc-6646 91 128 60 60 NUM dpc-6646 91 129 months month NOUN dpc-6646 91 130 , , PUNCT dpc-6646 91 131 they they PRON dpc-6646 91 132 were be AUX dpc-6646 91 133 72.0 72.0 NUM dpc-6646 91 134 % % NOUN dpc-6646 91 135 , , PUNCT dpc-6646 91 136 78.0 78.0 NUM dpc-6646 91 137 % % NOUN dpc-6646 91 138 , , PUNCT dpc-6646 91 139 and and CCONJ dpc-6646 91 140 66.0 66.0 NUM dpc-6646 91 141 % % NOUN dpc-6646 91 142 , , PUNCT dpc-6646 91 143 again again ADV dpc-6646 91 144 with with ADP dpc-6646 91 145 all all DET dpc-6646 91 146 comparisons comparison NOUN dpc-6646 91 147 showing show VERB dpc-6646 91 148 p>0.3 p>0.3 NOUN dpc-6646 91 149 . . PUNCT dpc-6646 92 1 no no DET dpc-6646 92 2 statistically statistically ADV dpc-6646 92 3 significant significant ADJ dpc-6646 92 4 difference difference NOUN dpc-6646 92 5 in in ADP dpc-6646 92 6 treatment treatment NOUN dpc-6646 92 7 persistence persistence NOUN dpc-6646 92 8 was be AUX dpc-6646 92 9 observed observe VERB dpc-6646 92 10 between between ADP dpc-6646 92 11 bmi bmi NOUN dpc-6646 92 12 groups group NOUN dpc-6646 92 13 at at ADP dpc-6646 92 14 any any DET dpc-6646 92 15 time time NOUN dpc-6646 92 16 point point NOUN dpc-6646 92 17 . . PUNCT dpc-6646 93 1 drug drug NOUN dpc-6646 93 2 survival survival NOUN dpc-6646 93 3 based base VERB dpc-6646 93 4 on on ADP dpc-6646 93 5 disease disease NOUN dpc-6646 93 6 severity severity NOUN dpc-6646 93 7 treatment treatment NOUN dpc-6646 93 8 persistence persistence NOUN dpc-6646 93 9 with with ADP dpc-6646 93 10 guselkumab guselkumab NOUN dpc-6646 93 11 was be AUX dpc-6646 93 12 assessed assess VERB dpc-6646 93 13 according accord VERB dpc-6646 93 14 to to ADP dpc-6646 93 15 baseline baseline PROPN dpc-6646 93 16 pasi pasi NOUN dpc-6646 93 17 score score NOUN dpc-6646 93 18 , , PUNCT dpc-6646 93 19 as as SCONJ dpc-6646 93 20 shown show VERB dpc-6646 93 21 in in ADP dpc-6646 93 22 figure figure NOUN dpc-6646 93 23 3 3 NUM dpc-6646 93 24 . . PUNCT dpc-6646 94 1 patients patient NOUN dpc-6646 94 2 were be AUX dpc-6646 94 3 stratified stratify VERB dpc-6646 94 4 into into ADP dpc-6646 94 5 two two NUM dpc-6646 94 6 groups group NOUN dpc-6646 94 7 : : PUNCT dpc-6646 94 8 pasi pasi NOUN dpc-6646 94 9 < < X dpc-6646 94 10 10 10 NUM dpc-6646 94 11 and and CCONJ dpc-6646 94 12 pasi pasi NOUN dpc-6646 94 13 > > NOUN dpc-6646 94 14 11 11 NUM dpc-6646 94 15 . . PUNCT dpc-6646 95 1 at at ADP dpc-6646 95 2 12 12 NUM dpc-6646 95 3 months month NOUN dpc-6646 95 4 , , PUNCT dpc-6646 95 5 persistence persistence NOUN dpc-6646 95 6 rates rate NOUN dpc-6646 95 7 were be AUX dpc-6646 95 8 95.5 95.5 NUM dpc-6646 95 9 % % NOUN dpc-6646 95 10 in in ADP dpc-6646 95 11 the the DET dpc-6646 95 12 pasi pasi NOUN dpc-6646 95 13 < < X dpc-6646 95 14 10 10 NUM dpc-6646 95 15 group group NOUN dpc-6646 95 16 and and CCONJ dpc-6646 95 17 95.3 95.3 NUM dpc-6646 95 18 % % NOUN dpc-6646 95 19 in in ADP dpc-6646 95 20 the the DET dpc-6646 95 21 pasi pasi NOUN dpc-6646 95 22 > > SYM dpc-6646 95 23 11 11 NUM dpc-6646 95 24 group group NOUN dpc-6646 95 25 , , PUNCT dpc-6646 95 26 with with ADP dpc-6646 95 27 no no DET dpc-6646 95 28 statistically statistically ADV dpc-6646 95 29 significant significant ADJ dpc-6646 95 30 difference difference NOUN dpc-6646 95 31 ( ( PUNCT dpc-6646 95 32 p=0.051 p=0.051 NOUN dpc-6646 95 33 ) ) PUNCT dpc-6646 95 34 . . PUNCT dpc-6646 96 1 over over ADP dpc-6646 96 2 time time NOUN dpc-6646 96 3 , , PUNCT dpc-6646 96 4 persistence persistence NOUN dpc-6646 96 5 declined decline VERB dpc-6646 96 6 similarly similarly ADV dpc-6646 96 7 across across ADP dpc-6646 96 8 both both DET dpc-6646 96 9 groups group NOUN dpc-6646 96 10 . . PUNCT dpc-6646 97 1 at at ADP dpc-6646 97 2 24 24 NUM dpc-6646 97 3 months month NOUN dpc-6646 97 4 , , PUNCT dpc-6646 97 5 persistence persistence NOUN dpc-6646 97 6 was be AUX dpc-6646 97 7 90.9 90.9 NUM dpc-6646 97 8 % % NOUN dpc-6646 97 9 for for ADP dpc-6646 97 10 pasi pasi NOUN dpc-6646 97 11 < < X dpc-6646 97 12 10 10 NUM dpc-6646 97 13 and and CCONJ dpc-6646 97 14 91.0 91.0 NUM dpc-6646 97 15 % % NOUN dpc-6646 97 16 for for ADP dpc-6646 97 17 pasi pasi NOUN dpc-6646 97 18 > > X dpc-6646 97 19 11 11 NUM dpc-6646 97 20 ( ( PUNCT dpc-6646 97 21 p=0.539 p=0.539 NOUN dpc-6646 97 22 ) ) PUNCT dpc-6646 97 23 . . PUNCT dpc-6646 98 1 at at ADP dpc-6646 98 2 36 36 NUM dpc-6646 98 3 months month NOUN dpc-6646 98 4 , , PUNCT dpc-6646 98 5 rates rate NOUN dpc-6646 98 6 were be AUX dpc-6646 98 7 86.4 86.4 NUM dpc-6646 98 8 % % NOUN dpc-6646 98 9 and and CCONJ dpc-6646 98 10 86.6 86.6 NUM dpc-6646 98 11 % % NOUN dpc-6646 98 12 , , PUNCT dpc-6646 98 13 respectively respectively ADV dpc-6646 98 14 ( ( PUNCT dpc-6646 98 15 p=0.715 p=0.715 NOUN dpc-6646 98 16 ) ) PUNCT dpc-6646 98 17 . . PUNCT dpc-6646 99 1 at at ADP dpc-6646 99 2 48 48 NUM dpc-6646 99 3 months month NOUN dpc-6646 99 4 , , PUNCT dpc-6646 99 5 persistence persistence NOUN dpc-6646 99 6 reached reach VERB dpc-6646 99 7 84.1 84.1 NUM dpc-6646 99 8 % % NOUN dpc-6646 99 9 and and CCONJ dpc-6646 99 10 83.6 83.6 NUM dpc-6646 99 11 % % NOUN dpc-6646 99 12 ( ( PUNCT dpc-6646 99 13 p=0.998 p=0.998 NOUN dpc-6646 99 14 ) ) PUNCT dpc-6646 99 15 and and CCONJ dpc-6646 99 16 at at ADP dpc-6646 99 17 60 60 NUM dpc-6646 99 18 months month NOUN dpc-6646 99 19 , , PUNCT dpc-6646 99 20 79.5 79.5 NUM dpc-6646 99 21 % % NOUN dpc-6646 99 22 and and CCONJ dpc-6646 99 23 78.4 78.4 NUM dpc-6646 99 24 % % NOUN dpc-6646 99 25 ( ( PUNCT dpc-6646 99 26 p=0.998 p=0.998 NOUN dpc-6646 99 27 ) ) PUNCT dpc-6646 99 28 , , PUNCT dpc-6646 99 29 again again ADV dpc-6646 99 30 with with SCONJ dpc-6646 99 31 no no DET dpc-6646 99 32 statistically statistically ADV dpc-6646 99 33 significant significant ADJ dpc-6646 99 34 difference difference NOUN dpc-6646 99 35 observed observe VERB dpc-6646 99 36 . . PUNCT dpc-6646 100 1 original original ADJ dpc-6646 100 2 article article NOUN dpc-6646 100 3 | | ADV dpc-6646 100 4 dermatol dermatol ADJ dpc-6646 100 5 pract pract NOUN dpc-6646 100 6 concept concept NOUN dpc-6646 100 7 . . PUNCT dpc-6646 101 1 2025;15(4):6646 2025;15(4):6646 NUM dpc-6646 101 2 5 5 NUM dpc-6646 101 3 figure figure NOUN dpc-6646 101 4 2 2 NUM dpc-6646 101 5 . . PUNCT dpc-6646 101 6 treatment treatment NOUN dpc-6646 101 7 persistence persistence NOUN dpc-6646 101 8 with with ADP dpc-6646 101 9 guselkumab guselkumab NOUN dpc-6646 101 10 stratified stratify VERB dpc-6646 101 11 by by ADP dpc-6646 101 12 baseline baseline NOUN dpc-6646 101 13 weight weight NOUN dpc-6646 101 14 ( ( PUNCT dpc-6646 101 15 a a NOUN dpc-6646 101 16 ) ) PUNCT dpc-6646 101 17 and and CCONJ dpc-6646 101 18 bmi bmi X dpc-6646 101 19 ( ( PUNCT dpc-6646 101 20 b b NOUN dpc-6646 101 21 ) ) PUNCT dpc-6646 101 22 . . PUNCT dpc-6646 102 1 ( ( PUNCT dpc-6646 102 2 a a X dpc-6646 102 3 ) ) PUNCT dpc-6646 102 4 patients patient NOUN dpc-6646 102 5 were be AUX dpc-6646 102 6 categorized categorize VERB dpc-6646 102 7 into into ADP dpc-6646 102 8 two two NUM dpc-6646 102 9 weight weight NOUN dpc-6646 102 10 groups group NOUN dpc-6646 102 11 : : PUNCT dpc-6646 102 12 < < X dpc-6646 102 13 90 90 NUM dpc-6646 102 14 kg kg NOUN dpc-6646 102 15 and and CCONJ dpc-6646 102 16 > > X dpc-6646 102 17 90 90 NUM dpc-6646 102 18 kg kg NOUN dpc-6646 102 19 . . PUNCT dpc-6646 103 1 ( ( PUNCT dpc-6646 103 2 b b X dpc-6646 103 3 ) ) PUNCT dpc-6646 103 4 patients patient NOUN dpc-6646 103 5 were be AUX dpc-6646 103 6 stratified stratify VERB dpc-6646 103 7 by by ADP dpc-6646 103 8 bmi bmi NOUN dpc-6646 103 9 into into ADP dpc-6646 103 10 three three NUM dpc-6646 103 11 categories category NOUN dpc-6646 103 12 : : PUNCT dpc-6646 103 13 ( ( PUNCT dpc-6646 103 14 < < X dpc-6646 103 15 20 20 NUM dpc-6646 103 16 ) ) PUNCT dpc-6646 103 17 , , PUNCT dpc-6646 103 18 ( ( PUNCT dpc-6646 103 19 21 21 NUM dpc-6646 103 20 - - SYM dpc-6646 103 21 30 30 NUM dpc-6646 103 22 ) ) PUNCT dpc-6646 103 23 , , PUNCT dpc-6646 103 24 and and CCONJ dpc-6646 103 25 ( ( PUNCT dpc-6646 103 26 ≥31 ≥31 NOUN dpc-6646 103 27 ) ) PUNCT dpc-6646 103 28 . . PUNCT dpc-6646 104 1 figure figure VERB dpc-6646 104 2 3 3 NUM dpc-6646 104 3 . . PUNCT dpc-6646 104 4 treatment treatment NOUN dpc-6646 104 5 persistence persistence NOUN dpc-6646 104 6 with with ADP dpc-6646 104 7 guselkumab guselkumab NOUN dpc-6646 104 8 stratified stratify VERB dpc-6646 104 9 by by ADP dpc-6646 104 10 baseline baseline NOUN dpc-6646 104 11 pasi pasi PROPN dpc-6646 104 12 score score NOUN dpc-6646 104 13 . . PUNCT dpc-6646 105 1 patients patient NOUN dpc-6646 105 2 were be AUX dpc-6646 105 3 grouped group VERB dpc-6646 105 4 into into ADP dpc-6646 105 5 three three NUM dpc-6646 105 6 categories category NOUN dpc-6646 105 7 according accord VERB dpc-6646 105 8 to to ADP dpc-6646 105 9 disease disease NOUN dpc-6646 105 10 severity severity NOUN dpc-6646 105 11 at at ADP dpc-6646 105 12 baseline baseline NOUN dpc-6646 105 13 : : PUNCT dpc-6646 105 14 pasi pasi NOUN dpc-6646 105 15 < < X dpc-6646 105 16 10 10 NUM dpc-6646 105 17 and and CCONJ dpc-6646 105 18 pasi pasi NOUN dpc-6646 105 19 > > NOUN dpc-6646 105 20 11 11 NUM dpc-6646 105 21 . . PUNCT dpc-6646 105 22 6 6 NUM dpc-6646 105 23 original original ADJ dpc-6646 105 24 article article NOUN dpc-6646 105 25 | | ADV dpc-6646 105 26 dermatol dermatol ADJ dpc-6646 105 27 pract pract NOUN dpc-6646 105 28 concept concept NOUN dpc-6646 105 29 . . PUNCT dpc-6646 106 1 2025;15(4):6646 2025;15(4):6646 NUM dpc-6646 106 2 figure figure NOUN dpc-6646 106 3 4 4 NUM dpc-6646 106 4 . . PUNCT dpc-6646 106 5 treatment treatment NOUN dpc-6646 106 6 persistence persistence NOUN dpc-6646 106 7 with with ADP dpc-6646 106 8 guselkumab guselkumab NOUN dpc-6646 106 9 stratified stratify VERB dpc-6646 106 10 by by ADP dpc-6646 106 11 prior prior ADJ dpc-6646 106 12 exposure exposure NOUN dpc-6646 106 13 to to ADP dpc-6646 106 14 biologic biologic ADJ dpc-6646 106 15 therapies therapy NOUN dpc-6646 106 16 . . PUNCT dpc-6646 107 1 patients patient NOUN dpc-6646 107 2 were be AUX dpc-6646 107 3 categorized categorize VERB dpc-6646 107 4 as as ADP dpc-6646 107 5 bio bio NOUN dpc-6646 107 6 - - ADJ dpc-6646 107 7 naïve naïve ADJ dpc-6646 107 8 ( ( PUNCT dpc-6646 107 9 no no DET dpc-6646 107 10 previous previous ADJ dpc-6646 107 11 biologic biologic NOUN dpc-6646 107 12 treatment treatment NOUN dpc-6646 107 13 ) ) PUNCT dpc-6646 107 14 or or CCONJ dpc-6646 107 15 bio bio ADV dpc-6646 107 16 - - ADJ dpc-6646 107 17 experienced experienced ADJ dpc-6646 107 18 ( ( PUNCT dpc-6646 107 19 previously previously ADV dpc-6646 107 20 treated treat VERB dpc-6646 107 21 with with ADP dpc-6646 107 22 one one NUM dpc-6646 107 23 or or CCONJ dpc-6646 107 24 more more ADJ dpc-6646 107 25 biologics biologic NOUN dpc-6646 107 26 ) ) PUNCT dpc-6646 107 27 . . PUNCT dpc-6646 108 1 drug drug NOUN dpc-6646 108 2 survival survival NOUN dpc-6646 108 3 based base VERB dpc-6646 108 4 on on ADP dpc-6646 108 5 prior prior ADJ dpc-6646 108 6 exposure exposure NOUN dpc-6646 108 7 to to ADP dpc-6646 108 8 biologic biologic NOUN dpc-6646 108 9 therapies therapy NOUN dpc-6646 108 10 treatment treatment NOUN dpc-6646 108 11 persistence persistence NOUN dpc-6646 108 12 with with ADP dpc-6646 108 13 guselkumab guselkumab NOUN dpc-6646 108 14 was be AUX dpc-6646 108 15 evaluated evaluate VERB dpc-6646 108 16 according accord VERB dpc-6646 108 17 to to ADP dpc-6646 108 18 prior prior ADJ dpc-6646 108 19 exposure exposure NOUN dpc-6646 108 20 to to ADP dpc-6646 108 21 biologic biologic NOUN dpc-6646 108 22 therapies therapy NOUN dpc-6646 108 23 , , PUNCT dpc-6646 108 24 as as SCONJ dpc-6646 108 25 illustrated illustrate VERB dpc-6646 108 26 in in ADP dpc-6646 108 27 figure figure NOUN dpc-6646 108 28 4 4 NUM dpc-6646 108 29 . . PUNCT dpc-6646 109 1 patients patient NOUN dpc-6646 109 2 were be AUX dpc-6646 109 3 classified classify VERB dpc-6646 109 4 as as ADP dpc-6646 109 5 either either DET dpc-6646 109 6 bio bio PROPN dpc-6646 109 7 - - ADJ dpc-6646 109 8 naïve naïve ADJ dpc-6646 109 9 or or CCONJ dpc-6646 109 10 bio bio ADV dpc-6646 109 11 - - ADJ dpc-6646 109 12 experienced experienced ADJ dpc-6646 109 13 . . PUNCT dpc-6646 110 1 at at ADP dpc-6646 110 2 12 12 NUM dpc-6646 110 3 months month NOUN dpc-6646 110 4 , , PUNCT dpc-6646 110 5 persistence persistence NOUN dpc-6646 110 6 was be AUX dpc-6646 110 7 95.7 95.7 NUM dpc-6646 110 8 % % NOUN dpc-6646 110 9 in in ADP dpc-6646 110 10 the the DET dpc-6646 110 11 bio bio ADJ dpc-6646 110 12 - - ADJ dpc-6646 110 13 naïve naïve ADJ dpc-6646 110 14 group group NOUN dpc-6646 110 15 and and CCONJ dpc-6646 110 16 90.8 90.8 NUM dpc-6646 110 17 % % NOUN dpc-6646 110 18 in in ADP dpc-6646 110 19 the the DET dpc-6646 110 20 bio bio ADJ dpc-6646 110 21 - - ADJ dpc-6646 110 22 experienced experienced ADJ dpc-6646 110 23 group group NOUN dpc-6646 110 24 ( ( PUNCT dpc-6646 110 25 p=0.960 p=0.960 NUM dpc-6646 110 26 ) ) PUNCT dpc-6646 110 27 . . PUNCT dpc-6646 111 1 at at ADP dpc-6646 111 2 24 24 NUM dpc-6646 111 3 months month NOUN dpc-6646 111 4 , , PUNCT dpc-6646 111 5 91.3 91.3 NUM dpc-6646 111 6 % % NOUN dpc-6646 111 7 of of ADP dpc-6646 111 8 bio bio ADJ dpc-6646 111 9 - - ADJ dpc-6646 111 10 naïve naïve ADJ dpc-6646 111 11 patients patient NOUN dpc-6646 111 12 and and CCONJ dpc-6646 111 13 82.4 82.4 NUM dpc-6646 111 14 % % NOUN dpc-6646 111 15 of of ADP dpc-6646 111 16 bio bio ADJ dpc-6646 111 17 - - ADJ dpc-6646 111 18 experienced experienced ADJ dpc-6646 111 19 patients patient NOUN dpc-6646 111 20 remained remain VERB dpc-6646 111 21 on on ADP dpc-6646 111 22 therapy therapy NOUN dpc-6646 111 23 ( ( PUNCT dpc-6646 111 24 p=0.411 p=0.411 NOUN dpc-6646 111 25 ) ) PUNCT dpc-6646 111 26 , , PUNCT dpc-6646 111 27 and and CCONJ dpc-6646 111 28 at at ADP dpc-6646 111 29 36 36 NUM dpc-6646 111 30 months month NOUN dpc-6646 111 31 , , PUNCT dpc-6646 111 32 the the DET dpc-6646 111 33 rates rate NOUN dpc-6646 111 34 were be AUX dpc-6646 111 35 87.8 87.8 NUM dpc-6646 111 36 % % NOUN dpc-6646 111 37 and and CCONJ dpc-6646 111 38 77.9 77.9 NUM dpc-6646 111 39 % % NOUN dpc-6646 111 40 , , PUNCT dpc-6646 111 41 respectively respectively ADV dpc-6646 111 42 ( ( PUNCT dpc-6646 111 43 p=0.340 p=0.340 NUM dpc-6646 111 44 ) ) PUNCT dpc-6646 111 45 . . PUNCT dpc-6646 112 1 by by ADP dpc-6646 112 2 48 48 NUM dpc-6646 112 3 months month NOUN dpc-6646 112 4 , , PUNCT dpc-6646 112 5 persistence persistence NOUN dpc-6646 112 6 declined decline VERB dpc-6646 112 7 to to ADP dpc-6646 112 8 85.2 85.2 NUM dpc-6646 112 9 % % NOUN dpc-6646 112 10 in in ADP dpc-6646 112 11 the the DET dpc-6646 112 12 bio bio ADJ dpc-6646 112 13 - - ADJ dpc-6646 112 14 naïve naïve ADJ dpc-6646 112 15 group group NOUN dpc-6646 112 16 and and CCONJ dpc-6646 112 17 73.3 73.3 NUM dpc-6646 112 18 % % NOUN dpc-6646 112 19 in in ADP dpc-6646 112 20 the the DET dpc-6646 112 21 bio bio ADJ dpc-6646 112 22 - - ADJ dpc-6646 112 23 experienced experienced ADJ dpc-6646 112 24 group group NOUN dpc-6646 112 25 ( ( PUNCT dpc-6646 112 26 p=0.999 p=0.999 NOUN dpc-6646 112 27 ) ) PUNCT dpc-6646 112 28 , , PUNCT dpc-6646 112 29 and and CCONJ dpc-6646 112 30 at at ADP dpc-6646 112 31 60 60 NUM dpc-6646 112 32 months month NOUN dpc-6646 112 33 , , PUNCT dpc-6646 112 34 it it PRON dpc-6646 112 35 reached reach VERB dpc-6646 112 36 82.6 82.6 NUM dpc-6646 112 37 % % NOUN dpc-6646 112 38 and and CCONJ dpc-6646 112 39 68.7 68.7 NUM dpc-6646 112 40 % % NOUN dpc-6646 112 41 , , PUNCT dpc-6646 112 42 respectively respectively ADV dpc-6646 112 43 ( ( PUNCT dpc-6646 112 44 p=0.999 p=0.999 NOUN dpc-6646 112 45 ) ) PUNCT dpc-6646 112 46 . . PUNCT dpc-6646 113 1 these these DET dpc-6646 113 2 differences difference NOUN dpc-6646 113 3 were be AUX dpc-6646 113 4 not not PART dpc-6646 113 5 statistically statistically ADV dpc-6646 113 6 significant significant ADJ dpc-6646 113 7 . . PUNCT dpc-6646 114 1 multivariate multivariate NOUN dpc-6646 114 2 analysis analysis NOUN dpc-6646 114 3 a a DET dpc-6646 114 4 multivariate multivariate NOUN dpc-6646 114 5 cox cox PROPN dpc-6646 114 6 regression regression NOUN dpc-6646 114 7 analysis analysis NOUN dpc-6646 114 8 was be AUX dpc-6646 114 9 performed perform VERB dpc-6646 114 10 to to PART dpc-6646 114 11 assess assess VERB dpc-6646 114 12 factors factor NOUN dpc-6646 114 13 associated associate VERB dpc-6646 114 14 with with ADP dpc-6646 114 15 treatment treatment NOUN dpc-6646 114 16 discontinuation discontinuation NOUN dpc-6646 114 17 ( ( PUNCT dpc-6646 114 18 table table NOUN dpc-6646 114 19 2 2 NUM dpc-6646 114 20 ) ) PUNCT dpc-6646 114 21 . . PUNCT dpc-6646 115 1 variables variable NOUN dpc-6646 115 2 included include VERB dpc-6646 115 3 in in ADP dpc-6646 115 4 the the DET dpc-6646 115 5 model model NOUN dpc-6646 115 6 were be AUX dpc-6646 115 7 age age NOUN dpc-6646 115 8 , , PUNCT dpc-6646 115 9 sex sex NOUN dpc-6646 115 10 , , PUNCT dpc-6646 115 11 bmi bmi PROPN dpc-6646 115 12 , , PUNCT dpc-6646 115 13 baseline baseline NOUN dpc-6646 115 14 pasi pasi NOUN dpc-6646 115 15 , , PUNCT dpc-6646 115 16 and and CCONJ dpc-6646 115 17 prior prior ADJ dpc-6646 115 18 exposure exposure NOUN dpc-6646 115 19 to to ADP dpc-6646 115 20 biologic biologic NOUN dpc-6646 115 21 therapies therapy NOUN dpc-6646 115 22 ( ( PUNCT dpc-6646 115 23 bio bio NOUN dpc-6646 115 24 - - NOUN dpc-6646 115 25 experience experience NOUN dpc-6646 115 26 ) ) PUNCT dpc-6646 115 27 . . PUNCT dpc-6646 116 1 among among ADP dpc-6646 116 2 these these PRON dpc-6646 116 3 , , PUNCT dpc-6646 116 4 prior prior ADJ dpc-6646 116 5 biologic biologic NOUN dpc-6646 116 6 experience experience NOUN dpc-6646 116 7 emerged emerge VERB dpc-6646 116 8 as as ADP dpc-6646 116 9 the the DET dpc-6646 116 10 only only ADJ dpc-6646 116 11 statistically statistically ADV dpc-6646 116 12 significant significant ADJ dpc-6646 116 13 predictor predictor NOUN dpc-6646 116 14 of of ADP dpc-6646 116 15 discontinuation discontinuation NOUN dpc-6646 116 16 ( ( PUNCT dpc-6646 116 17 hr hr NOUN dpc-6646 116 18 = = NOUN dpc-6646 116 19 1.84 1.84 NUM dpc-6646 116 20 , , PUNCT dpc-6646 116 21 coefficient=0.6101 coefficient=0.6101 PRON dpc-6646 116 22 ; ; PUNCT dpc-6646 116 23 se=0.2640 se=0.2640 ADJ dpc-6646 116 24 ; ; PUNCT dpc-6646 116 25 z=2.311 z=2.311 NUM dpc-6646 116 26 ; ; PUNCT dpc-6646 116 27 p=0.0208 p=0.0208 NUM dpc-6646 116 28 ) ) PUNCT dpc-6646 116 29 , , PUNCT dpc-6646 116 30 indicating indicate VERB dpc-6646 116 31 a a DET dpc-6646 116 32 higher high ADJ dpc-6646 116 33 risk risk NOUN dpc-6646 116 34 of of ADP dpc-6646 116 35 treatment treatment NOUN dpc-6646 116 36 interruption interruption NOUN dpc-6646 116 37 in in ADP dpc-6646 116 38 bio bio PROPN dpc-6646 116 39 experienced experienced ADJ dpc-6646 116 40 patients patient NOUN dpc-6646 116 41 . . PUNCT dpc-6646 117 1 other other ADJ dpc-6646 117 2 variables variable NOUN dpc-6646 117 3 , , PUNCT dpc-6646 117 4 including include VERB dpc-6646 117 5 bmi bmi NOUN dpc-6646 117 6 ( ( PUNCT dpc-6646 117 7 coefficient coefficient NOUN dpc-6646 117 8 : : PUNCT dpc-6646 117 9 0.0330 0.0330 NUM dpc-6646 117 10 ; ; PUNCT dpc-6646 117 11 p=0.1628 p=0.1628 PROPN dpc-6646 117 12 ) ) PUNCT dpc-6646 117 13 , , PUNCT dpc-6646 117 14 age age NOUN dpc-6646 117 15 ( ( PUNCT dpc-6646 117 16 coefficient coefficient NOUN dpc-6646 117 17 : : PUNCT dpc-6646 117 18 – – PUNCT dpc-6646 117 19 0.0059 0.0059 NUM dpc-6646 117 20 ; ; PUNCT dpc-6646 117 21 p=0.5238 p=0.5238 NOUN dpc-6646 117 22 ) ) PUNCT dpc-6646 117 23 , , PUNCT dpc-6646 117 24 sex sex NOUN dpc-6646 117 25 ( ( PUNCT dpc-6646 117 26 coefficient coefficient NOUN dpc-6646 117 27 : : PUNCT dpc-6646 117 28 0.4376 0.4376 NOUN dpc-6646 117 29 ; ; PUNCT dpc-6646 117 30 p=0.0828 p=0.0828 NOUN dpc-6646 117 31 ) ) PUNCT dpc-6646 117 32 , , PUNCT dpc-6646 117 33 and and CCONJ dpc-6646 117 34 pasi pasi NOUN dpc-6646 117 35 ( ( PUNCT dpc-6646 117 36 coefficient coefficient NOUN dpc-6646 117 37 : : PUNCT dpc-6646 117 38 – – PUNCT dpc-6646 117 39 0.0038 0.0038 NUM dpc-6646 117 40 ; ; PUNCT dpc-6646 117 41 p=0.8394 p=0.8394 PROPN dpc-6646 117 42 ) ) PUNCT dpc-6646 117 43 were be AUX dpc-6646 117 44 not not PART dpc-6646 117 45 significantly significantly ADV dpc-6646 117 46 linked link VERB dpc-6646 117 47 with with ADP dpc-6646 117 48 persistence persistence NOUN dpc-6646 117 49 outcomes outcome NOUN dpc-6646 117 50 . . PUNCT dpc-6646 118 1 a a DET dpc-6646 118 2 separate separate ADJ dpc-6646 118 3 model model NOUN dpc-6646 118 4 evaluated evaluate VERB dpc-6646 118 5 the the DET dpc-6646 118 6 impact impact NOUN dpc-6646 118 7 of of ADP dpc-6646 118 8 previous previous ADJ dpc-6646 118 9 biologic biologic NOUN dpc-6646 118 10 class class NOUN dpc-6646 118 11 exposure exposure NOUN dpc-6646 118 12 ( ( PUNCT dpc-6646 118 13 table table NOUN dpc-6646 118 14 3 3 NUM dpc-6646 118 15 ) ) PUNCT dpc-6646 118 16 . . PUNCT dpc-6646 119 1 prior prior ADJ dpc-6646 119 2 use use NOUN dpc-6646 119 3 of of ADP dpc-6646 119 4 il-17 il-17 NOUN dpc-6646 119 5 inhibitors inhibitor NOUN dpc-6646 119 6 was be AUX dpc-6646 119 7 significantly significantly ADV dpc-6646 119 8 associated associate VERB dpc-6646 119 9 with with ADP dpc-6646 119 10 an an DET dpc-6646 119 11 increased increase VERB dpc-6646 119 12 risk risk NOUN dpc-6646 119 13 of of ADP dpc-6646 119 14 discontinuation discontinuation NOUN dpc-6646 119 15 ( ( PUNCT dpc-6646 119 16 coefficient coefficient NOUN dpc-6646 119 17 : : PUNCT dpc-6646 119 18 0.7613 0.7613 NUM dpc-6646 119 19 ; ; PUNCT dpc-6646 119 20 se=0.3128 se=0.3128 NOUN dpc-6646 119 21 ; ; PUNCT dpc-6646 119 22 z=2.433 z=2.433 NUM dpc-6646 119 23 ; ; PUNCT dpc-6646 119 24 p=0.0150 p=0.0150 NUM dpc-6646 119 25 ) ) PUNCT dpc-6646 119 26 , , PUNCT dpc-6646 119 27 corresponding correspond VERB dpc-6646 119 28 to to ADP dpc-6646 119 29 an an DET dpc-6646 119 30 hr hr NOUN dpc-6646 119 31 of of ADP dpc-6646 119 32 2.14 2.14 NUM dpc-6646 119 33 . . PUNCT dpc-6646 120 1 no no DET dpc-6646 120 2 statistically statistically ADV dpc-6646 120 3 significant significant ADJ dpc-6646 120 4 association association NOUN dpc-6646 120 5 was be AUX dpc-6646 120 6 found find VERB dpc-6646 120 7 for for ADP dpc-6646 120 8 prior prior ADJ dpc-6646 120 9 exposure exposure NOUN dpc-6646 120 10 to to ADP dpc-6646 120 11 anti anti ADJ dpc-6646 120 12 - - ADJ dpc-6646 120 13 tnf tnf ADJ dpc-6646 120 14 - - PUNCT dpc-6646 120 15 α α NOUN dpc-6646 120 16 agents agent NOUN dpc-6646 120 17 ( ( PUNCT dpc-6646 120 18 coefficient coefficient NOUN dpc-6646 120 19 : : PUNCT dpc-6646 120 20 0.3182 0.3182 NUM dpc-6646 120 21 ; ; PUNCT dpc-6646 120 22 hr hr NOUN dpc-6646 120 23 : : PUNCT dpc-6646 120 24 1.37 1.37 NUM dpc-6646 120 25 ; ; PUNCT dpc-6646 120 26 p=0.2190 p=0.2190 NOUN dpc-6646 120 27 ) ) PUNCT dpc-6646 120 28 , , PUNCT dpc-6646 120 29 il-12/23 il-12/23 ADJ dpc-6646 120 30 inhibitors inhibitor NOUN dpc-6646 120 31 ( ( PUNCT dpc-6646 120 32 coefficient coefficient NOUN dpc-6646 120 33 : : PUNCT dpc-6646 120 34 0.2939 0.2939 NUM dpc-6646 120 35 ; ; PUNCT dpc-6646 120 36 hr hr NOUN dpc-6646 120 37 : : PUNCT dpc-6646 120 38 table table NOUN dpc-6646 120 39 2 2 NUM dpc-6646 120 40 . . X dpc-6646 120 41 multivariate multivariate NOUN dpc-6646 120 42 cox cox PROPN dpc-6646 120 43 regression regression VERB dpc-6646 120 44 analysis analysis NOUN dpc-6646 120 45 of of ADP dpc-6646 120 46 factors factor NOUN dpc-6646 120 47 associated associate VERB dpc-6646 120 48 with with ADP dpc-6646 120 49 treatment treatment NOUN dpc-6646 120 50 discontinuation discontinuation NOUN dpc-6646 120 51 . . PUNCT dpc-6646 121 1 the the DET dpc-6646 121 2 model model NOUN dpc-6646 121 3 included include VERB dpc-6646 121 4 baseline baseline NOUN dpc-6646 121 5 bmi bmi NOUN dpc-6646 121 6 , , PUNCT dpc-6646 121 7 age age NOUN dpc-6646 121 8 , , PUNCT dpc-6646 121 9 sex sex NOUN dpc-6646 121 10 , , PUNCT dpc-6646 121 11 pasi pasi NOUN dpc-6646 121 12 , , PUNCT dpc-6646 121 13 and and CCONJ dpc-6646 121 14 previous previous ADJ dpc-6646 121 15 exposure exposure NOUN dpc-6646 121 16 to to ADP dpc-6646 121 17 biologic biologic ADJ dpc-6646 121 18 therapies therapy NOUN dpc-6646 121 19 . . PUNCT dpc-6646 122 1 variable variable ADJ dpc-6646 122 2 coef coef PROPN dpc-6646 122 3 exp(coef exp(coef X dpc-6646 122 4 ) ) PUNCT dpc-6646 122 5 se(coef se(coef PROPN dpc-6646 122 6 ) ) PUNCT dpc-6646 122 7 z z NOUN dpc-6646 122 8 p p ADJ dpc-6646 122 9 - - PUNCT dpc-6646 122 10 value value NOUN dpc-6646 122 11     SPACE dpc-6646 122 12 bmi bmi VERB dpc-6646 122 13 0.032964 0.032964 NUM dpc-6646 122 14 1.033514 1.033514 NUM dpc-6646 122 15 0.023617 0.023617 NUM dpc-6646 122 16 1.396 1.396 NUM dpc-6646 122 17 0.1628 0.1628 NUM dpc-6646 122 18     SPACE dpc-6646 122 19 age age NOUN dpc-6646 122 20 -0.005853 -0.005853 NOUN dpc-6646 122 21 0.994164 0.994164 NUM dpc-6646 122 22 0.009181 0.009181 NUM dpc-6646 122 23 -0.637 -0.637 NOUN dpc-6646 122 24 0.5238 0.5238 NUM dpc-6646 122 25     SPACE dpc-6646 122 26 sex sex NOUN dpc-6646 122 27 0.437617 0.437617 NUM dpc-6646 122 28 1.549012 1.549012 NUM dpc-6646 122 29 0.252292 0.252292 NUM dpc-6646 122 30 1.735 1.735 NUM dpc-6646 122 31 0.0828 0.0828 NUM dpc-6646 122 32     SPACE dpc-6646 122 33 pasi pasi NOUN dpc-6646 122 34 -0.003767 -0.003767 PART dpc-6646 122 35 0.996240 0.996240 NUM dpc-6646 122 36 0.018592 0.018592 NUM dpc-6646 122 37 -0.203 -0.203 NUM dpc-6646 122 38 0.8394 0.8394 NUM dpc-6646 122 39 bio bio NOUN dpc-6646 122 40 - - NOUN dpc-6646 122 41 experience experience NOUN dpc-6646 122 42 0.610064 0.610064 NUM dpc-6646 122 43 1.840549 1.840549 NUM dpc-6646 122 44 0.263955 0.263955 NUM dpc-6646 122 45 2.311 2.311 NUM dpc-6646 122 46 0.0208 0.0208 NUM dpc-6646 122 47 * * PUNCT dpc-6646 122 48 original original ADJ dpc-6646 122 49 article article NOUN dpc-6646 122 50 | | ADV dpc-6646 122 51 dermatol dermatol ADJ dpc-6646 122 52 pract pract NOUN dpc-6646 122 53 concept concept NOUN dpc-6646 122 54 . . PUNCT dpc-6646 123 1 2025;15(4):6646 2025;15(4):6646 NUM dpc-6646 123 2 7 7 NUM dpc-6646 123 3 1.34 1.34 NUM dpc-6646 123 4 ; ; PUNCT dpc-6646 123 5 p=0.3330 p=0.3330 X dpc-6646 123 6 ) ) PUNCT dpc-6646 123 7 , , PUNCT dpc-6646 123 8 or or CCONJ dpc-6646 123 9 il-23 il-23 NOUN dpc-6646 123 10 inhibitors inhibitor NOUN dpc-6646 123 11 ( ( PUNCT dpc-6646 123 12 coefficient coefficient NOUN dpc-6646 123 13 : : PUNCT dpc-6646 123 14 – – PUNCT dpc-6646 123 15 1.5120 1.5120 NUM dpc-6646 123 16 ; ; PUNCT dpc-6646 123 17 hr hr NOUN dpc-6646 123 18 : : PUNCT dpc-6646 123 19 ≈ ≈ PROPN dpc-6646 123 20 0.22 0.22 NUM dpc-6646 123 21 ; ; PUNCT dpc-6646 123 22 p=0.9950 p=0.9950 PROPN dpc-6646 123 23 ) ) PUNCT dpc-6646 123 24 . . PUNCT dpc-6646 124 1 a a DET dpc-6646 124 2 further further ADJ dpc-6646 124 3 multivariate multivariate NOUN dpc-6646 124 4 analysis analysis NOUN dpc-6646 124 5 investigated investigate VERB dpc-6646 124 6 the the DET dpc-6646 124 7 association association NOUN dpc-6646 124 8 between between ADP dpc-6646 124 9 psoriasis psoriasis NOUN dpc-6646 124 10 involvement involvement NOUN dpc-6646 124 11 in in ADP dpc-6646 124 12 difficult difficult ADJ dpc-6646 124 13 - - PUNCT dpc-6646 124 14 to to ADP dpc-6646 124 15 - - PUNCT dpc-6646 124 16 treat treat NOUN dpc-6646 124 17 areas area NOUN dpc-6646 124 18 and and CCONJ dpc-6646 124 19 the the DET dpc-6646 124 20 treatment treatment NOUN dpc-6646 124 21 persistence persistence NOUN dpc-6646 124 22 . . PUNCT dpc-6646 125 1 genital genital ADJ dpc-6646 125 2 involvement involvement NOUN dpc-6646 125 3 was be AUX dpc-6646 125 4 associated associate VERB dpc-6646 125 5 with with ADP dpc-6646 125 6 a a DET dpc-6646 125 7 trend trend NOUN dpc-6646 125 8 toward toward ADP dpc-6646 125 9 reduced reduce VERB dpc-6646 125 10 discontinuation discontinuation NOUN dpc-6646 125 11 ( ( PUNCT dpc-6646 125 12 estimate estimate NOUN dpc-6646 125 13 : : PUNCT dpc-6646 125 14 – – PUNCT dpc-6646 125 15 0.1173 0.1173 NUM dpc-6646 125 16 ; ; PUNCT dpc-6646 125 17 se se X dpc-6646 125 18 : : PUNCT dpc-6646 125 19 0.0605 0.0605 NUM dpc-6646 125 20 ; ; PUNCT dpc-6646 125 21 t t PROPN dpc-6646 125 22 = = PUNCT dpc-6646 125 23 – – PUNCT dpc-6646 125 24 1.938 1.938 NUM dpc-6646 125 25 ; ; PUNCT dpc-6646 125 26 p=0.0539 p=0.0539 NOUN dpc-6646 125 27 ) ) PUNCT dpc-6646 125 28 . . PUNCT dpc-6646 126 1 nail nail NOUN dpc-6646 126 2 ( ( PUNCT dpc-6646 126 3 estimate estimate NOUN dpc-6646 126 4 : : PUNCT dpc-6646 126 5 0.0595 0.0595 NUM dpc-6646 126 6 ; ; PUNCT dpc-6646 126 7 p=0.3253 p=0.3253 PROPN dpc-6646 126 8 ) ) PUNCT dpc-6646 126 9 , , PUNCT dpc-6646 126 10 scalp scalp NOUN dpc-6646 126 11 ( ( PUNCT dpc-6646 126 12 estimate estimate NOUN dpc-6646 126 13 : : PUNCT dpc-6646 126 14 0.0744 0.0744 NUM dpc-6646 126 15 ; ; PUNCT dpc-6646 126 16 p=0.1755 p=0.1755 NOUN dpc-6646 126 17 ) ) PUNCT dpc-6646 126 18 , , PUNCT dpc-6646 126 19 and and CCONJ dpc-6646 126 20 pretibial pretibial ADJ dpc-6646 126 21 involvement involvement NOUN dpc-6646 126 22 ( ( PUNCT dpc-6646 126 23 estimate estimate NOUN dpc-6646 126 24 : : PUNCT dpc-6646 126 25 – – PUNCT dpc-6646 126 26 0.0560 0.0560 NUM dpc-6646 126 27 ; ; PUNCT dpc-6646 126 28 p=0.2799 p=0.2799 PROPN dpc-6646 126 29 ) ) PUNCT dpc-6646 126 30 were be AUX dpc-6646 126 31 not not PART dpc-6646 126 32 significantly significantly ADV dpc-6646 126 33 associated associate VERB dpc-6646 126 34 with with ADP dpc-6646 126 35 treatment treatment NOUN dpc-6646 126 36 persistence persistence NOUN dpc-6646 126 37 . . PUNCT dpc-6646 127 1 discussion discussion NOUN dpc-6646 127 2 psoriasis psoriasis NOUN dpc-6646 127 3 is be AUX dpc-6646 127 4 a a DET dpc-6646 127 5 clinically clinically ADV dpc-6646 127 6 heterogeneous heterogeneous ADJ dpc-6646 127 7 lifelong lifelong ADJ dpc-6646 127 8 skin skin NOUN dpc-6646 127 9 disease disease NOUN dpc-6646 127 10 characterized characterize VERB dpc-6646 127 11 by by ADP dpc-6646 127 12 various various ADJ dpc-6646 127 13 forms form NOUN dpc-6646 127 14 , , PUNCT dpc-6646 127 15 including include VERB dpc-6646 127 16 plaque plaque NOUN dpc-6646 127 17 , , PUNCT dpc-6646 127 18 flexural flexural ADJ dpc-6646 127 19 , , PUNCT dpc-6646 127 20 guttate guttate ADJ dpc-6646 127 21 , , PUNCT dpc-6646 127 22 pustular pustular ADJ dpc-6646 127 23 , , PUNCT dpc-6646 127 24 and and CCONJ dpc-6646 127 25 erythrodermic erythrodermic ADJ dpc-6646 127 26 . . PUNCT dpc-6646 128 1 it it PRON dpc-6646 128 2 affects affect VERB dpc-6646 128 3 approximately approximately ADV dpc-6646 128 4 60 60 NUM dpc-6646 128 5 million million NUM dpc-6646 128 6 people people NOUN dpc-6646 128 7 globally globally ADV dpc-6646 128 8 [ [ X dpc-6646 128 9 14 14 NUM dpc-6646 128 10 ] ] PUNCT dpc-6646 128 11 , , PUNCT dpc-6646 128 12 and and CCONJ dpc-6646 128 13 its its PRON dpc-6646 128 14 prevalence prevalence NOUN dpc-6646 128 15 in in ADP dpc-6646 128 16 italy italy PROPN dpc-6646 128 17 ranges range VERB dpc-6646 128 18 from from ADP dpc-6646 128 19 1.8 1.8 NUM dpc-6646 128 20 % % NOUN dpc-6646 128 21 to to PART dpc-6646 128 22 4.8 4.8 NUM dpc-6646 128 23 % % NOUN dpc-6646 128 24 , , PUNCT dpc-6646 128 25 with with ADP dpc-6646 128 26 an an DET dpc-6646 128 27 incidence incidence NOUN dpc-6646 128 28 between between ADP dpc-6646 128 29 107.742 107.742 NUM dpc-6646 128 30 and and CCONJ dpc-6646 128 31 230.62 230.62 NUM dpc-6646 128 32 per per ADP dpc-6646 128 33 100,000 100,000 NUM dpc-6646 128 34 person person NOUN dpc-6646 128 35 - - PUNCT dpc-6646 128 36 years year NOUN dpc-6646 129 1 [ [ X dpc-6646 129 2 15 15 NUM dpc-6646 129 3 ] ] PUNCT dpc-6646 129 4 . . PUNCT dpc-6646 130 1 guselkumab guselkumab NOUN dpc-6646 130 2 is be AUX dpc-6646 130 3 a a DET dpc-6646 130 4 monoclonal monoclonal NOUN dpc-6646 130 5 antibody antibody NOUN dpc-6646 130 6 that that PRON dpc-6646 130 7 targets target VERB dpc-6646 130 8 interleukin interleukin NOUN dpc-6646 130 9 ( ( PUNCT dpc-6646 130 10 il)-23 il)-23 PROPN dpc-6646 130 11 , , PUNCT dpc-6646 130 12 approved approve VERB dpc-6646 130 13 for for ADP dpc-6646 130 14 treating treat VERB dpc-6646 130 15 adults adult NOUN dpc-6646 130 16 with with ADP dpc-6646 130 17 moderate moderate ADJ dpc-6646 130 18 - - PUNCT dpc-6646 130 19 to to ADP dpc-6646 130 20 severe severe ADJ dpc-6646 130 21 plaque plaque NOUN dpc-6646 130 22 psoriasis psoriasis NOUN dpc-6646 130 23 [ [ X dpc-6646 130 24 16 16 NUM dpc-6646 130 25 ] ] PUNCT dpc-6646 130 26 . . PUNCT dpc-6646 131 1 it it PRON dpc-6646 131 2 has have AUX dpc-6646 131 3 demonstrated demonstrate VERB dpc-6646 131 4 sustained sustained ADJ dpc-6646 131 5 efficacy efficacy NOUN dpc-6646 131 6 and and CCONJ dpc-6646 131 7 safety safety NOUN dpc-6646 131 8 over over ADP dpc-6646 131 9 five five NUM dpc-6646 131 10 years year NOUN dpc-6646 131 11 , , PUNCT dpc-6646 131 12 with with ADP dpc-6646 131 13 significant significant ADJ dpc-6646 131 14 improvements improvement NOUN dpc-6646 131 15 in in ADP dpc-6646 131 16 psoriasis psoriasis NOUN dpc-6646 131 17 area area NOUN dpc-6646 131 18 and and CCONJ dpc-6646 131 19 severity severity NOUN dpc-6646 131 20 index index NOUN dpc-6646 131 21 ( ( PUNCT dpc-6646 131 22 pasi pasi NOUN dpc-6646 131 23 ) ) PUNCT dpc-6646 131 24 scores score NOUN dpc-6646 131 25 and and CCONJ dpc-6646 131 26 dermatology dermatology NOUN dpc-6646 131 27 life life NOUN dpc-6646 131 28 quality quality NOUN dpc-6646 131 29 index index NOUN dpc-6646 131 30 ( ( PUNCT dpc-6646 131 31 dlqi dlqi PROPN dpc-6646 131 32 ) ) PUNCT dpc-6646 131 33 scores score NOUN dpc-6646 132 1 [ [ X dpc-6646 132 2 17,18 17,18 X dpc-6646 132 3 ] ] PUNCT dpc-6646 132 4 . . PUNCT dpc-6646 133 1 additionally additionally ADV dpc-6646 133 2 , , PUNCT dpc-6646 133 3 guselkumab guselkumab NOUN dpc-6646 133 4 has have AUX dpc-6646 133 5 demonstrated demonstrate VERB dpc-6646 133 6 significant significant ADJ dpc-6646 133 7 drug drug NOUN dpc-6646 133 8 survival survival NOUN dpc-6646 133 9 in in ADP dpc-6646 133 10 patients patient NOUN dpc-6646 133 11 with with ADP dpc-6646 133 12 moderate moderate ADJ dpc-6646 133 13 - - PUNCT dpc-6646 133 14 to to ADP dpc-6646 133 15 - - PUNCT dpc-6646 133 16 severe severe ADJ dpc-6646 133 17 psoriasis psoriasis NOUN dpc-6646 133 18 across across ADP dpc-6646 133 19 various various ADJ dpc-6646 133 20 real real ADJ dpc-6646 133 21 - - PUNCT dpc-6646 133 22 world world NOUN dpc-6646 133 23 settings setting NOUN dpc-6646 133 24 . . PUNCT dpc-6646 134 1 an an DET dpc-6646 134 2 australian australian ADJ dpc-6646 134 3 multicenter multicenter NOUN dpc-6646 134 4 retrospective retrospective ADJ dpc-6646 134 5 study study NOUN dpc-6646 134 6 aimed aim VERB dpc-6646 134 7 to to PART dpc-6646 134 8 determine determine VERB dpc-6646 134 9 the the DET dpc-6646 134 10 drug drug NOUN dpc-6646 134 11 survival survival NOUN dpc-6646 134 12 rates rate NOUN dpc-6646 134 13 of of ADP dpc-6646 134 14 biologics biologic NOUN dpc-6646 134 15 available available ADJ dpc-6646 134 16 in in ADP dpc-6646 134 17 australia australia PROPN dpc-6646 134 18 for for ADP dpc-6646 134 19 treating treat VERB dpc-6646 134 20 chronic chronic ADJ dpc-6646 134 21 plaque plaque NOUN dpc-6646 134 22 psoriasis psoriasis NOUN dpc-6646 134 23 , , PUNCT dpc-6646 134 24 analyzing analyze VERB dpc-6646 134 25 data datum NOUN dpc-6646 134 26 from from ADP dpc-6646 134 27 306 306 NUM dpc-6646 134 28 patients patient NOUN dpc-6646 134 29 and and CCONJ dpc-6646 134 30 566 566 NUM dpc-6646 134 31 treatment treatment NOUN dpc-6646 134 32 courses course NOUN dpc-6646 134 33 collected collect VERB dpc-6646 134 34 from from ADP dpc-6646 134 35 two two NUM dpc-6646 134 36 outpatient outpatient NOUN dpc-6646 134 37 dermatology dermatology NOUN dpc-6646 134 38 clinics clinic NOUN dpc-6646 134 39 between between ADP dpc-6646 134 40 april april PROPN dpc-6646 134 41 2006 2006 NUM dpc-6646 134 42 and and CCONJ dpc-6646 134 43 december december PROPN dpc-6646 134 44 2020 2020 NUM dpc-6646 134 45 . . PUNCT dpc-6646 135 1 results result NOUN dpc-6646 135 2 indicated indicate VERB dpc-6646 135 3 that that SCONJ dpc-6646 135 4 guselkumab guselkumab NOUN dpc-6646 135 5 had have VERB dpc-6646 135 6 the the DET dpc-6646 135 7 longest long ADJ dpc-6646 135 8 drug drug NOUN dpc-6646 135 9 survival survival NOUN dpc-6646 135 10 rates rate NOUN dpc-6646 135 11 at at ADP dpc-6646 135 12 94.2 94.2 NUM dpc-6646 135 13 % % NOUN dpc-6646 135 14 at at ADP dpc-6646 135 15 both both CCONJ dpc-6646 135 16 one one NUM dpc-6646 135 17 and and CCONJ dpc-6646 135 18 five five NUM dpc-6646 135 19 years year NOUN dpc-6646 135 20 , , PUNCT dpc-6646 135 21 followed follow VERB dpc-6646 135 22 by by ADP dpc-6646 135 23 ixekizumab ixekizumab NOUN dpc-6646 135 24 with with ADP dpc-6646 135 25 rates rate NOUN dpc-6646 135 26 of of ADP dpc-6646 135 27 87.2 87.2 NUM dpc-6646 135 28 % % NOUN dpc-6646 135 29 at at ADP dpc-6646 135 30 one one NUM dpc-6646 135 31 year year NOUN dpc-6646 135 32 and and CCONJ dpc-6646 135 33 59.4 59.4 NUM dpc-6646 135 34 % % NOUN dpc-6646 135 35 at at ADP dpc-6646 135 36 five five NUM dpc-6646 135 37 years year NOUN dpc-6646 135 38 [ [ X dpc-6646 135 39 19 19 NUM dpc-6646 135 40 ] ] PUNCT dpc-6646 135 41 . . PUNCT dpc-6646 136 1 mastorino mastorino PROPN dpc-6646 136 2 et et PROPN dpc-6646 136 3 al al PROPN dpc-6646 136 4 . . PROPN dpc-6646 136 5 evaluated evaluate VERB dpc-6646 136 6 the the DET dpc-6646 136 7 drug drug NOUN dpc-6646 136 8 survival survival NOUN dpc-6646 136 9 , , PUNCT dpc-6646 136 10 effectiveness effectiveness NOUN dpc-6646 136 11 , , PUNCT dpc-6646 136 12 and and CCONJ dpc-6646 136 13 safety safety NOUN dpc-6646 136 14 of of ADP dpc-6646 136 15 guselkumab guselkumab NOUN dpc-6646 136 16 for for ADP dpc-6646 136 17 treating treat VERB dpc-6646 136 18 moderate moderate ADJ dpc-6646 136 19 to to ADP dpc-6646 136 20 - - PUNCT dpc-6646 136 21 severe severe ADJ dpc-6646 136 22 psoriasis psoriasis NOUN dpc-6646 136 23 over over ADP dpc-6646 136 24 208 208 NUM dpc-6646 136 25 weeks week NOUN dpc-6646 136 26 , , PUNCT dpc-6646 136 27 involving involve VERB dpc-6646 136 28 202 202 NUM dpc-6646 136 29 patients patient NOUN dpc-6646 136 30 . . PUNCT dpc-6646 137 1 the the DET dpc-6646 137 2 estimated estimate VERB dpc-6646 137 3 drug drug NOUN dpc-6646 137 4 survival survival NOUN dpc-6646 137 5 rate rate NOUN dpc-6646 137 6 at at ADP dpc-6646 137 7 almost almost ADV dpc-6646 137 8 four four NUM dpc-6646 137 9 years year NOUN dpc-6646 137 10 ( ( PUNCT dpc-6646 137 11 208 208 NUM dpc-6646 137 12 weeks week NOUN dpc-6646 137 13 ) ) PUNCT dpc-6646 137 14 was be AUX dpc-6646 137 15 68.5 68.5 NUM dpc-6646 137 16 % % NOUN dpc-6646 137 17 , , PUNCT dpc-6646 137 18 with with ADP dpc-6646 137 19 factors factor NOUN dpc-6646 137 20 such such ADJ dpc-6646 137 21 as as ADP dpc-6646 137 22 being be AUX dpc-6646 137 23 a a DET dpc-6646 137 24 super super ADJ dpc-6646 137 25 responder responder NOUN dpc-6646 137 26 and and CCONJ dpc-6646 137 27 having have VERB dpc-6646 137 28 cardiovascular cardiovascular ADJ dpc-6646 137 29 comorbidities comorbiditie NOUN dpc-6646 137 30 associated associate VERB dpc-6646 137 31 with with ADP dpc-6646 137 32 a a DET dpc-6646 137 33 reduced reduced ADJ dpc-6646 137 34 risk risk NOUN dpc-6646 137 35 of of ADP dpc-6646 137 36 drug drug NOUN dpc-6646 137 37 interruption interruption NOUN dpc-6646 137 38 [ [ X dpc-6646 137 39 20 20 NUM dpc-6646 137 40 ] ] PUNCT dpc-6646 137 41 . . PUNCT dpc-6646 138 1 a a DET dpc-6646 138 2 retrospective retrospective ADJ dpc-6646 138 3 study study NOUN dpc-6646 138 4 analyzed analyze VERB dpc-6646 138 5 real real ADJ dpc-6646 138 6 - - PUNCT dpc-6646 138 7 world world NOUN dpc-6646 138 8 data datum NOUN dpc-6646 138 9 from from ADP dpc-6646 138 10 the the DET dpc-6646 138 11 czech czech PROPN dpc-6646 138 12 republic republic NOUN dpc-6646 138 13 biorep biorep PROPN dpc-6646 138 14 registry registry NOUN dpc-6646 138 15 involving involve VERB dpc-6646 138 16 333 333 NUM dpc-6646 138 17 patients patient NOUN dpc-6646 138 18 treated treat VERB dpc-6646 138 19 with with ADP dpc-6646 138 20 guselkumab guselkumab NOUN dpc-6646 138 21 for for ADP dpc-6646 138 22 psoriasis psoriasis NOUN dpc-6646 138 23 . . PUNCT dpc-6646 139 1 drug drug NOUN dpc-6646 139 2 survival survival NOUN dpc-6646 139 3 remained remain VERB dpc-6646 139 4 high high ADJ dpc-6646 139 5 at at ADP dpc-6646 139 6 91.6 91.6 NUM dpc-6646 139 7 % % NOUN dpc-6646 139 8 , , PUNCT dpc-6646 139 9 87.0 87.0 NUM dpc-6646 139 10 % % NOUN dpc-6646 139 11 , , PUNCT dpc-6646 139 12 and and CCONJ dpc-6646 139 13 85.5 85.5 NUM dpc-6646 139 14 % % NOUN dpc-6646 139 15 after after ADP dpc-6646 139 16 12 12 NUM dpc-6646 139 17 , , PUNCT dpc-6646 139 18 24 24 NUM dpc-6646 139 19 , , PUNCT dpc-6646 139 20 and and CCONJ dpc-6646 139 21 36 36 NUM dpc-6646 139 22 months month NOUN dpc-6646 139 23 , , PUNCT dpc-6646 139 24 respectively respectively ADV dpc-6646 139 25 [ [ X dpc-6646 139 26 21 21 NUM dpc-6646 139 27 ] ] PUNCT dpc-6646 139 28 . . PUNCT dpc-6646 140 1 in in ADP dpc-6646 140 2 our our PRON dpc-6646 140 3 study study NOUN dpc-6646 140 4 , , PUNCT dpc-6646 140 5 we we PRON dpc-6646 140 6 observed observe VERB dpc-6646 140 7 a a DET dpc-6646 140 8 high high ADJ dpc-6646 140 9 long long ADJ dpc-6646 140 10 - - PUNCT dpc-6646 140 11 term term NOUN dpc-6646 140 12 treatment treatment NOUN dpc-6646 140 13 persistence persistence NOUN dpc-6646 140 14 , , PUNCT dpc-6646 140 15 with with ADP dpc-6646 140 16 80.2 80.2 NUM dpc-6646 140 17 % % NOUN dpc-6646 140 18 of of ADP dpc-6646 140 19 patients patient NOUN dpc-6646 140 20 still still ADV dpc-6646 140 21 receiving receive VERB dpc-6646 140 22 treatment treatment NOUN dpc-6646 140 23 after after ADP dpc-6646 140 24 three three NUM dpc-6646 140 25 years year NOUN dpc-6646 140 26 . . PUNCT dpc-6646 141 1 this this DET dpc-6646 141 2 result result NOUN dpc-6646 141 3 aligns align VERB dpc-6646 141 4 with with ADP dpc-6646 141 5 the the DET dpc-6646 141 6 findings finding NOUN dpc-6646 141 7 reported report VERB dpc-6646 141 8 by by ADP dpc-6646 141 9 torres torre NOUN dpc-6646 141 10 et et PROPN dpc-6646 141 11 al al PROPN dpc-6646 141 12 . . PROPN dpc-6646 141 13 , , PUNCT dpc-6646 141 14 who who PRON dpc-6646 141 15 noted note VERB dpc-6646 141 16 3 3 NUM dpc-6646 141 17 - - PUNCT dpc-6646 141 18 year year NOUN dpc-6646 141 19 persistence persistence NOUN dpc-6646 141 20 rates rate NOUN dpc-6646 141 21 of of ADP dpc-6646 141 22 over over ADP dpc-6646 141 23 80 80 NUM dpc-6646 141 24 % % NOUN dpc-6646 141 25 for for ADP dpc-6646 141 26 guselkumab guselkumab NOUN dpc-6646 141 27 in in ADP dpc-6646 141 28 a a DET dpc-6646 141 29 large large ADJ dpc-6646 141 30 international international ADJ dpc-6646 141 31 real real ADJ dpc-6646 141 32 - - PUNCT dpc-6646 141 33 world world NOUN dpc-6646 141 34 cohort cohort NOUN dpc-6646 141 35 [ [ X dpc-6646 141 36 22 22 NUM dpc-6646 141 37 ] ] PUNCT dpc-6646 141 38 . . PUNCT dpc-6646 142 1 after after ADP dpc-6646 142 2 five five NUM dpc-6646 142 3 years year NOUN dpc-6646 142 4 , , PUNCT dpc-6646 142 5 72.8 72.8 NUM dpc-6646 142 6 % % NOUN dpc-6646 142 7 continued continue VERB dpc-6646 142 8 the the DET dpc-6646 142 9 therapy therapy NOUN dpc-6646 142 10 . . PUNCT dpc-6646 143 1 this this DET dpc-6646 143 2 high high ADJ dpc-6646 143 3 long long ADJ dpc-6646 143 4 - - PUNCT dpc-6646 143 5 term term NOUN dpc-6646 143 6 persistence persistence NOUN dpc-6646 143 7 rate rate NOUN dpc-6646 143 8 matches match VERB dpc-6646 143 9 previous previous ADJ dpc-6646 143 10 reports report NOUN dpc-6646 143 11 in in ADP dpc-6646 143 12 the the DET dpc-6646 143 13 literature literature NOUN dpc-6646 143 14 and and CCONJ dpc-6646 143 15 reflects reflect VERB dpc-6646 143 16 the the DET dpc-6646 143 17 favorable favorable ADJ dpc-6646 143 18 tolerability tolerability NOUN dpc-6646 143 19 and and CCONJ dpc-6646 143 20 sustained sustained ADJ dpc-6646 143 21 effectiveness effectiveness NOUN dpc-6646 143 22 of of ADP dpc-6646 143 23 guselkumab guselkumab NOUN dpc-6646 143 24 in in ADP dpc-6646 143 25 real real ADJ dpc-6646 143 26 - - PUNCT dpc-6646 143 27 life life NOUN dpc-6646 143 28 clinical clinical ADJ dpc-6646 143 29 practice practice NOUN dpc-6646 143 30 [ [ X dpc-6646 143 31 19 19 NUM dpc-6646 143 32 - - PUNCT dpc-6646 143 33 21,23 21,23 NUM dpc-6646 143 34 ] ] PUNCT dpc-6646 143 35 . . PUNCT dpc-6646 144 1 the the DET dpc-6646 144 2 analysis analysis NOUN dpc-6646 144 3 considers consider VERB dpc-6646 144 4 all all DET dpc-6646 144 5 causes cause NOUN dpc-6646 144 6 of of ADP dpc-6646 144 7 discontinuation discontinuation NOUN dpc-6646 144 8 , , PUNCT dpc-6646 144 9 including include VERB dpc-6646 144 10 both both CCONJ dpc-6646 144 11 clinical clinical ADJ dpc-6646 144 12 and and CCONJ dpc-6646 144 13 non non ADJ dpc-6646 144 14 - - ADJ dpc-6646 144 15 clinical clinical ADJ dpc-6646 144 16 factors factor NOUN dpc-6646 144 17 , , PUNCT dpc-6646 144 18 providing provide VERB dpc-6646 144 19 a a DET dpc-6646 144 20 comprehensive comprehensive ADJ dpc-6646 144 21 overview overview NOUN dpc-6646 144 22 of of ADP dpc-6646 144 23 treatment treatment NOUN dpc-6646 144 24 retention retention NOUN dpc-6646 144 25 . . PUNCT dpc-6646 145 1 treatment treatment NOUN dpc-6646 145 2 persistence persistence NOUN dpc-6646 145 3 with with ADP dpc-6646 145 4 guselkumab guselkumab NOUN dpc-6646 145 5 was be AUX dpc-6646 145 6 evaluated evaluate VERB dpc-6646 145 7 based base VERB dpc-6646 145 8 on on ADP dpc-6646 145 9 baseline baseline ADJ dpc-6646 145 10 weight weight NOUN dpc-6646 145 11 and and CCONJ dpc-6646 145 12 bmi bmi NOUN dpc-6646 145 13 . . PUNCT dpc-6646 146 1 in in ADP dpc-6646 146 2 the the DET dpc-6646 146 3 present present ADJ dpc-6646 146 4 cohort cohort NOUN dpc-6646 146 5 , , PUNCT dpc-6646 146 6 patients patient NOUN dpc-6646 146 7 were be AUX dpc-6646 146 8 stratified stratify VERB dpc-6646 146 9 by by ADP dpc-6646 146 10 body body NOUN dpc-6646 146 11 weight weight NOUN dpc-6646 146 12 into into ADP dpc-6646 146 13 two two NUM dpc-6646 146 14 categories category NOUN dpc-6646 146 15 : : PUNCT dpc-6646 146 16 ≤90 ≤90 PROPN dpc-6646 146 17 kg kg PROPN dpc-6646 146 18 and and CCONJ dpc-6646 146 19 > > X dpc-6646 146 20 90 90 NUM dpc-6646 146 21 kg kg NOUN dpc-6646 146 22 . . PUNCT dpc-6646 147 1 persistence persistence NOUN dpc-6646 147 2 rates rate NOUN dpc-6646 147 3 at at ADP dpc-6646 147 4 12 12 NUM dpc-6646 147 5 months month NOUN dpc-6646 147 6 were be AUX dpc-6646 147 7 high high ADJ dpc-6646 147 8 in in ADP dpc-6646 147 9 both both DET dpc-6646 147 10 groups group NOUN dpc-6646 147 11 ( ( PUNCT dpc-6646 147 12 97.0 97.0 NUM dpc-6646 147 13 % % NOUN dpc-6646 147 14 and and CCONJ dpc-6646 147 15 95.0 95.0 NUM dpc-6646 147 16 % % NOUN dpc-6646 147 17 , , PUNCT dpc-6646 147 18 respectively respectively ADV dpc-6646 147 19 ) ) PUNCT dpc-6646 147 20 and and CCONJ dpc-6646 147 21 gradually gradually ADV dpc-6646 147 22 declined decline VERB dpc-6646 147 23 over over ADP dpc-6646 147 24 time time NOUN dpc-6646 147 25 . . PUNCT dpc-6646 148 1 at at ADP dpc-6646 148 2 24 24 NUM dpc-6646 148 3 months month NOUN dpc-6646 148 4 , , PUNCT dpc-6646 148 5 persistence persistence NOUN dpc-6646 148 6 was be AUX dpc-6646 148 7 92.0 92.0 NUM dpc-6646 148 8 % % NOUN dpc-6646 148 9 in in ADP dpc-6646 148 10 the the DET dpc-6646 148 11 ≤90 ≤90 PROPN dpc-6646 148 12 kg kg PROPN dpc-6646 148 13 group group NOUN dpc-6646 148 14 and and CCONJ dpc-6646 148 15 89.0 89.0 NUM dpc-6646 148 16 % % NOUN dpc-6646 148 17 in in ADP dpc-6646 148 18 the the DET dpc-6646 148 19 > > SYM dpc-6646 148 20 90 90 NUM dpc-6646 148 21 kg kg NOUN dpc-6646 148 22 group group NOUN dpc-6646 148 23 ; ; PUNCT dpc-6646 148 24 at at ADP dpc-6646 148 25 36 36 NUM dpc-6646 148 26 months month NOUN dpc-6646 148 27 , , PUNCT dpc-6646 148 28 88.0 88.0 NUM dpc-6646 148 29 % % NOUN dpc-6646 148 30 and and CCONJ dpc-6646 148 31 82.0 82.0 NUM dpc-6646 148 32 % % NOUN dpc-6646 148 33 ; ; PUNCT dpc-6646 148 34 at at ADP dpc-6646 148 35 48 48 NUM dpc-6646 148 36 months month NOUN dpc-6646 148 37 , , PUNCT dpc-6646 148 38 84.0 84.0 NUM dpc-6646 148 39 % % NOUN dpc-6646 148 40 and and CCONJ dpc-6646 148 41 75.0 75.0 NUM dpc-6646 148 42 % % NOUN dpc-6646 148 43 ; ; PUNCT dpc-6646 148 44 and and CCONJ dpc-6646 148 45 at at ADP dpc-6646 148 46 60 60 NUM dpc-6646 148 47 months month NOUN dpc-6646 148 48 , , PUNCT dpc-6646 148 49 80.0 80.0 NUM dpc-6646 148 50 % % NOUN dpc-6646 148 51 and and CCONJ dpc-6646 148 52 70.0 70.0 NUM dpc-6646 148 53 % % NOUN dpc-6646 148 54 , , PUNCT dpc-6646 148 55 respectively respectively ADV dpc-6646 148 56 . . PUNCT dpc-6646 149 1 in in ADP dpc-6646 149 2 the the DET dpc-6646 149 3 analysis analysis NOUN dpc-6646 149 4 by by ADP dpc-6646 149 5 body body NOUN dpc-6646 149 6 mass mass NOUN dpc-6646 149 7 index index NOUN dpc-6646 149 8 ( ( PUNCT dpc-6646 149 9 bmi bmi PROPN dpc-6646 149 10 ) ) PUNCT dpc-6646 149 11 , , PUNCT dpc-6646 149 12 patients patient NOUN dpc-6646 149 13 were be AUX dpc-6646 149 14 classified classify VERB dpc-6646 149 15 into into ADP dpc-6646 149 16 three three NUM dpc-6646 149 17 categories category NOUN dpc-6646 149 18 : : PUNCT dpc-6646 149 19 bmi bmi PROPN dpc-6646 149 20 < < X dpc-6646 149 21 20 20 NUM dpc-6646 149 22 , , PUNCT dpc-6646 149 23 bmi bmi NOUN dpc-6646 149 24 21–30 21–30 NUM dpc-6646 149 25 , , PUNCT dpc-6646 149 26 and and CCONJ dpc-6646 149 27 bmi bmi X dpc-6646 149 28 > > PROPN dpc-6646 149 29 31 31 NUM dpc-6646 149 30 . . PUNCT dpc-6646 150 1 at at ADP dpc-6646 150 2 12 12 NUM dpc-6646 150 3 months month NOUN dpc-6646 150 4 , , PUNCT dpc-6646 150 5 persistence persistence NOUN dpc-6646 150 6 rates rate NOUN dpc-6646 150 7 were be AUX dpc-6646 150 8 95.0 95.0 NUM dpc-6646 150 9 % % NOUN dpc-6646 150 10 in in ADP dpc-6646 150 11 the the DET dpc-6646 150 12 bmi bmi NOUN dpc-6646 150 13 < < X dpc-6646 150 14 20 20 NUM dpc-6646 150 15 group group NOUN dpc-6646 150 16 , , PUNCT dpc-6646 150 17 96.0 96.0 NUM dpc-6646 150 18 % % NOUN dpc-6646 150 19 in in ADP dpc-6646 150 20 the the DET dpc-6646 150 21 bmi bmi NOUN dpc-6646 150 22 21–30 21–30 NUM dpc-6646 150 23 group group NOUN dpc-6646 150 24 , , PUNCT dpc-6646 150 25 and and CCONJ dpc-6646 150 26 94.0 94.0 NUM dpc-6646 150 27 % % NOUN dpc-6646 150 28 in in ADP dpc-6646 150 29 the the DET dpc-6646 150 30 bmi bmi NOUN dpc-6646 150 31 > > X dpc-6646 150 32 31 31 NUM dpc-6646 150 33 group group NOUN dpc-6646 150 34 . . PUNCT dpc-6646 151 1 these these DET dpc-6646 151 2 rates rate NOUN dpc-6646 151 3 declined decline VERB dpc-6646 151 4 progressively progressively ADV dpc-6646 151 5 over over ADP dpc-6646 151 6 time time NOUN dpc-6646 151 7 : : PUNCT dpc-6646 151 8 at at ADP dpc-6646 151 9 24 24 NUM dpc-6646 151 10 months month NOUN dpc-6646 151 11 , , PUNCT dpc-6646 151 12 persistence persistence NOUN dpc-6646 151 13 was be AUX dpc-6646 151 14 91.0 91.0 NUM dpc-6646 151 15 % % NOUN dpc-6646 151 16 , , PUNCT dpc-6646 151 17 91.0 91.0 NUM dpc-6646 151 18 % % NOUN dpc-6646 151 19 , , PUNCT dpc-6646 151 20 and and CCONJ dpc-6646 151 21 87.0 87.0 NUM dpc-6646 151 22 % % NOUN dpc-6646 151 23 , , PUNCT dpc-6646 151 24 respectively respectively ADV dpc-6646 151 25 ; ; PUNCT dpc-6646 151 26 at at ADP dpc-6646 151 27 36 36 NUM dpc-6646 151 28 months month NOUN dpc-6646 151 29 , , PUNCT dpc-6646 151 30 85.0 85.0 NUM dpc-6646 151 31 % % NOUN dpc-6646 151 32 , , PUNCT dpc-6646 151 33 87.0 87.0 NUM dpc-6646 151 34 % % NOUN dpc-6646 151 35 , , PUNCT dpc-6646 151 36 and and CCONJ dpc-6646 151 37 80.0 80.0 NUM dpc-6646 151 38 % % NOUN dpc-6646 151 39 ; ; PUNCT dpc-6646 151 40 at at ADP dpc-6646 151 41 48 48 NUM dpc-6646 151 42 months month NOUN dpc-6646 151 43 , , PUNCT dpc-6646 151 44 78.0 78.0 NUM dpc-6646 151 45 % % NOUN dpc-6646 151 46 , , PUNCT dpc-6646 151 47 83.0 83.0 NUM dpc-6646 151 48 % % NOUN dpc-6646 151 49 , , PUNCT dpc-6646 151 50 and and CCONJ dpc-6646 151 51 72.0 72.0 NUM dpc-6646 151 52 % % NOUN dpc-6646 151 53 ; ; PUNCT dpc-6646 151 54 and and CCONJ dpc-6646 151 55 at at ADP dpc-6646 151 56 60 60 NUM dpc-6646 151 57 months month NOUN dpc-6646 151 58 , , PUNCT dpc-6646 151 59 72.0 72.0 NUM dpc-6646 151 60 % % NOUN dpc-6646 151 61 , , PUNCT dpc-6646 151 62 78.0 78.0 NUM dpc-6646 151 63 % % NOUN dpc-6646 151 64 , , PUNCT dpc-6646 151 65 and and CCONJ dpc-6646 151 66 66.0 66.0 NUM dpc-6646 151 67 % % NOUN dpc-6646 151 68 , , PUNCT dpc-6646 151 69 respectively respectively ADV dpc-6646 151 70 , , PUNCT dpc-6646 151 71 for for ADP dpc-6646 151 72 the the DET dpc-6646 151 73 bmi bmi NOUN dpc-6646 151 74 < < X dpc-6646 151 75 20 20 NUM dpc-6646 151 76 , , PUNCT dpc-6646 151 77 bmi bmi NOUN dpc-6646 151 78 21–30 21–30 NUM dpc-6646 151 79 , , PUNCT dpc-6646 151 80 and and CCONJ dpc-6646 151 81 bmi bmi X dpc-6646 151 82 > > SYM dpc-6646 151 83 31 31 NUM dpc-6646 151 84 categories category NOUN dpc-6646 151 85 . . PUNCT dpc-6646 152 1 these these DET dpc-6646 152 2 findings finding NOUN dpc-6646 152 3 indicate indicate VERB dpc-6646 152 4 that that PRON dpc-6646 152 5 treatment treatment NOUN dpc-6646 152 6 persistence persistence NOUN dpc-6646 152 7 with with ADP dpc-6646 152 8 guselkumab guselkumab NOUN dpc-6646 152 9 was be AUX dpc-6646 152 10 table table NOUN dpc-6646 152 11 3 3 NUM dpc-6646 152 12 . . PUNCT dpc-6646 152 13 multivariate multivariate NOUN dpc-6646 152 14 cox cox PROPN dpc-6646 152 15 regression regression VERB dpc-6646 152 16 analysis analysis NOUN dpc-6646 152 17 evaluating evaluate VERB dpc-6646 152 18 the the DET dpc-6646 152 19 impact impact NOUN dpc-6646 152 20 of of ADP dpc-6646 152 21 prior prior ADJ dpc-6646 152 22 biologic biologic ADJ dpc-6646 152 23 drug drug NOUN dpc-6646 152 24 classes class NOUN dpc-6646 152 25 on on ADP dpc-6646 152 26 treatment treatment NOUN dpc-6646 152 27 discontinuation discontinuation NOUN dpc-6646 152 28 with with ADP dpc-6646 152 29 guselkumab guselkumab NOUN dpc-6646 152 30 . . PUNCT dpc-6646 153 1 variable variable ADJ dpc-6646 153 2 n n PRON dpc-6646 153 3 patients patient NOUN dpc-6646 153 4 ( ( PUNCT dpc-6646 153 5 y y NOUN dpc-6646 153 6 / / SYM dpc-6646 153 7 n n CCONJ dpc-6646 153 8 ) ) PUNCT dpc-6646 153 9 coef coef PROPN dpc-6646 153 10 exp(coef exp(coef X dpc-6646 153 11 ) ) PUNCT dpc-6646 153 12 se(coef se(coef PROPN dpc-6646 153 13 ) ) PUNCT dpc-6646 153 14 z z NOUN dpc-6646 154 1 p p NOUN dpc-6646 154 2     SPACE dpc-6646 154 3 anti anti ADJ dpc-6646 154 4 - - ADJ dpc-6646 154 5 tnf tnf ADJ dpc-6646 154 6 - - PUNCT dpc-6646 154 7 α α NOUN dpc-6646 154 8 82/165 82/165 NUM dpc-6646 154 9 0.3182 0.3182 NUM dpc-6646 154 10 1.3750 1.3750 NUM dpc-6646 154 11 0.258800 0.258800 NUM dpc-6646 154 12 1.2290 1.2290 NUM dpc-6646 154 13 0.2190 0.2190 NUM dpc-6646 154 14     SPACE dpc-6646 154 15 il12 il12 PROPN dpc-6646 154 16 / / SYM dpc-6646 154 17 il23 il23 PROPN dpc-6646 154 18 inhibitor inhibitor NOUN dpc-6646 154 19 45 45 NUM dpc-6646 154 20 / / SYM dpc-6646 154 21 202 202 NUM dpc-6646 154 22 0.2939 0.2939 NUM dpc-6646 154 23 1.3420 1.3420 NUM dpc-6646 154 24 0.303500 0.303500 NUM dpc-6646 154 25 0.9680 0.9680 NUM dpc-6646 154 26 0.3330 0.3330 NUM dpc-6646 154 27     SPACE dpc-6646 155 1 il17 il17 PROPN dpc-6646 155 2 inhibitor inhibitor NOUN dpc-6646 155 3 38 38 NUM dpc-6646 155 4 / / SYM dpc-6646 155 5 209 209 NUM dpc-6646 155 6 0.7613 0.7613 NUM dpc-6646 155 7 2.1410 2.1410 NUM dpc-6646 155 8 0.312800 0.312800 NUM dpc-6646 155 9 2.4330 2.4330 NUM dpc-6646 155 10 0.0150 0.0150 NUM dpc-6646 155 11 * * PUNCT dpc-6646 155 12 il23 il23 PROPN dpc-6646 155 13 inhibitor inhibitor NOUN dpc-6646 155 14 2 2 NUM dpc-6646 155 15 / / SYM dpc-6646 155 16 242 242 NUM dpc-6646 155 17 -1.5120 -1.5120 NOUN dpc-6646 155 18 0.0000 0.0000 NUM dpc-6646 155 19 0.244292 0.244292 NUM dpc-6646 155 20 -0.0060 -0.0060 NOUN dpc-6646 155 21 0.9950 0.9950 NUM dpc-6646 155 22     SPACE dpc-6646 155 23 8 8 NUM dpc-6646 155 24 original original ADJ dpc-6646 155 25 article article NOUN dpc-6646 155 26 | | ADV dpc-6646 155 27 dermatol dermatol ADJ dpc-6646 155 28 pract pract NOUN dpc-6646 155 29 concept concept NOUN dpc-6646 155 30 . . PUNCT dpc-6646 156 1 2025;15(4):6646 2025;15(4):6646 NUM dpc-6646 156 2 findings finding NOUN dpc-6646 156 3 suggest suggest VERB dpc-6646 156 4 that that SCONJ dpc-6646 156 5 , , PUNCT dpc-6646 156 6 as as SCONJ dpc-6646 156 7 already already ADV dpc-6646 156 8 reported report VERB dpc-6646 156 9 for for ADP dpc-6646 156 10 other other ADJ dpc-6646 156 11 biological biological ADJ dpc-6646 156 12 treatments treatment NOUN dpc-6646 156 13 , , PUNCT dpc-6646 156 14 being be AUX dpc-6646 156 15 bio bio ADV dpc-6646 156 16 - - ADJ dpc-6646 156 17 experienced experienced ADJ dpc-6646 156 18 lowers lower VERB dpc-6646 156 19 the the DET dpc-6646 156 20 likelihood likelihood NOUN dpc-6646 156 21 of of ADP dpc-6646 156 22 retaining retain VERB dpc-6646 156 23 the the DET dpc-6646 156 24 current current ADJ dpc-6646 156 25 drug drug NOUN dpc-6646 156 26 ; ; PUNCT dpc-6646 156 27 moreover moreover ADV dpc-6646 156 28 , , PUNCT dpc-6646 156 29 in in ADP dpc-6646 156 30 our our PRON dpc-6646 156 31 cohort cohort NOUN dpc-6646 156 32 , , PUNCT dpc-6646 156 33 we we PRON dpc-6646 156 34 demonstrated demonstrate VERB dpc-6646 156 35 that that SCONJ dpc-6646 156 36 specifically specifically ADV dpc-6646 156 37 a a DET dpc-6646 156 38 history history NOUN dpc-6646 156 39 of of ADP dpc-6646 156 40 treatment treatment NOUN dpc-6646 156 41 with with ADP dpc-6646 156 42 il-17 il-17 NOUN dpc-6646 156 43 inhibitors inhibitor NOUN dpc-6646 156 44 may may AUX dpc-6646 156 45 predict predict VERB dpc-6646 156 46 reduced reduce VERB dpc-6646 156 47 persistence persistence NOUN dpc-6646 156 48 with with ADP dpc-6646 156 49 guselkumab guselkumab NOUN dpc-6646 156 50 , , PUNCT dpc-6646 156 51 whereas whereas SCONJ dpc-6646 156 52 prior prior ADJ dpc-6646 156 53 use use NOUN dpc-6646 156 54 of of ADP dpc-6646 156 55 other other ADJ dpc-6646 156 56 biologic biologic NOUN dpc-6646 156 57 classes class NOUN dpc-6646 156 58 does do AUX dpc-6646 156 59 not not PART dpc-6646 156 60 appear appear VERB dpc-6646 156 61 to to PART dpc-6646 156 62 have have VERB dpc-6646 156 63 a a DET dpc-6646 156 64 significant significant ADJ dpc-6646 156 65 impact impact NOUN dpc-6646 156 66 . . PUNCT dpc-6646 157 1 interestingly interestingly ADV dpc-6646 157 2 , , PUNCT dpc-6646 157 3 the the DET dpc-6646 157 4 involvement involvement NOUN dpc-6646 157 5 of of ADP dpc-6646 157 6 difficult difficult ADJ dpc-6646 157 7 - - PUNCT dpc-6646 157 8 to to ADP dpc-6646 157 9 - - PUNCT dpc-6646 157 10 treat treat NOUN dpc-6646 157 11 areas area NOUN dpc-6646 157 12 did do AUX dpc-6646 157 13 not not PART dpc-6646 157 14 appear appear VERB dpc-6646 157 15 as as ADP dpc-6646 157 16 a a DET dpc-6646 157 17 significant significant ADJ dpc-6646 157 18 predictor predictor NOUN dpc-6646 157 19 of of ADP dpc-6646 157 20 treatment treatment NOUN dpc-6646 157 21 discontinuation discontinuation NOUN dpc-6646 157 22 in in ADP dpc-6646 157 23 the the DET dpc-6646 157 24 multivariate multivariate NOUN dpc-6646 157 25 analysis analysis NOUN dpc-6646 157 26 , , PUNCT dpc-6646 157 27 except except SCONJ dpc-6646 157 28 for for ADP dpc-6646 157 29 genital genital ADJ dpc-6646 157 30 psoriasis psoriasis NOUN dpc-6646 157 31 , , PUNCT dpc-6646 157 32 which which PRON dpc-6646 157 33 showed show VERB dpc-6646 157 34 a a DET dpc-6646 157 35 trend trend NOUN dpc-6646 157 36 toward toward ADP dpc-6646 157 37 a a DET dpc-6646 157 38 lower low ADJ dpc-6646 157 39 dropout dropout NOUN dpc-6646 157 40 risk risk NOUN dpc-6646 157 41 ( ( PUNCT dpc-6646 157 42 p=0.0539 p=0.0539 NOUN dpc-6646 157 43 ) ) PUNCT dpc-6646 157 44 . . PUNCT dpc-6646 158 1 this this DET dpc-6646 158 2 observation observation NOUN dpc-6646 158 3 may may AUX dpc-6646 158 4 reflect reflect VERB dpc-6646 158 5 a a DET dpc-6646 158 6 higher high ADJ dpc-6646 158 7 observed observe VERB dpc-6646 158 8 benefit benefit NOUN dpc-6646 158 9 among among ADP dpc-6646 158 10 patients patient NOUN dpc-6646 158 11 with with ADP dpc-6646 158 12 diseases disease NOUN dpc-6646 158 13 in in ADP dpc-6646 158 14 sensitive sensitive ADJ dpc-6646 158 15 or or CCONJ dpc-6646 158 16 high high ADJ dpc-6646 158 17 impact impact NOUN dpc-6646 158 18 locations location NOUN dpc-6646 158 19 , , PUNCT dpc-6646 158 20 potentially potentially ADV dpc-6646 158 21 improving improve VERB dpc-6646 158 22 treatment treatment NOUN dpc-6646 158 23 adherence adherence NOUN dpc-6646 158 24 . . PUNCT dpc-6646 159 1 this this DET dpc-6646 159 2 study study NOUN dpc-6646 159 3 presents present VERB dpc-6646 159 4 some some DET dpc-6646 159 5 limitations limitation NOUN dpc-6646 159 6 . . PUNCT dpc-6646 160 1 first first ADV dpc-6646 160 2 , , PUNCT dpc-6646 160 3 the the DET dpc-6646 160 4 retrospective retrospective ADJ dpc-6646 160 5 design design NOUN dpc-6646 160 6 may may AUX dpc-6646 160 7 have have AUX dpc-6646 160 8 introduced introduce VERB dpc-6646 160 9 selection selection NOUN dpc-6646 160 10 and and CCONJ dpc-6646 160 11 information information NOUN dpc-6646 160 12 biases bias NOUN dpc-6646 160 13 , , PUNCT dpc-6646 160 14 and and CCONJ dpc-6646 160 15 some some DET dpc-6646 160 16 clinical clinical ADJ dpc-6646 160 17 data datum NOUN dpc-6646 160 18 , , PUNCT dpc-6646 160 19 such such ADJ dpc-6646 160 20 as as ADP dpc-6646 160 21 patient patient NOUN dpc-6646 160 22 - - PUNCT dpc-6646 160 23 reported report VERB dpc-6646 160 24 outcomes outcome NOUN dpc-6646 160 25 or or CCONJ dpc-6646 160 26 reasons reason NOUN dpc-6646 160 27 for for ADP dpc-6646 160 28 discontinuation discontinuation NOUN dpc-6646 160 29 , , PUNCT dpc-6646 160 30 may may AUX dpc-6646 160 31 be be AUX dpc-6646 160 32 incomplete incomplete ADJ dpc-6646 160 33 or or CCONJ dpc-6646 160 34 have have AUX dpc-6646 160 35 been be AUX dpc-6646 160 36 recorded record VERB dpc-6646 160 37 inconsistently inconsistently ADV dpc-6646 160 38 across across ADP dpc-6646 160 39 centers center NOUN dpc-6646 160 40 . . PUNCT dpc-6646 161 1 moreover moreover ADV dpc-6646 161 2 , , PUNCT dpc-6646 161 3 the the DET dpc-6646 161 4 lack lack NOUN dpc-6646 161 5 of of ADP dpc-6646 161 6 formal formal ADJ dpc-6646 161 7 diagnostic diagnostic ADJ dpc-6646 161 8 assessment assessment NOUN dpc-6646 161 9 for for ADP dpc-6646 161 10 comorbid comorbid NOUN dpc-6646 161 11 psoriatic psoriatic ADJ dpc-6646 161 12 arthritis arthritis NOUN dpc-6646 161 13 may may AUX dpc-6646 161 14 have have AUX dpc-6646 161 15 affected affect VERB dpc-6646 161 16 persistence persistence NOUN dpc-6646 161 17 estimates estimate NOUN dpc-6646 161 18 in in ADP dpc-6646 161 19 certain certain ADJ dpc-6646 161 20 cases case NOUN dpc-6646 161 21 . . PUNCT dpc-6646 162 1 future future ADJ dpc-6646 162 2 prospective prospective ADJ dpc-6646 162 3 studies study NOUN dpc-6646 162 4 integrating integrate VERB dpc-6646 162 5 clinical clinical ADJ dpc-6646 162 6 , , PUNCT dpc-6646 162 7 patient patient NOUN dpc-6646 162 8 reported report VERB dpc-6646 162 9 , , PUNCT dpc-6646 162 10 and and CCONJ dpc-6646 162 11 biomarker biomarker NOUN dpc-6646 162 12 data datum NOUN dpc-6646 162 13 are be AUX dpc-6646 162 14 necessary necessary ADJ dpc-6646 162 15 to to PART dpc-6646 162 16 better well ADV dpc-6646 162 17 characterize characterize VERB dpc-6646 162 18 long long ADJ dpc-6646 162 19 - - PUNCT dpc-6646 162 20 term term NOUN dpc-6646 162 21 treatment treatment NOUN dpc-6646 162 22 trajectories trajectory NOUN dpc-6646 162 23 with with ADP dpc-6646 162 24 guselkumab guselkumab NOUN dpc-6646 162 25 . . PUNCT dpc-6646 163 1 acknowledgments acknowledgment NOUN dpc-6646 163 2 : : PUNCT dpc-6646 164 1 editorial editorial NOUN dpc-6646 164 2 and and CCONJ dpc-6646 164 3 writing writing NOUN dpc-6646 164 4 assistance assistance NOUN dpc-6646 164 5 was be AUX dpc-6646 164 6 provided provide VERB dpc-6646 164 7 by by ADP dpc-6646 164 8 ctp ctp PROPN dpc-6646 164 9 , , PUNCT dpc-6646 164 10 srl srl PROPN dpc-6646 164 11 , , PUNCT dpc-6646 164 12 and and CCONJ dpc-6646 164 13 enrica enrica PROPN dpc-6646 164 14 piras piras PROPN dpc-6646 164 15 . . PUNCT dpc-6646 165 1 statistical statistical ADJ dpc-6646 165 2 analyses analysis NOUN dpc-6646 165 3 were be AUX dpc-6646 165 4 provided provide VERB dpc-6646 165 5 by by ADP dpc-6646 165 6 ctp ctp PROPN dpc-6646 165 7 , , PUNCT dpc-6646 165 8 srl srl PROPN dpc-6646 165 9 , , PUNCT dpc-6646 165 10 and and CCONJ dpc-6646 165 11 camilla camilla NOUN dpc-6646 165 12 ceccarani ceccarani NOUN dpc-6646 165 13 . . PUNCT dpc-6646 166 1 references reference NOUN dpc-6646 166 2 1 1 NUM dpc-6646 166 3 . . PUNCT dpc-6646 166 4 gisondi gisondi PROPN dpc-6646 166 5 p p NOUN dpc-6646 166 6 , , PUNCT dpc-6646 166 7 bellinato bellinato PROPN dpc-6646 166 8 f f PROPN dpc-6646 166 9 , , PUNCT dpc-6646 166 10 girolomoni girolomoni VERB dpc-6646 166 11 g g NOUN dpc-6646 166 12 , , PUNCT dpc-6646 166 13 albanesi albanesi PROPN dpc-6646 166 14 c. c. PROPN dpc-6646 166 15 pathogenesis pathogenesis PROPN dpc-6646 166 16 of of ADP dpc-6646 166 17 chronic chronic ADJ dpc-6646 166 18 plaque plaque NOUN dpc-6646 166 19 psoriasis psoriasis NOUN dpc-6646 166 20 and and CCONJ dpc-6646 166 21 its its PRON dpc-6646 166 22 intersection intersection NOUN dpc-6646 166 23 with with ADP dpc-6646 166 24 cardio cardio NOUN dpc-6646 166 25 - - PUNCT dpc-6646 166 26 metabolic metabolic NOUN dpc-6646 166 27 comorbidities comorbiditie NOUN dpc-6646 166 28 . . PUNCT dpc-6646 167 1 front front ADJ dpc-6646 167 2 pharmacol pharmacol PROPN dpc-6646 167 3 . . PUNCT dpc-6646 168 1 2020;11 2020;11 NUM dpc-6646 168 2 . . PUNCT dpc-6646 169 1 doi:10.3389 doi:10.3389 PROPN dpc-6646 169 2 / / SYM dpc-6646 169 3 fphar.2020.00117 fphar.2020.00117 PROPN dpc-6646 169 4 . . PROPN dpc-6646 170 1 2 2 X dpc-6646 170 2 . . X dpc-6646 170 3 thakre thakre PROPN dpc-6646 170 4 t t PROPN dpc-6646 170 5 , , PUNCT dpc-6646 170 6 deshmukh deshmukh PROPN dpc-6646 170 7 s. s. PROPN dpc-6646 170 8 article article PROPN dpc-6646 170 9 images image VERB dpc-6646 170 10 in in ADP dpc-6646 170 11 clinical clinical ADJ dpc-6646 170 12 medicine medicine NOUN dpc-6646 170 13 chronic chronic ADJ dpc-6646 170 14 plaque plaque NOUN dpc-6646 170 15 psoriasis psoriasis NOUN dpc-6646 170 16 . . PUNCT dpc-6646 171 1 doi:10.11604 doi:10.11604 VERB dpc-6646 171 2 / / SYM dpc-6646 171 3 pamj pamj NOUN dpc-6646 171 4 . . PUNCT dpc-6646 172 1 3 3 X dpc-6646 172 2 . . X dpc-6646 172 3 campione campione PROPN dpc-6646 172 4 e e NOUN dpc-6646 172 5 , , PUNCT dpc-6646 172 6 cosio cosio PROPN dpc-6646 172 7 t t PROPN dpc-6646 172 8 , , PUNCT dpc-6646 172 9 di di NOUN dpc-6646 172 10 prete prete PROPN dpc-6646 172 11 m m PROPN dpc-6646 172 12 , , PUNCT dpc-6646 172 13 lanna lanna PROPN dpc-6646 172 14 c c PROPN dpc-6646 172 15 , , PUNCT dpc-6646 172 16 dattola dattola PROPN dpc-6646 172 17 a a PRON dpc-6646 172 18 , , PUNCT dpc-6646 172 19 bianchi bianchi PROPN dpc-6646 172 20 l. l. PROPN dpc-6646 172 21 experimental experimental ADJ dpc-6646 172 22 pharmacological pharmacological NOUN dpc-6646 172 23 management management NOUN dpc-6646 172 24 of of ADP dpc-6646 172 25 psoriasis psoriasis NOUN dpc-6646 172 26 . . PUNCT dpc-6646 173 1 j j PROPN dpc-6646 173 2 exp exp NOUN dpc-6646 173 3 pharmacol pharmacol NOUN dpc-6646 173 4 . . PUNCT dpc-6646 174 1 2021;13:725 2021;13:725 VERB dpc-6646 174 2 - - PUNCT dpc-6646 174 3 737 737 NUM dpc-6646 174 4 . . PUNCT dpc-6646 174 5 doi:10.2147 doi:10.2147 NOUN dpc-6646 174 6 / / SYM dpc-6646 174 7 jep.s265632 jep.s265632 PROPN dpc-6646 174 8 . . PUNCT dpc-6646 175 1 4 4 X dpc-6646 175 2 . . X dpc-6646 175 3 chiricozzi chiricozzi PROPN dpc-6646 175 4 a a PROPN dpc-6646 175 5 , , PUNCT dpc-6646 175 6 zhang zhang PROPN dpc-6646 175 7 s s PROPN dpc-6646 175 8 , , PUNCT dpc-6646 175 9 dattola dattola PROPN dpc-6646 175 10 a a PRON dpc-6646 175 11 , , PUNCT dpc-6646 175 12 gabellini gabellini NOUN dpc-6646 175 13 m m PROPN dpc-6646 175 14 , , PUNCT dpc-6646 175 15 chimenti chimenti PROPN dpc-6646 175 16 s s PROPN dpc-6646 175 17 , , PUNCT dpc-6646 175 18 nistico nistico NOUN dpc-6646 175 19 sp sp NOUN dpc-6646 175 20 . . NOUN dpc-6646 175 21 role role NOUN dpc-6646 175 22 of of ADP dpc-6646 175 23 th17 th17 PROPN dpc-6646 175 24 in in ADP dpc-6646 175 25 the the DET dpc-6646 175 26 pathogenesis pathogenesis NOUN dpc-6646 175 27 of of ADP dpc-6646 175 28 cutaneous cutaneous ADJ dpc-6646 175 29 inflammatory inflammatory ADJ dpc-6646 175 30 diseases disease NOUN dpc-6646 175 31 . . PUNCT dpc-6646 176 1 j j PROPN dpc-6646 176 2 biol biol PROPN dpc-6646 176 3 regul regul PROPN dpc-6646 176 4 homeost homeost ADJ dpc-6646 176 5 agents agent NOUN dpc-6646 176 6 . . PUNCT dpc-6646 177 1 2012;26(3):313 2012;26(3):313 NUM dpc-6646 177 2 - - PUNCT dpc-6646 177 3 318 318 NUM dpc-6646 177 4 . . PUNCT dpc-6646 178 1 5 5 NUM dpc-6646 178 2 . . X dpc-6646 179 1 sbidian sbidian PROPN dpc-6646 179 2 e e PROPN dpc-6646 179 3 , , PUNCT dpc-6646 179 4 chaimani chaimani X dpc-6646 179 5 a a PRON dpc-6646 179 6 , , PUNCT dpc-6646 179 7 garcia garcia PROPN dpc-6646 179 8 - - PUNCT dpc-6646 179 9 doval doval PROPN dpc-6646 179 10 i i PROPN dpc-6646 179 11 , , PUNCT dpc-6646 179 12 et et PROPN dpc-6646 179 13 al al PROPN dpc-6646 179 14 . . PUNCT dpc-6646 180 1 systemic systemic ADJ dpc-6646 180 2 pharmacological pharmacological ADJ dpc-6646 180 3 treatments treatment NOUN dpc-6646 180 4 for for ADP dpc-6646 180 5 chronic chronic ADJ dpc-6646 180 6 plaque plaque NOUN dpc-6646 180 7 psoriasis psoriasis NOUN dpc-6646 180 8 : : PUNCT dpc-6646 180 9 a a DET dpc-6646 180 10 network network NOUN dpc-6646 180 11 meta meta NOUN dpc-6646 180 12 - - PUNCT dpc-6646 180 13 analysis analysis NOUN dpc-6646 180 14 . . PUNCT dpc-6646 181 1 cochrane cochrane NOUN dpc-6646 181 2 database database PROPN dpc-6646 181 3 syst syst PROPN dpc-6646 181 4 rev rev PROPN dpc-6646 181 5 . . PUNCT dpc-6646 182 1 2022;5(5):cd011535 2022;5(5):cd011535 NUM dpc-6646 182 2 . . PUNCT dpc-6646 183 1 published publish VERB dpc-6646 183 2 2022 2022 NUM dpc-6646 183 3 may may AUX dpc-6646 183 4 23 23 NUM dpc-6646 183 5 . . PUNCT dpc-6646 184 1 doi:10.1002/14651858.cd011535 doi:10.1002/14651858.cd011535 PROPN dpc-6646 184 2 . . PUNCT dpc-6646 185 1 pub5 pub5 NOUN dpc-6646 185 2 . . PUNCT dpc-6646 186 1 6 6 NUM dpc-6646 186 2 . . X dpc-6646 186 3 colombo colombo PROPN dpc-6646 186 4 d d PROPN dpc-6646 186 5 , , PUNCT dpc-6646 186 6 perego perego PROPN dpc-6646 186 7 r. r. PROPN dpc-6646 186 8 quality quality NOUN dpc-6646 186 9 of of ADP dpc-6646 186 10 life life NOUN dpc-6646 186 11 in in ADP dpc-6646 186 12 psoriasis psoriasis NOUN dpc-6646 186 13 . . PUNCT dpc-6646 187 1 in in ADP dpc-6646 187 2 : : PUNCT dpc-6646 187 3 psoriasis psoriasis NOUN dpc-6646 187 4 types type NOUN dpc-6646 187 5 , , PUNCT dpc-6646 187 6 causes cause NOUN dpc-6646 187 7 and and CCONJ dpc-6646 187 8 medication medication NOUN dpc-6646 187 9 . . PUNCT dpc-6646 188 1 intech intech PROPN dpc-6646 188 2 ; ; PUNCT dpc-6646 188 3 2013 2013 NUM dpc-6646 188 4 . . PUNCT dpc-6646 189 1 doi:10.5772/53998 doi:10.5772/53998 X dpc-6646 189 2 . . PUNCT dpc-6646 190 1 consistently consistently ADV dpc-6646 190 2 high high ADV dpc-6646 190 3 and and CCONJ dpc-6646 190 4 did do AUX dpc-6646 190 5 not not PART dpc-6646 190 6 appear appear VERB dpc-6646 190 7 to to PART dpc-6646 190 8 be be AUX dpc-6646 190 9 significantly significantly ADV dpc-6646 190 10 influenced influence VERB dpc-6646 190 11 by by ADP dpc-6646 190 12 baseline baseline ADJ dpc-6646 190 13 weight weight NOUN dpc-6646 190 14 or or CCONJ dpc-6646 190 15 bmi bmi NOUN dpc-6646 190 16 . . PUNCT dpc-6646 191 1 these these DET dpc-6646 191 2 results result NOUN dpc-6646 191 3 align align VERB dpc-6646 191 4 with with ADP dpc-6646 191 5 findings finding NOUN dpc-6646 191 6 from from ADP dpc-6646 191 7 other other ADJ dpc-6646 191 8 studies study NOUN dpc-6646 191 9 , , PUNCT dpc-6646 191 10 which which PRON dpc-6646 191 11 have have AUX dpc-6646 191 12 shown show VERB dpc-6646 191 13 that that SCONJ dpc-6646 191 14 drug drug NOUN dpc-6646 191 15 survival survival NOUN dpc-6646 191 16 is be AUX dpc-6646 191 17 not not PART dpc-6646 191 18 affected affect VERB dpc-6646 191 19 by by ADP dpc-6646 191 20 patient patient ADJ dpc-6646 191 21 weight weight NOUN dpc-6646 191 22 or or CCONJ dpc-6646 191 23 bmi bmi NOUN dpc-6646 191 24 [ [ X dpc-6646 191 25 21,24 21,24 X dpc-6646 191 26 ] ] PUNCT dpc-6646 191 27 . . PUNCT dpc-6646 192 1 chiricozzi chiricozzi PROPN dpc-6646 192 2 et et PROPN dpc-6646 192 3 al al PROPN dpc-6646 192 4 . . PROPN dpc-6646 192 5 investigated investigate VERB dpc-6646 192 6 how how SCONJ dpc-6646 192 7 age age NOUN dpc-6646 192 8 affects affect VERB dpc-6646 192 9 the the DET dpc-6646 192 10 drug drug NOUN dpc-6646 192 11 survival survival NOUN dpc-6646 192 12 of of ADP dpc-6646 192 13 il-17 il-17 NUM dpc-6646 192 14 and and CCONJ dpc-6646 192 15 il-23 il-23 VERB dpc-6646 192 16 inhibitors inhibitor NOUN dpc-6646 192 17 in in ADP dpc-6646 192 18 patients patient NOUN dpc-6646 192 19 with with ADP dpc-6646 192 20 moderate moderate ADJ dpc-6646 192 21 - - PUNCT dpc-6646 192 22 to to ADP dpc-6646 192 23 - - PUNCT dpc-6646 192 24 severe severe ADJ dpc-6646 192 25 plaque plaque NOUN dpc-6646 192 26 psoriasis psoriasis NOUN dpc-6646 192 27 , , PUNCT dpc-6646 192 28 analyzing analyze VERB dpc-6646 192 29 4,178 4,178 NUM dpc-6646 192 30 patients patient NOUN dpc-6646 192 31 and and CCONJ dpc-6646 192 32 4,866 4,866 NUM dpc-6646 192 33 treatment treatment NOUN dpc-6646 192 34 lines line NOUN dpc-6646 192 35 in in ADP dpc-6646 192 36 a a DET dpc-6646 192 37 large large ADJ dpc-6646 192 38 retrospective retrospective ADJ dpc-6646 192 39 multicenter multicenter NOUN dpc-6646 192 40 cohort cohort NOUN dpc-6646 192 41 . . PUNCT dpc-6646 193 1 the the DET dpc-6646 193 2 results result NOUN dpc-6646 193 3 showed show VERB dpc-6646 193 4 that that SCONJ dpc-6646 193 5 aging age VERB dpc-6646 193 6 negatively negatively ADV dpc-6646 193 7 affects affect VERB dpc-6646 193 8 overall overall ADJ dpc-6646 193 9 treatment treatment NOUN dpc-6646 193 10 persistence persistence NOUN dpc-6646 193 11 , , PUNCT dpc-6646 193 12 but but CCONJ dpc-6646 193 13 this this DET dpc-6646 193 14 impact impact NOUN dpc-6646 193 15 was be AUX dpc-6646 193 16 notably notably ADV dpc-6646 193 17 stronger strong ADJ dpc-6646 193 18 for for ADP dpc-6646 193 19 il-17 il-17 X dpc-6646 193 20 inhibitors inhibitor NOUN dpc-6646 193 21 . . PUNCT dpc-6646 194 1 conversely conversely ADV dpc-6646 194 2 , , PUNCT dpc-6646 194 3 il-23 il-23 ADJ dpc-6646 194 4 inhibitors inhibitor NOUN dpc-6646 194 5 maintained maintain VERB dpc-6646 194 6 high high ADJ dpc-6646 194 7 drug drug NOUN dpc-6646 194 8 survival survival NOUN dpc-6646 194 9 even even ADV dpc-6646 194 10 in in ADP dpc-6646 194 11 elderly elderly ADJ dpc-6646 194 12 patients patient NOUN dpc-6646 194 13 , , PUNCT dpc-6646 194 14 indicating indicate VERB dpc-6646 194 15 greater great ADJ dpc-6646 194 16 resilience resilience NOUN dpc-6646 194 17 to to ADP dpc-6646 194 18 age age NOUN dpc-6646 194 19 - - PUNCT dpc-6646 194 20 related relate VERB dpc-6646 194 21 discontinuation discontinuation NOUN dpc-6646 194 22 [ [ X dpc-6646 194 23 25 25 NUM dpc-6646 194 24 ] ] PUNCT dpc-6646 194 25 . . PUNCT dpc-6646 195 1 these these DET dpc-6646 195 2 findings finding NOUN dpc-6646 195 3 suggest suggest VERB dpc-6646 195 4 that that SCONJ dpc-6646 195 5 , , PUNCT dpc-6646 195 6 unlike unlike ADP dpc-6646 195 7 il-17 il-17 ADP dpc-6646 195 8 inhibitors inhibitor NOUN dpc-6646 195 9 , , PUNCT dpc-6646 195 10 the the DET dpc-6646 195 11 persistence persistence NOUN dpc-6646 195 12 of of ADP dpc-6646 195 13 il-23 il-23 NOUN dpc-6646 195 14 inhibitors inhibitor NOUN dpc-6646 195 15 is be AUX dpc-6646 195 16 minimally minimally ADV dpc-6646 195 17 influenced influence VERB dpc-6646 195 18 by by ADP dpc-6646 195 19 patient patient ADJ dpc-6646 195 20 age age NOUN dpc-6646 195 21 . . PUNCT dpc-6646 196 1 this this DET dpc-6646 196 2 age age NOUN dpc-6646 196 3 - - PUNCT dpc-6646 196 4 related relate VERB dpc-6646 196 5 trend trend NOUN dpc-6646 196 6 was be AUX dpc-6646 196 7 also also ADV dpc-6646 196 8 confirmed confirm VERB dpc-6646 196 9 in in ADP dpc-6646 196 10 our our PRON dpc-6646 196 11 study study NOUN dpc-6646 196 12 , , PUNCT dpc-6646 196 13 where where SCONJ dpc-6646 196 14 patient patient ADJ dpc-6646 196 15 age age NOUN dpc-6646 196 16 did do AUX dpc-6646 196 17 not not PART dpc-6646 196 18 significantly significantly ADV dpc-6646 196 19 affect affect VERB dpc-6646 196 20 the the DET dpc-6646 196 21 long long ADJ dpc-6646 196 22 - - PUNCT dpc-6646 196 23 term term NOUN dpc-6646 196 24 drug drug NOUN dpc-6646 196 25 survival survival NOUN dpc-6646 196 26 of of ADP dpc-6646 196 27 guselkumab guselkumab NOUN dpc-6646 196 28 . . PUNCT dpc-6646 197 1 in in ADP dpc-6646 197 2 the the DET dpc-6646 197 3 australian australian ADJ dpc-6646 197 4 psoriasis psoriasis NOUN dpc-6646 197 5 registry registry NOUN dpc-6646 197 6 , , PUNCT dpc-6646 197 7 guselkumab guselkumab NOUN dpc-6646 197 8 demonstrated demonstrate VERB dpc-6646 197 9 high high ADJ dpc-6646 197 10 drug drug NOUN dpc-6646 197 11 survival survival NOUN dpc-6646 197 12 rates rate NOUN dpc-6646 197 13 , , PUNCT dpc-6646 197 14 with with ADP dpc-6646 197 15 93.1 93.1 NUM dpc-6646 197 16 % % NOUN dpc-6646 197 17 at at ADP dpc-6646 197 18 nine nine NUM dpc-6646 197 19 months month NOUN dpc-6646 197 20 for for ADP dpc-6646 197 21 bio bio ADJ dpc-6646 197 22 - - ADJ dpc-6646 197 23 experienced experienced ADJ dpc-6646 197 24 patients patient NOUN dpc-6646 197 25 , , PUNCT dpc-6646 197 26 compared compare VERB dpc-6646 197 27 to to ADP dpc-6646 197 28 100 100 NUM dpc-6646 197 29 % % NOUN dpc-6646 197 30 for for ADP dpc-6646 197 31 bionaïve bionaïve NOUN dpc-6646 197 32 patients patient NOUN dpc-6646 197 33 . . PUNCT dpc-6646 198 1 overall overall ADJ dpc-6646 198 2 drug drug NOUN dpc-6646 198 3 survival survival NOUN dpc-6646 198 4 was be AUX dpc-6646 198 5 99.0 99.0 NUM dpc-6646 198 6 % % NOUN dpc-6646 198 7 , , PUNCT dpc-6646 198 8 83.3 83.3 NUM dpc-6646 198 9 % % NOUN dpc-6646 198 10 , , PUNCT dpc-6646 198 11 and and CCONJ dpc-6646 198 12 77.1 77.1 NUM dpc-6646 198 13 % % NOUN dpc-6646 198 14 at at ADP dpc-6646 198 15 three three NUM dpc-6646 198 16 , , PUNCT dpc-6646 198 17 15 15 NUM dpc-6646 198 18 , , PUNCT dpc-6646 198 19 and and CCONJ dpc-6646 198 20 27 27 NUM dpc-6646 198 21 months month NOUN dpc-6646 198 22 , , PUNCT dpc-6646 198 23 respectively respectively ADV dpc-6646 198 24 . . PUNCT dpc-6646 199 1 the the DET dpc-6646 199 2 study study NOUN dpc-6646 199 3 found find VERB dpc-6646 199 4 that that SCONJ dpc-6646 199 5 bio bio ADJ dpc-6646 199 6 - - ADJ dpc-6646 199 7 naïve naïve ADJ dpc-6646 199 8 patients patient NOUN dpc-6646 199 9 had have VERB dpc-6646 199 10 more more ADJ dpc-6646 199 11 prolonged prolonged ADJ dpc-6646 199 12 drug drug NOUN dpc-6646 199 13 survival survival NOUN dpc-6646 199 14 than than ADP dpc-6646 199 15 those those PRON dpc-6646 199 16 with with ADP dpc-6646 199 17 prior prior ADJ dpc-6646 199 18 biologic biologic NOUN dpc-6646 199 19 therapy therapy NOUN dpc-6646 199 20 [ [ X dpc-6646 199 21 26 26 NUM dpc-6646 199 22 ] ] PUNCT dpc-6646 199 23 . . PUNCT dpc-6646 200 1 li li PROPN dpc-6646 200 2 et et PROPN dpc-6646 200 3 al al PROPN dpc-6646 200 4 . . PROPN dpc-6646 200 5 conducted conduct VERB dpc-6646 200 6 a a DET dpc-6646 200 7 retrospective retrospective ADJ dpc-6646 200 8 analysis analysis NOUN dpc-6646 200 9 of of ADP dpc-6646 200 10 386 386 NUM dpc-6646 200 11 patients patient NOUN dpc-6646 200 12 with with ADP dpc-6646 200 13 plaque plaque NOUN dpc-6646 200 14 psoriasis psoriasis NOUN dpc-6646 200 15 treated treat VERB dpc-6646 200 16 with with ADP dpc-6646 200 17 biologics biologic NOUN dpc-6646 200 18 ( ( PUNCT dpc-6646 200 19 ixekizumab ixekizumab NOUN dpc-6646 200 20 , , PUNCT dpc-6646 200 21 secukinumab secukinumab NOUN dpc-6646 200 22 , , PUNCT dpc-6646 200 23 guselkumab guselkumab NOUN dpc-6646 200 24 , , PUNCT dpc-6646 200 25 and and CCONJ dpc-6646 200 26 adalimumab adalimumab NOUN dpc-6646 200 27 ) ) PUNCT dpc-6646 200 28 over over ADP dpc-6646 200 29 a a DET dpc-6646 200 30 52 52 NUM dpc-6646 200 31 - - PUNCT dpc-6646 200 32 week week NOUN dpc-6646 200 33 period period NOUN dpc-6646 200 34 , , PUNCT dpc-6646 200 35 revealing reveal VERB dpc-6646 200 36 that that DET dpc-6646 200 37 guselkumab guselkumab NOUN dpc-6646 200 38 had have VERB dpc-6646 200 39 the the DET dpc-6646 200 40 highest high ADJ dpc-6646 200 41 drug drug NOUN dpc-6646 200 42 survival survival NOUN dpc-6646 200 43 rate rate NOUN dpc-6646 200 44 at at ADP dpc-6646 200 45 72.2 72.2 NUM dpc-6646 200 46 % % NOUN dpc-6646 200 47 . . PUNCT dpc-6646 201 1 additionally additionally ADV dpc-6646 201 2 , , PUNCT dpc-6646 201 3 results result NOUN dpc-6646 201 4 showed show VERB dpc-6646 201 5 that that SCONJ dpc-6646 201 6 , , PUNCT dpc-6646 201 7 among among ADP dpc-6646 201 8 bio bio ADJ dpc-6646 201 9 - - ADJ dpc-6646 201 10 naive naive ADJ dpc-6646 201 11 patients patient NOUN dpc-6646 201 12 , , PUNCT dpc-6646 201 13 drug drug NOUN dpc-6646 201 14 survival survival NOUN dpc-6646 201 15 rates rate NOUN dpc-6646 201 16 tended tend VERB dpc-6646 201 17 to to PART dpc-6646 201 18 be be AUX dpc-6646 201 19 higher high ADJ dpc-6646 201 20 compared compare VERB dpc-6646 201 21 to to ADP dpc-6646 201 22 bio bio ADJ dpc-6646 201 23 - - ADJ dpc-6646 201 24 experienced experienced ADJ dpc-6646 201 25 patients patient NOUN dpc-6646 201 26 , , PUNCT dpc-6646 201 27 although although SCONJ dpc-6646 201 28 these these DET dpc-6646 201 29 differences difference NOUN dpc-6646 201 30 were be AUX dpc-6646 201 31 not not PART dpc-6646 201 32 statistically statistically ADV dpc-6646 201 33 significant significant ADJ dpc-6646 201 34 [ [ X dpc-6646 201 35 27 27 NUM dpc-6646 201 36 ] ] PUNCT dpc-6646 201 37 . . PUNCT dpc-6646 202 1 according accord VERB dpc-6646 202 2 to to ADP dpc-6646 202 3 these these DET dpc-6646 202 4 studies study NOUN dpc-6646 202 5 , , PUNCT dpc-6646 202 6 in in ADP dpc-6646 202 7 our our PRON dpc-6646 202 8 work work NOUN dpc-6646 202 9 , , PUNCT dpc-6646 202 10 treatment treatment NOUN dpc-6646 202 11 persistence persistence NOUN dpc-6646 202 12 with with ADP dpc-6646 202 13 guselkumab guselkumab NOUN dpc-6646 202 14 was be AUX dpc-6646 202 15 analyzed analyze VERB dpc-6646 202 16 based base VERB dpc-6646 202 17 on on ADP dpc-6646 202 18 previous previous ADJ dpc-6646 202 19 exposure exposure NOUN dpc-6646 202 20 to to ADP dpc-6646 202 21 biologic biologic ADJ dpc-6646 202 22 therapies therapy NOUN dpc-6646 202 23 . . PUNCT dpc-6646 203 1 patients patient NOUN dpc-6646 203 2 were be AUX dpc-6646 203 3 categorized categorize VERB dpc-6646 203 4 as as ADP dpc-6646 203 5 bio bio NOUN dpc-6646 203 6 - - ADJ dpc-6646 203 7 naïve naïve ADJ dpc-6646 203 8 or or CCONJ dpc-6646 203 9 bio bio ADV dpc-6646 203 10 - - ADJ dpc-6646 203 11 experienced experienced ADJ dpc-6646 203 12 . . PUNCT dpc-6646 204 1 at at ADP dpc-6646 204 2 12 12 NUM dpc-6646 204 3 months month NOUN dpc-6646 204 4 , , PUNCT dpc-6646 204 5 persistence persistence NOUN dpc-6646 204 6 was be AUX dpc-6646 204 7 95.7 95.7 NUM dpc-6646 204 8 % % NOUN dpc-6646 204 9 in in ADP dpc-6646 204 10 the the DET dpc-6646 204 11 bio bio ADJ dpc-6646 204 12 - - ADJ dpc-6646 204 13 naïve naïve ADJ dpc-6646 204 14 group group NOUN dpc-6646 204 15 and and CCONJ dpc-6646 204 16 90.8 90.8 NUM dpc-6646 204 17 % % NOUN dpc-6646 204 18 in in ADP dpc-6646 204 19 the the DET dpc-6646 204 20 bio bio ADJ dpc-6646 204 21 - - PUNCT dpc-6646 204 22 experienced experienced ADJ dpc-6646 204 23 group group NOUN dpc-6646 204 24 . . PUNCT dpc-6646 205 1 this this DET dpc-6646 205 2 difference difference NOUN dpc-6646 205 3 remained remain VERB dpc-6646 205 4 evident evident ADJ dpc-6646 205 5 over over ADP dpc-6646 205 6 time time NOUN dpc-6646 205 7 : : PUNCT dpc-6646 205 8 at at ADP dpc-6646 205 9 60 60 NUM dpc-6646 205 10 months month NOUN dpc-6646 205 11 , , PUNCT dpc-6646 205 12 82.6 82.6 NUM dpc-6646 205 13 % % NOUN dpc-6646 205 14 of of ADP dpc-6646 205 15 bionaïve bionaïve NOUN dpc-6646 205 16 patients patient NOUN dpc-6646 205 17 were be AUX dpc-6646 205 18 still still ADV dpc-6646 205 19 on on ADP dpc-6646 205 20 treatment treatment NOUN dpc-6646 205 21 , , PUNCT dpc-6646 205 22 compared compare VERB dpc-6646 205 23 to to ADP dpc-6646 205 24 68.7 68.7 NUM dpc-6646 205 25 % % NOUN dpc-6646 205 26 of of ADP dpc-6646 205 27 bio bio ADJ dpc-6646 205 28 - - ADJ dpc-6646 205 29 experienced experienced ADJ dpc-6646 205 30 patients patient NOUN dpc-6646 205 31 . . PUNCT dpc-6646 206 1 these these DET dpc-6646 206 2 data datum NOUN dpc-6646 206 3 suggest suggest VERB dpc-6646 206 4 a a DET dpc-6646 206 5 higher high ADJ dpc-6646 206 6 longterm longterm ADJ dpc-6646 206 7 persistence persistence NOUN dpc-6646 206 8 among among ADP dpc-6646 206 9 patients patient NOUN dpc-6646 206 10 who who PRON dpc-6646 206 11 had have AUX dpc-6646 206 12 not not PART dpc-6646 206 13 previously previously ADV dpc-6646 206 14 received receive VERB dpc-6646 206 15 biologic biologic NOUN dpc-6646 206 16 therapies therapy NOUN dpc-6646 206 17 , , PUNCT dpc-6646 206 18 indicating indicate VERB dpc-6646 206 19 that that SCONJ dpc-6646 206 20 a a DET dpc-6646 206 21 previous previous ADJ dpc-6646 206 22 exposure exposure NOUN dpc-6646 206 23 to to ADP dpc-6646 206 24 biologics biologic NOUN dpc-6646 206 25 may may AUX dpc-6646 206 26 be be AUX dpc-6646 206 27 associated associate VERB dpc-6646 206 28 with with ADP dpc-6646 206 29 an an DET dpc-6646 206 30 increased increase VERB dpc-6646 206 31 likelihood likelihood NOUN dpc-6646 206 32 of of ADP dpc-6646 206 33 treatment treatment NOUN dpc-6646 206 34 discontinuation discontinuation NOUN dpc-6646 206 35 . . PUNCT dpc-6646 207 1 the the DET dpc-6646 207 2 multivariate multivariate NOUN dpc-6646 207 3 analysis analysis NOUN dpc-6646 207 4 investigating investigate VERB dpc-6646 207 5 the the DET dpc-6646 207 6 impact impact NOUN dpc-6646 207 7 of of ADP dpc-6646 207 8 previous previous ADJ dpc-6646 207 9 biologic biologic NOUN dpc-6646 207 10 drug drug NOUN dpc-6646 207 11 classes class NOUN dpc-6646 207 12 on on ADP dpc-6646 207 13 guselkumab guselkumab NOUN dpc-6646 207 14 persistence persistence NOUN dpc-6646 207 15 revealed reveal VERB dpc-6646 207 16 that that SCONJ dpc-6646 207 17 the the DET dpc-6646 207 18 prior prior ADJ dpc-6646 207 19 use use NOUN dpc-6646 207 20 of of ADP dpc-6646 207 21 il-17 il-17 NOUN dpc-6646 207 22 inhibitors inhibitor NOUN dpc-6646 207 23 was be AUX dpc-6646 207 24 significantly significantly ADV dpc-6646 207 25 associated associate VERB dpc-6646 207 26 with with ADP dpc-6646 207 27 a a DET dpc-6646 207 28 higher high ADJ dpc-6646 207 29 risk risk NOUN dpc-6646 207 30 of of ADP dpc-6646 207 31 treatment treatment NOUN dpc-6646 207 32 discontinuation discontinuation NOUN dpc-6646 207 33 ( ( PUNCT dpc-6646 207 34 coefficient coefficient NOUN dpc-6646 207 35 : : PUNCT dpc-6646 207 36 0.7613 0.7613 NUM dpc-6646 207 37 ; ; PUNCT dpc-6646 207 38 p=0.0150 p=0.0150 NUM dpc-6646 207 39 ) ) PUNCT dpc-6646 207 40 . . PUNCT dpc-6646 208 1 no no DET dpc-6646 208 2 statistically statistically ADV dpc-6646 208 3 significant significant ADJ dpc-6646 208 4 association association NOUN dpc-6646 208 5 was be AUX dpc-6646 208 6 observed observe VERB dpc-6646 208 7 for for ADP dpc-6646 208 8 prior prior ADJ dpc-6646 208 9 exposure exposure NOUN dpc-6646 208 10 to to ADP dpc-6646 208 11 anti anti ADJ dpc-6646 208 12 - - ADJ dpc-6646 208 13 tnf tnf ADJ dpc-6646 208 14 - - PUNCT dpc-6646 208 15 α α NOUN dpc-6646 208 16 agents agent NOUN dpc-6646 208 17 ( ( PUNCT dpc-6646 208 18 p=0.2190 p=0.2190 PROPN dpc-6646 208 19 ) ) PUNCT dpc-6646 208 20 , , PUNCT dpc-6646 208 21 il-12/23 il-12/23 ADJ dpc-6646 208 22 inhibitors inhibitor NOUN dpc-6646 208 23 ( ( PUNCT dpc-6646 208 24 p=0.3330 p=0.3330 NOUN dpc-6646 208 25 ) ) PUNCT dpc-6646 208 26 , , PUNCT dpc-6646 208 27 or or CCONJ dpc-6646 208 28 il-23 il-23 NOUN dpc-6646 208 29 inhibitors inhibitor NOUN dpc-6646 208 30 ( ( PUNCT dpc-6646 208 31 p=0.9950 p=0.9950 PROPN dpc-6646 208 32 ) ) PUNCT dpc-6646 208 33 . . PUNCT dpc-6646 209 1 these these DET dpc-6646 209 2 original original ADJ dpc-6646 209 3 article article NOUN dpc-6646 209 4 | | ADV dpc-6646 209 5 dermatol dermatol ADJ dpc-6646 209 6 pract pract NOUN dpc-6646 209 7 concept concept NOUN dpc-6646 209 8 . . PUNCT dpc-6646 210 1 2025;15(4):6646 2025;15(4):6646 NUM dpc-6646 210 2 9 9 NUM dpc-6646 210 3 with with ADP dpc-6646 210 4 confirmed confirm VERB dpc-6646 210 5 diagnosis diagnosis NOUN dpc-6646 210 6 of of ADP dpc-6646 210 7 enthesitis enthesitis NOUN dpc-6646 210 8 . . PUNCT dpc-6646 211 1 ital ital PROPN dpc-6646 211 2 j j PROPN dpc-6646 211 3 dermatol dermatol PROPN dpc-6646 211 4 venerol venerol PROPN dpc-6646 211 5 . . PUNCT dpc-6646 212 1 2024;159(4):467 2024;159(4):467 NUM dpc-6646 212 2 - - SYM dpc-6646 212 3 469 469 NUM dpc-6646 212 4 . . PUNCT dpc-6646 212 5 doi:10.23736 doi:10.23736 PROPN dpc-6646 212 6 / / SYM dpc-6646 212 7 s2784 s2784 PROPN dpc-6646 212 8 - - PUNCT dpc-6646 212 9 8671.24.07921 8671.24.07921 NUM dpc-6646 212 10 - - SYM dpc-6646 212 11 0 0 NUM dpc-6646 212 12 . . NOUN dpc-6646 212 13 19 19 NUM dpc-6646 212 14 . . PUNCT dpc-6646 213 1 ting ting PROPN dpc-6646 213 2 s s PROPN dpc-6646 213 3 , , PUNCT dpc-6646 213 4 lowe lowe PROPN dpc-6646 213 5 p p PROPN dpc-6646 213 6 , , PUNCT dpc-6646 213 7 smith smith PROPN dpc-6646 213 8 a a PRON dpc-6646 213 9 , , PUNCT dpc-6646 213 10 fernández fernández PROPN dpc-6646 213 11 - - PUNCT dpc-6646 213 12 peñas peñas PROPN dpc-6646 213 13 p. p. PROPN dpc-6646 213 14 drug drug NOUN dpc-6646 213 15 survival survival NOUN dpc-6646 213 16 of of ADP dpc-6646 213 17 biologics biologic NOUN dpc-6646 213 18 in in ADP dpc-6646 213 19 psoriasis psoriasis NOUN dpc-6646 213 20 : : PUNCT dpc-6646 213 21 an an DET dpc-6646 213 22 australian australian ADJ dpc-6646 213 23 multicentre multicentre NOUN dpc-6646 213 24 retrospective retrospective ADJ dpc-6646 213 25 study study NOUN dpc-6646 213 26 . . PUNCT dpc-6646 214 1 australasian australasian ADJ dpc-6646 214 2 journal journal NOUN dpc-6646 214 3 of of ADP dpc-6646 214 4 dermatology dermatology NOUN dpc-6646 214 5 . . PUNCT dpc-6646 215 1 2024;65(4 2024;65(4 NUM dpc-6646 215 2 ): ): PUNCT dpc-6646 215 3 350 350 NUM dpc-6646 215 4 - - SYM dpc-6646 215 5 357 357 NUM dpc-6646 215 6 . . PUNCT dpc-6646 216 1 doi:10.1111 doi:10.1111 NOUN dpc-6646 216 2 / / SYM dpc-6646 216 3 ajd.14254 ajd.14254 NUM dpc-6646 216 4 . . PUNCT dpc-6646 217 1 20 20 NUM dpc-6646 217 2 . . PUNCT dpc-6646 217 3 mastorino mastorino PROPN dpc-6646 217 4 l l NOUN dpc-6646 217 5 , , PUNCT dpc-6646 217 6 dapavo dapavo VERB dpc-6646 217 7 p p NOUN dpc-6646 217 8 , , PUNCT dpc-6646 217 9 ortoncelli ortoncelli PROPN dpc-6646 217 10 m m PROPN dpc-6646 217 11 , , PUNCT dpc-6646 217 12 et et PROPN dpc-6646 217 13 al al PROPN dpc-6646 217 14 . . PROPN dpc-6646 217 15 drug drug NOUN dpc-6646 217 16 survival survival NOUN dpc-6646 217 17 , , PUNCT dpc-6646 217 18 effectiveness effectiveness NOUN dpc-6646 217 19 and and CCONJ dpc-6646 217 20 safety safety NOUN dpc-6646 217 21 of of ADP dpc-6646 217 22 guselkumab guselkumab NOUN dpc-6646 217 23 for for ADP dpc-6646 217 24 moderate moderate ADJ dpc-6646 217 25 - - PUNCT dpc-6646 217 26 to to ADP dpc-6646 217 27 - - PUNCT dpc-6646 217 28 severe severe ADJ dpc-6646 217 29 psoriasis psoriasis NOUN dpc-6646 217 30 for for ADP dpc-6646 217 31 up up ADP dpc-6646 217 32 to to PART dpc-6646 217 33 4 4 NUM dpc-6646 217 34 years year NOUN dpc-6646 217 35 . . PUNCT dpc-6646 218 1 clin clin PROPN dpc-6646 218 2 exp exp NOUN dpc-6646 218 3 dermatol dermatol NOUN dpc-6646 218 4 . . PUNCT dpc-6646 219 1 2025;50(8):1590 2025;50(8):1590 NUM dpc-6646 219 2 - - SYM dpc-6646 219 3 1597 1597 NUM dpc-6646 219 4 . . PUNCT dpc-6646 220 1 doi:10.1093 doi:10.1093 NOUN dpc-6646 220 2 / / SYM dpc-6646 220 3 ced ced PROPN dpc-6646 220 4 / / SYM dpc-6646 220 5 llaf010 llaf010 PROPN dpc-6646 220 6 . . PROPN dpc-6646 221 1 21 21 NUM dpc-6646 221 2 . . PUNCT dpc-6646 222 1 hugo hugo PROPN dpc-6646 222 2 j j PROPN dpc-6646 222 3 , , PUNCT dpc-6646 222 4 kojanova kojanova PROPN dpc-6646 222 5 m m PROPN dpc-6646 222 6 , , PUNCT dpc-6646 222 7 turkova turkova PRON dpc-6646 222 8 b b X dpc-6646 222 9 , , PUNCT dpc-6646 222 10 et et PROPN dpc-6646 222 11 al al PROPN dpc-6646 222 12 . . PUNCT dpc-6646 223 1 long long ADJ dpc-6646 223 2 - - PUNCT dpc-6646 223 3 term term NOUN dpc-6646 223 4 efficacy efficacy NOUN dpc-6646 223 5 , , PUNCT dpc-6646 223 6 safety safety NOUN dpc-6646 223 7 , , PUNCT dpc-6646 223 8 and and CCONJ dpc-6646 223 9 drug drug NOUN dpc-6646 223 10 survival survival NOUN dpc-6646 223 11 of of ADP dpc-6646 223 12 guselkumab guselkumab NOUN dpc-6646 223 13 in in ADP dpc-6646 223 14 patients patient NOUN dpc-6646 223 15 with with ADP dpc-6646 223 16 psoriasis psoriasis NOUN dpc-6646 223 17 : : PUNCT dpc-6646 223 18 real real ADJ dpc-6646 223 19 - - PUNCT dpc-6646 223 20 world world NOUN dpc-6646 223 21 data datum NOUN dpc-6646 223 22 from from ADP dpc-6646 223 23 the the DET dpc-6646 223 24 czech czech PROPN dpc-6646 223 25 republic republic NOUN dpc-6646 223 26 biorep biorep PROPN dpc-6646 223 27 registry registry PROPN dpc-6646 223 28 . . PUNCT dpc-6646 224 1 dermatol dermatol NOUN dpc-6646 224 2 ther ther ADV dpc-6646 224 3 ( ( PUNCT dpc-6646 224 4 heidelb heidelb NOUN dpc-6646 224 5 ) ) PUNCT dpc-6646 224 6 . . PUNCT dpc-6646 225 1 2023;13(3):787 2023;13(3):787 NUM dpc-6646 225 2 - - PUNCT dpc-6646 225 3 801 801 NUM dpc-6646 225 4 . . PUNCT dpc-6646 226 1 doi:10.1007 doi:10.1007 VERB dpc-6646 226 2 /s13555 /s13555 PROPN dpc-6646 226 3 - - PUNCT dpc-6646 226 4 023 023 NUM dpc-6646 226 5 - - PUNCT dpc-6646 226 6 00893 00893 NUM dpc-6646 226 7 - - PUNCT dpc-6646 226 8 4 4 NUM dpc-6646 226 9 . . NOUN dpc-6646 226 10 22 22 NUM dpc-6646 226 11 . . PUNCT dpc-6646 227 1 torres torres PROPN dpc-6646 227 2 t t PROPN dpc-6646 227 3 , , PUNCT dpc-6646 227 4 puig puig PROPN dpc-6646 227 5 l l NOUN dpc-6646 227 6 , , PUNCT dpc-6646 227 7 vender vender NOUN dpc-6646 227 8 r r NOUN dpc-6646 227 9 , , PUNCT dpc-6646 227 10 et et PROPN dpc-6646 227 11 al al PROPN dpc-6646 227 12 . . PROPN dpc-6646 227 13 drug drug PROPN dpc-6646 227 14 survival survival NOUN dpc-6646 227 15 of of ADP dpc-6646 227 16 interleukin interleukin NOUN dpc-6646 227 17 ( ( PUNCT dpc-6646 227 18 il)-17 il)-17 PROPN dpc-6646 227 19 and and CCONJ dpc-6646 227 20 il-23 il-23 VERB dpc-6646 227 21 inhibitors inhibitor NOUN dpc-6646 227 22 for for ADP dpc-6646 227 23 the the DET dpc-6646 227 24 treatment treatment NOUN dpc-6646 227 25 of of ADP dpc-6646 227 26 psoriasis psoriasis NOUN dpc-6646 227 27 : : PUNCT dpc-6646 227 28 a a DET dpc-6646 227 29 retrospective retrospective ADJ dpc-6646 227 30 multi multi ADJ dpc-6646 227 31 - - NOUN dpc-6646 227 32 country country NOUN dpc-6646 227 33 , , PUNCT dpc-6646 227 34 multicentric multicentric ADJ dpc-6646 227 35 cohort cohort NOUN dpc-6646 227 36 study study NOUN dpc-6646 227 37 . . PUNCT dpc-6646 228 1 am be AUX dpc-6646 228 2 j j PROPN dpc-6646 228 3 clin clin PROPN dpc-6646 228 4 dermatol.2022;23(6):891 dermatol.2022;23(6):891 PROPN dpc-6646 228 5 - - PUNCT dpc-6646 228 6 904.doi:10.1007 904.doi:10.1007 NUM dpc-6646 228 7 /s40257 /s40257 NOUN dpc-6646 228 8 - - PUNCT dpc-6646 228 9 022 022 NUM dpc-6646 228 10 - - PUNCT dpc-6646 228 11 00722 00722 NUM dpc-6646 228 12 - - PUNCT dpc-6646 228 13 y. y. NOUN dpc-6646 228 14 23 23 NUM dpc-6646 228 15 . . PUNCT dpc-6646 229 1 gargiulo gargiulo PROPN dpc-6646 229 2 l l NOUN dpc-6646 229 3 , , PUNCT dpc-6646 229 4 ibba ibba ADJ dpc-6646 229 5 l l NOUN dpc-6646 229 6 , , PUNCT dpc-6646 229 7 malagoli malagoli NOUN dpc-6646 229 8 p p NOUN dpc-6646 229 9 , , PUNCT dpc-6646 229 10 et et PROPN dpc-6646 229 11 al al PROPN dpc-6646 229 12 . . PUNCT dpc-6646 230 1 real real ADJ dpc-6646 230 2 - - PUNCT dpc-6646 230 3 life life NOUN dpc-6646 230 4 effectiveness effectiveness NOUN dpc-6646 230 5 and and CCONJ dpc-6646 230 6 safety safety NOUN dpc-6646 230 7 of of ADP dpc-6646 230 8 guselkumab guselkumab NOUN dpc-6646 230 9 in in ADP dpc-6646 230 10 patients patient NOUN dpc-6646 230 11 with with ADP dpc-6646 230 12 psoriasis psoriasis NOUN dpc-6646 230 13 who who PRON dpc-6646 230 14 have have VERB dpc-6646 230 15 an an DET dpc-6646 230 16 inadequate inadequate ADJ dpc-6646 230 17 response response NOUN dpc-6646 230 18 to to ADP dpc-6646 230 19 ustekinumab ustekinumab NOUN dpc-6646 230 20 : : PUNCT dpc-6646 230 21 a a DET dpc-6646 230 22     SPACE dpc-6646 230 23 104 104 NUM dpc-6646 230 24 - - PUNCT dpc-6646 230 25 week week NOUN dpc-6646 230 26 multicenter multicenter NOUN dpc-6646 230 27 retrospective retrospective ADJ dpc-6646 230 28 study study NOUN dpc-6646 230 29 – – PUNCT dpc-6646 230 30 il il PROPN dpc-6646 230 31 pso pso NOUN dpc-6646 230 32 ( ( PUNCT dpc-6646 230 33 italian italian ADJ dpc-6646 230 34 landscape landscape NOUN dpc-6646 230 35 psoriasis psoriasis NOUN dpc-6646 230 36 ) ) PUNCT dpc-6646 230 37 . . PUNCT dpc-6646 231 1 journal journal NOUN dpc-6646 231 2 of of ADP dpc-6646 231 3 the the DET dpc-6646 231 4 european european PROPN dpc-6646 231 5 academy academy PROPN dpc-6646 231 6 of of ADP dpc-6646 231 7 dermatology dermatology NOUN dpc-6646 231 8 and and CCONJ dpc-6646 231 9 venereology venereology NOUN dpc-6646 231 10 . . PUNCT dpc-6646 232 1 2023;37(5):1017 2023;37(5):1017 NUM dpc-6646 232 2 - - PUNCT dpc-6646 232 3 1027 1027 NUM dpc-6646 232 4 . . PUNCT dpc-6646 233 1 doi:10.1111 doi:10.1111 ADJ dpc-6646 233 2 / / SYM dpc-6646 233 3 jdv.18913 jdv.18913 PROPN dpc-6646 233 4 . . NOUN dpc-6646 233 5 24 24 NUM dpc-6646 233 6 . . PUNCT dpc-6646 233 7 del del PROPN dpc-6646 233 8 alcázar alcázar PROPN dpc-6646 233 9 e e PROPN dpc-6646 233 10 , , PUNCT dpc-6646 233 11 lópez lópez PROPN dpc-6646 233 12 - - PUNCT dpc-6646 233 13 ferrer ferrer PROPN dpc-6646 233 14 a a PRON dpc-6646 233 15 , , PUNCT dpc-6646 233 16 martínez martínez NOUN dpc-6646 233 17 - - PUNCT dpc-6646 233 18 doménech doménech PROPN dpc-6646 233 19 á á PROPN dpc-6646 233 20 , , PUNCT dpc-6646 233 21 et et PROPN dpc-6646 233 22 al al PROPN dpc-6646 233 23 . . PROPN dpc-6646 233 24 survival survival PROPN dpc-6646 233 25 of of ADP dpc-6646 233 26 guselkumab guselkumab NOUN dpc-6646 233 27 therapy therapy NOUN dpc-6646 233 28 in in ADP dpc-6646 233 29 moderate moderate ADJ dpc-6646 233 30 to to ADP dpc-6646 233 31 severe severe ADJ dpc-6646 233 32 plaque plaque NOUN dpc-6646 233 33 psoriasis psoriasis NOUN dpc-6646 233 34 at at ADP dpc-6646 233 35 52 52 NUM dpc-6646 233 36 weeks week NOUN dpc-6646 233 37 in in ADP dpc-6646 233 38 a a DET dpc-6646 233 39 real real ADJ dpc-6646 233 40 - - PUNCT dpc-6646 233 41 world world NOUN dpc-6646 233 42 clinical clinical ADJ dpc-6646 233 43 setting setting NOUN dpc-6646 233 44 : : PUNCT dpc-6646 233 45 observational observational ADJ dpc-6646 233 46 , , PUNCT dpc-6646 233 47 retrospective retrospective ADJ dpc-6646 233 48 , , PUNCT dpc-6646 233 49 multi multi ADJ dpc-6646 233 50 - - ADJ dpc-6646 233 51 centre centre ADJ dpc-6646 233 52 study study NOUN dpc-6646 233 53 by by ADP dpc-6646 233 54 the the DET dpc-6646 233 55 spanish spanish ADJ dpc-6646 233 56 psoriasis psoriasis NOUN dpc-6646 233 57 group group NOUN dpc-6646 233 58 . . PUNCT dpc-6646 234 1 journal journal PROPN dpc-6646 234 2 of of ADP dpc-6646 234 3 dermatological dermatological ADJ dpc-6646 234 4 treatment treatment NOUN dpc-6646 234 5 . . PUNCT dpc-6646 235 1 2022;33(6):2878 2022;33(6):2878 PROPN dpc-6646 235 2 - - SYM dpc-6646 235 3 2880 2880 NUM dpc-6646 235 4 . . PUNCT dpc-6646 236 1 doi:10.1080/09546634.2022.2079596 doi:10.1080/09546634.2022.2079596 PROPN dpc-6646 236 2 . . PROPN dpc-6646 236 3 25 25 NUM dpc-6646 236 4 . . PUNCT dpc-6646 236 5 chiricozzi chiricozzi PROPN dpc-6646 236 6 a a PRON dpc-6646 236 7 , , PUNCT dpc-6646 236 8 coscarella coscarella NOUN dpc-6646 236 9 g g NOUN dpc-6646 236 10 , , PUNCT dpc-6646 236 11 puig puig X dpc-6646 236 12 l l NOUN dpc-6646 236 13 , , PUNCT dpc-6646 236 14 vender vender PROPN dpc-6646 236 15 r r PROPN dpc-6646 236 16 , , PUNCT dpc-6646 236 17 yeung yeung PROPN dpc-6646 236 18 j j PROPN dpc-6646 236 19 , , PUNCT dpc-6646 236 20 carrascosa carrascosa PROPN dpc-6646 236 21 j j PROPN dpc-6646 236 22 - - PROPN dpc-6646 236 23 m m PROPN dpc-6646 236 24 , , PUNCT dpc-6646 236 25 et et PROPN dpc-6646 236 26 al al PROPN dpc-6646 236 27 . . PROPN dpc-6646 236 28 age age NOUN dpc-6646 236 29 affects affect VERB dpc-6646 236 30 drug drug NOUN dpc-6646 236 31 survival survival NOUN dpc-6646 236 32 rates rate NOUN dpc-6646 236 33 of of ADP dpc-6646 236 34 interleukin interleukin NOUN dpc-6646 236 35 ( ( PUNCT dpc-6646 236 36 il)-17 il)-17 PROPN dpc-6646 236 37 and and CCONJ dpc-6646 236 38 il-23 il-23 VERB dpc-6646 236 39 inhibitors inhibitor NOUN dpc-6646 236 40 in in ADP dpc-6646 236 41 patients patient NOUN dpc-6646 236 42 with with ADP dpc-6646 236 43 plaque plaque NOUN dpc-6646 236 44 psoriasis psoriasis NOUN dpc-6646 236 45 : : PUNCT dpc-6646 236 46 results result VERB dpc-6646 236 47 from from ADP dpc-6646 236 48 a a DET dpc-6646 236 49 retrospective retrospective ADJ dpc-6646 236 50 , , PUNCT dpc-6646 236 51 multicentric multicentric ADJ dpc-6646 236 52 , , PUNCT dpc-6646 236 53 multi multi ADJ dpc-6646 236 54 - - NOUN dpc-6646 236 55 country country NOUN dpc-6646 236 56 , , PUNCT dpc-6646 236 57 cohort cohort NOUN dpc-6646 236 58 study study NOUN dpc-6646 236 59 . . PUNCT dpc-6646 237 1 j j PROPN dpc-6646 237 2 eur eur PROPN dpc-6646 237 3 acad acad PROPN dpc-6646 237 4 dermatol dermatol NOUN dpc-6646 237 5 venereol venereol NOUN dpc-6646 237 6 . . PUNCT dpc-6646 238 1 2024 2024 NUM dpc-6646 238 2 ; ; PUNCT dpc-6646 238 3 38 38 NUM dpc-6646 238 4 : : SYM dpc-6646 238 5 2175–2185 2175–2185 NUM dpc-6646 238 6 . . PUNCT dpc-6646 239 1 doi:10.1111 doi:10.1111 PROPN dpc-6646 239 2 / / SYM dpc-6646 239 3 jdv.20143 jdv.20143 PROPN dpc-6646 239 4 . . PROPN dpc-6646 240 1 26 26 NUM dpc-6646 240 2 . . PUNCT dpc-6646 241 1 manuelpillai manuelpillai PROPN dpc-6646 241 2 n n PRON dpc-6646 241 3 , , PUNCT dpc-6646 241 4 armstrong armstrong PROPN dpc-6646 241 5 j j PROPN dpc-6646 241 6 , , PUNCT dpc-6646 241 7 ismail ismail PROPN dpc-6646 241 8 ff ff PROPN dpc-6646 241 9 , , PUNCT dpc-6646 241 10 et et PROPN dpc-6646 241 11 al al PROPN dpc-6646 241 12 . . PUNCT dpc-6646 242 1 real real ADJ dpc-6646 242 2 - - PUNCT dpc-6646 242 3 world world NOUN dpc-6646 242 4 guselkumab guselkumab NOUN dpc-6646 242 5 response response NOUN dpc-6646 242 6 and and CCONJ dpc-6646 242 7 drug drug NOUN dpc-6646 242 8 survival survival NOUN dpc-6646 242 9 in in ADP dpc-6646 242 10 australian australian ADJ dpc-6646 242 11 patients patient NOUN dpc-6646 242 12 with with ADP dpc-6646 242 13 psoriasis psoriasis NOUN dpc-6646 242 14 : : PUNCT dpc-6646 242 15 results result VERB dpc-6646 242 16 from from ADP dpc-6646 242 17 the the DET dpc-6646 242 18 australasian australasian ADJ dpc-6646 242 19 psoriasis psoriasis NOUN dpc-6646 242 20 registry registry NOUN dpc-6646 242 21 . . PUNCT dpc-6646 243 1 dermatol dermatol NOUN dpc-6646 243 2 ther ther ADV dpc-6646 243 3 . . PUNCT dpc-6646 244 1 2024;2024(1 2024;2024(1 NUM dpc-6646 244 2 ) ) PUNCT dpc-6646 244 3 . . PUNCT dpc-6646 245 1 doi:10.1155 doi:10.1155 NOUN dpc-6646 245 2 / / SYM dpc-6646 245 3 dth/8724445 dth/8724445 NOUN dpc-6646 245 4 . . PUNCT dpc-6646 246 1 27 27 NUM dpc-6646 246 2 . . PUNCT dpc-6646 247 1 li li PROPN dpc-6646 247 2 y y PROPN dpc-6646 247 3 , , PUNCT dpc-6646 247 4 lu lu PROPN dpc-6646 247 5 jj jj PROPN dpc-6646 247 6 , , PUNCT dpc-6646 247 7 zhong zhong PROPN dpc-6646 247 8 xy xy PROPN dpc-6646 247 9 , , PUNCT dpc-6646 247 10 et et PROPN dpc-6646 247 11 al al PROPN dpc-6646 247 12 . . PROPN dpc-6646 247 13 drug drug PROPN dpc-6646 247 14 survival survival NOUN dpc-6646 247 15 outcomes outcome NOUN dpc-6646 247 16 associated associate VERB dpc-6646 247 17 with with ADP dpc-6646 247 18 the the DET dpc-6646 247 19 real real ADJ dpc-6646 247 20 - - PUNCT dpc-6646 247 21 world world NOUN dpc-6646 247 22 use use NOUN dpc-6646 247 23 of of ADP dpc-6646 247 24 ixekizumab ixekizumab NOUN dpc-6646 247 25 , , PUNCT dpc-6646 247 26 secukinumab secukinumab NOUN dpc-6646 247 27 , , PUNCT dpc-6646 247 28 guselkumab guselkumab NOUN dpc-6646 247 29 , , PUNCT dpc-6646 247 30 and and CCONJ dpc-6646 247 31 adalimumab adalimumab NOUN dpc-6646 247 32 for for ADP dpc-6646 247 33 the the DET dpc-6646 247 34 treatment treatment NOUN dpc-6646 247 35 of of ADP dpc-6646 247 36 plaque plaque NOUN dpc-6646 247 37 psoriasis psoriasis NOUN dpc-6646 247 38 in in ADP dpc-6646 247 39 china china PROPN dpc-6646 247 40 : : PUNCT dpc-6646 247 41 a a DET dpc-6646 247 42 52 52 NUM dpc-6646 247 43 - - PUNCT dpc-6646 247 44 week week NOUN dpc-6646 247 45 single single ADJ dpc-6646 247 46 - - PUNCT dpc-6646 247 47 center center NOUN dpc-6646 247 48 retrospective retrospective ADJ dpc-6646 247 49 study study NOUN dpc-6646 247 50 . . PUNCT dpc-6646 248 1 clin clin PROPN dpc-6646 248 2 cosmet cosmet PROPN dpc-6646 248 3 investig investig NOUN dpc-6646 248 4 dermatol dermatol NOUN dpc-6646 248 5 . . PUNCT dpc-6646 249 1 2022;15:2245 2022;15:2245 NUM dpc-6646 249 2 - - SYM dpc-6646 249 3 2252 2252 NUM dpc-6646 249 4 . . PUNCT dpc-6646 249 5 doi:10.2147 doi:10.2147 NOUN dpc-6646 250 1 /ccid.s387759 /ccid.s387759 PROPN dpc-6646 250 2 . . PUNCT dpc-6646 251 1 7 7 X dpc-6646 251 2 . . X dpc-6646 251 3 butler butler PROPN dpc-6646 251 4 d d PROPN dpc-6646 251 5 , , PUNCT dpc-6646 251 6 huynh huynh PROPN dpc-6646 251 7 m m PROPN dpc-6646 251 8 , , PUNCT dpc-6646 251 9 gupta gupta PROPN dpc-6646 251 10 r r PROPN dpc-6646 251 11 , , PUNCT dpc-6646 251 12 levin levin PROPN dpc-6646 251 13 e e PROPN dpc-6646 251 14 , , PUNCT dpc-6646 251 15 leon leon PROPN dpc-6646 251 16 a a PROPN dpc-6646 251 17 , , PUNCT dpc-6646 251 18 koo koo PROPN dpc-6646 251 19 j. j. PROPN dpc-6646 251 20 psoriasis psoriasis NOUN dpc-6646 251 21 : : PUNCT dpc-6646 251 22 impact impact NOUN dpc-6646 251 23 on on ADP dpc-6646 251 24 quality quality NOUN dpc-6646 251 25 of of ADP dpc-6646 251 26 life life NOUN dpc-6646 251 27 . . PUNCT dpc-6646 252 1 psoriasis psoriasis NOUN dpc-6646 252 2 forum forum NOUN dpc-6646 252 3 . . PUNCT dpc-6646 253 1 2013;19a(1):16 2013;19a(1):16 NUM dpc-6646 253 2 - - SYM dpc-6646 253 3 20 20 NUM dpc-6646 253 4 . . PUNCT dpc-6646 253 5 doi:10.1177/247553031319a00102 doi:10.1177/247553031319a00102 NOUN dpc-6646 253 6 . . PUNCT dpc-6646 254 1 8 8 X dpc-6646 254 2 . . X dpc-6646 255 1 dattola dattola PROPN dpc-6646 255 2 a a PRON dpc-6646 255 3 , , PUNCT dpc-6646 255 4 silvestri silvestri PROPN dpc-6646 255 5 m m PROPN dpc-6646 255 6 , , PUNCT dpc-6646 255 7 tamburi tamburi PROPN dpc-6646 255 8 f f PROPN dpc-6646 255 9 , , PUNCT dpc-6646 255 10 amoruso amoruso PROPN dpc-6646 255 11 gf gf PROPN dpc-6646 255 12 , , PUNCT dpc-6646 255 13 bennardo bennardo PROPN dpc-6646 255 14 l l NOUN dpc-6646 255 15 , , PUNCT dpc-6646 255 16 nisticò nisticò PROPN dpc-6646 255 17 sp sp PROPN dpc-6646 255 18 . . PUNCT dpc-6646 255 19 emerging emerge VERB dpc-6646 255 20 role role NOUN dpc-6646 255 21 of of ADP dpc-6646 255 22 anti anti ADJ dpc-6646 255 23 - - ADJ dpc-6646 255 24 il23 il23 PROPN dpc-6646 255 25 in in ADP dpc-6646 255 26 the the DET dpc-6646 255 27 treatment treatment NOUN dpc-6646 255 28 of of ADP dpc-6646 255 29 psoriasis psoriasis NOUN dpc-6646 255 30 : : PUNCT dpc-6646 255 31 when when SCONJ dpc-6646 255 32 humanized humanize VERB dpc-6646 255 33 is be AUX dpc-6646 255 34 very very ADV dpc-6646 255 35 promising promising ADJ dpc-6646 255 36 . . PUNCT dpc-6646 256 1 dermatol dermatol NOUN dpc-6646 256 2 ther ther ADV dpc-6646 256 3 . . PUNCT dpc-6646 257 1 2020;33(6 2020;33(6 NUM dpc-6646 257 2 ) ) PUNCT dpc-6646 257 3 . . PUNCT dpc-6646 258 1 doi:10.1111 doi:10.1111 PROPN dpc-6646 258 2 / / SYM dpc-6646 258 3 dth.14504 dth.14504 ADV dpc-6646 258 4 . . NOUN dpc-6646 259 1 9 9 X dpc-6646 259 2 . . PUNCT dpc-6646 259 3 rasouliyan rasouliyan PROPN dpc-6646 259 4 l l PROPN dpc-6646 259 5 , , PUNCT dpc-6646 259 6 rasouliyan rasouliyan PROPN dpc-6646 259 7 l l PROPN dpc-6646 259 8 , , PUNCT dpc-6646 259 9 fitzgerald fitzgerald PROPN dpc-6646 259 10 t t PROPN dpc-6646 259 11 , , PUNCT dpc-6646 259 12 teneralli teneralli PROPN dpc-6646 259 13 r r NOUN dpc-6646 259 14 , , PUNCT dpc-6646 259 15 zhao zhao PROPN dpc-6646 259 16 j j PROPN dpc-6646 259 17 , , PUNCT dpc-6646 259 18 wu wu PROPN dpc-6646 259 19 d. d. PROPN dpc-6646 259 20 54043 54043 NUM dpc-6646 259 21 guselkumab guselkumab NOUN dpc-6646 259 22 for for ADP dpc-6646 259 23 treatment treatment NOUN dpc-6646 259 24 of of ADP dpc-6646 259 25 plaque plaque NOUN dpc-6646 259 26 psoriasis psoriasis NOUN dpc-6646 259 27 : : PUNCT dpc-6646 259 28 persistence persistence NOUN dpc-6646 259 29 and and CCONJ dpc-6646 259 30 switching switch VERB dpc-6646 259 31 in in ADP dpc-6646 259 32 real real ADJ dpc-6646 259 33 - - PUNCT dpc-6646 259 34 world world NOUN dpc-6646 259 35 clinical clinical ADJ dpc-6646 259 36 practices practice NOUN dpc-6646 259 37 in in ADP dpc-6646 259 38 the the DET dpc-6646 259 39 us us PROPN dpc-6646 259 40 . . PUNCT dpc-6646 260 1 j j PROPN dpc-6646 260 2 am be AUX dpc-6646 260 3 acad acad ADJ dpc-6646 260 4 dermatol dermatol NOUN dpc-6646 260 5 . . PUNCT dpc-6646 261 1 2024;91(3):ab223 2024;91(3):ab223 NOUN dpc-6646 261 2 . . PUNCT dpc-6646 262 1 doi:10.1016 doi:10.1016 PROPN dpc-6646 262 2 / / SYM dpc-6646 262 3 j. j. PROPN dpc-6646 262 4 jaad.2024.07.885 jaad.2024.07.885 PROPN dpc-6646 262 5 . . PROPN dpc-6646 263 1 10 10 NUM dpc-6646 263 2 . . PUNCT dpc-6646 264 1 puig puig PROPN dpc-6646 264 2 l. l. PROPN dpc-6646 264 3 guselkumab guselkumab NOUN dpc-6646 264 4 for for ADP dpc-6646 264 5 the the DET dpc-6646 264 6 treatment treatment NOUN dpc-6646 264 7 of of ADP dpc-6646 264 8 adults adult NOUN dpc-6646 264 9 with with ADP dpc-6646 264 10 moderate moderate ADJ dpc-6646 264 11 to to ADP dpc-6646 264 12 severe severe ADJ dpc-6646 264 13 plaque plaque NOUN dpc-6646 264 14 psoriasis psoriasis NOUN dpc-6646 264 15 . . PUNCT dpc-6646 265 1 expert expert NOUN dpc-6646 265 2 rev rev VERB dpc-6646 265 3 clin clin PROPN dpc-6646 265 4 immunol immunol PROPN dpc-6646 265 5 . . PUNCT dpc-6646 266 1 2019;15(6):589 2019;15(6):589 NUM dpc-6646 266 2 - - PUNCT dpc-6646 266 3 597 597 NUM dpc-6646 266 4 . . PUNCT dpc-6646 267 1 doi:10.1080/1744666x.2019.1601014 doi:10.1080/1744666x.2019.1601014 NOUN dpc-6646 267 2 . . PUNCT dpc-6646 268 1 11 11 NUM dpc-6646 268 2 . . PUNCT dpc-6646 268 3 zhdanava zhdanava PROPN dpc-6646 268 4 m m PROPN dpc-6646 268 5 , , PUNCT dpc-6646 268 6 fitzgerald fitzgerald PROPN dpc-6646 268 7 t t PROPN dpc-6646 268 8 , , PUNCT dpc-6646 268 9 pilon pilon PROPN dpc-6646 268 10 d d PROPN dpc-6646 268 11 , , PUNCT dpc-6646 268 12 et et PROPN dpc-6646 268 13 al al PROPN dpc-6646 268 14 . . PROPN dpc-6646 268 15 comparative comparative ADJ dpc-6646 268 16 analysis analysis NOUN dpc-6646 268 17 of of ADP dpc-6646 268 18 persistence persistence NOUN dpc-6646 268 19 and and CCONJ dpc-6646 268 20 remission remission NOUN dpc-6646 268 21 with with ADP dpc-6646 268 22 guselkumab guselkumab NOUN dpc-6646 268 23 versus versus ADP dpc-6646 268 24 secukinumab secukinumab NOUN dpc-6646 268 25 and and CCONJ dpc-6646 268 26 ixekizumab ixekizumab NOUN dpc-6646 268 27 in in ADP dpc-6646 268 28 the the DET dpc-6646 268 29 united united PROPN dpc-6646 268 30 states states PROPN dpc-6646 268 31 . . PUNCT dpc-6646 269 1 journal journal NOUN dpc-6646 269 2 of of ADP dpc-6646 269 3 dermatological dermatological ADJ dpc-6646 269 4 treatment treatment NOUN dpc-6646 269 5 . . PUNCT dpc-6646 270 1 2024;35(1 2024;35(1 NUM dpc-6646 270 2 ) ) PUNCT dpc-6646 270 3 . . PUNCT dpc-6646 271 1 doi:10.1080/09546634.2024.2349658 doi:10.1080/09546634.2024.2349658 NOUN dpc-6646 271 2 . . PROPN dpc-6646 272 1 12 12 NUM dpc-6646 272 2 . . PUNCT dpc-6646 273 1 mease mease PROPN dpc-6646 273 2 pj pj PROPN dpc-6646 273 3 , , PUNCT dpc-6646 273 4 ferrante ferrante PROPN dpc-6646 273 5 sa sa PROPN dpc-6646 273 6 , , PUNCT dpc-6646 273 7 shiff shiff PROPN dpc-6646 273 8 nj nj PROPN dpc-6646 273 9 , , PUNCT dpc-6646 273 10 fitzgerald fitzgerald PROPN dpc-6646 273 11 tp tp PROPN dpc-6646 273 12 , , PUNCT dpc-6646 273 13 chakravarty chakravarty NOUN dpc-6646 273 14 sd sd PROPN dpc-6646 273 15 , , PUNCT dpc-6646 273 16 walsh walsh PROPN dpc-6646 273 17 ja ja PROPN dpc-6646 273 18 . . PROPN dpc-6646 273 19 comparison comparison NOUN dpc-6646 273 20 of of ADP dpc-6646 273 21 on on ADP dpc-6646 273 22 - - PUNCT dpc-6646 273 23 label label NOUN dpc-6646 273 24 treatment treatment NOUN dpc-6646 273 25 persistence persistence NOUN dpc-6646 273 26 in in ADP dpc-6646 273 27 real real ADJ dpc-6646 273 28 - - PUNCT dpc-6646 273 29 world world NOUN dpc-6646 273 30 patients patient NOUN dpc-6646 273 31 with with ADP dpc-6646 273 32 psoriatic psoriatic ADJ dpc-6646 273 33 arthritis arthritis NOUN dpc-6646 273 34 receiving receive VERB dpc-6646 273 35 guselkumab guselkumab NOUN dpc-6646 273 36 versus versus ADP dpc-6646 273 37 subcutaneous subcutaneous ADJ dpc-6646 273 38 interleukin-17a interleukin-17a PROPN dpc-6646 273 39 inhibitors inhibitor NOUN dpc-6646 273 40 . . PUNCT dpc-6646 274 1 adv adv INTJ dpc-6646 274 2 ther ther ADV dpc-6646 274 3 . . PUNCT dpc-6646 275 1 2025;42(2):734 2025;42(2):734 NUM dpc-6646 275 2 - - PUNCT dpc-6646 275 3 751 751 NUM dpc-6646 275 4 . . PUNCT dpc-6646 276 1 doi:10.1007 doi:10.1007 PROPN dpc-6646 276 2 / / SYM dpc-6646 276 3 s12325 s12325 PROPN dpc-6646 276 4 - - PUNCT dpc-6646 276 5 024 024 NUM dpc-6646 276 6 - - PUNCT dpc-6646 276 7 03042 03042 NUM dpc-6646 276 8 - - SYM dpc-6646 276 9 1 1 NUM dpc-6646 276 10 . . NOUN dpc-6646 276 11 13 13 NUM dpc-6646 276 12 . . PUNCT dpc-6646 277 1 mohino mohino NOUN dpc-6646 277 2 - - PUNCT dpc-6646 277 3 farré farré NOUN dpc-6646 277 4 n n CCONJ dpc-6646 277 5 , , PUNCT dpc-6646 277 6 pujol pujol NOUN dpc-6646 277 7 - - PUNCT dpc-6646 277 8 montcusi montcusi NOUN dpc-6646 277 9 j j PROPN dpc-6646 277 10 , , PUNCT dpc-6646 277 11 martin martin PROPN dpc-6646 277 12 - - PUNCT dpc-6646 277 13 callizo callizo NOUN dpc-6646 277 14 c c NOUN dpc-6646 277 15 , , PUNCT dpc-6646 277 16 et et PROPN dpc-6646 277 17 al al PROPN dpc-6646 277 18 . . PROPN dpc-6646 277 19 39 39 NUM dpc-6646 277 20 effectiveness effectiveness NOUN dpc-6646 277 21 , , PUNCT dpc-6646 277 22 persistence persistence NOUN dpc-6646 277 23 of of ADP dpc-6646 277 24 use use NOUN dpc-6646 277 25 , , PUNCT dpc-6646 277 26 and and CCONJ dpc-6646 277 27 safety safety NOUN dpc-6646 277 28 of of ADP dpc-6646 277 29 guselkumab guselkumab NOUN dpc-6646 277 30 in in ADP dpc-6646 277 31 real real ADJ dpc-6646 277 32 clinical clinical ADJ dpc-6646 277 33 practice practice NOUN dpc-6646 277 34 : : PUNCT dpc-6646 277 35 a a DET dpc-6646 277 36 case case NOUN dpc-6646 277 37 series series NOUN dpc-6646 277 38 of of ADP dpc-6646 277 39 27 27 NUM dpc-6646 277 40 patients patient NOUN dpc-6646 277 41 . . PUNCT dpc-6646 278 1 journal journal NOUN dpc-6646 278 2 of of ADP dpc-6646 278 3 investigative investigative ADJ dpc-6646 278 4 dermatology dermatology NOUN dpc-6646 278 5 . . PUNCT dpc-6646 279 1 2023;143(11):s339 2023;143(11):s339 NUM dpc-6646 279 2 . . PUNCT dpc-6646 279 3 doi:10.1016 doi:10.1016 PROPN dpc-6646 279 4 / / SYM dpc-6646 279 5 j j PROPN dpc-6646 279 6 .jid.2023.09.047 .jid.2023.09.047 PROPN dpc-6646 279 7 . . PUNCT dpc-6646 280 1 14 14 NUM dpc-6646 280 2 . . PUNCT dpc-6646 280 3 raharja raharja PROPN dpc-6646 280 4 a a PROPN dpc-6646 280 5 , , PUNCT dpc-6646 280 6 mahil mahil NOUN dpc-6646 280 7 sk sk PROPN dpc-6646 280 8 , , PUNCT dpc-6646 280 9 barker barker PROPN dpc-6646 280 10 jn jn PROPN dpc-6646 280 11 . . PUNCT dpc-6646 280 12 psoriasis psoriasis NOUN dpc-6646 280 13 : : PUNCT dpc-6646 280 14 a a DET dpc-6646 280 15 brief brief ADJ dpc-6646 280 16 overview overview NOUN dpc-6646 280 17 . . PUNCT dpc-6646 281 1 clinical clinical ADJ dpc-6646 281 2 medicine medicine NOUN dpc-6646 281 3 , , PUNCT dpc-6646 281 4 journal journal NOUN dpc-6646 281 5 of of ADP dpc-6646 281 6 the the DET dpc-6646 281 7 royal royal PROPN dpc-6646 281 8 college college PROPN dpc-6646 281 9 of of ADP dpc-6646 281 10 physicians physician NOUN dpc-6646 281 11 of of ADP dpc-6646 281 12 london london PROPN dpc-6646 281 13 . . PUNCT dpc-6646 282 1 2021;21(3):170 2021;21(3):170 PROPN dpc-6646 282 2 - - PUNCT dpc-6646 282 3 173 173 NUM dpc-6646 282 4 . . PUNCT dpc-6646 283 1 doi:10.7861 doi:10.7861 ADJ dpc-6646 283 2 / / SYM dpc-6646 283 3 clinmed.2021 clinmed.2021 NOUN dpc-6646 283 4 - - PUNCT dpc-6646 283 5 0257 0257 NUM dpc-6646 283 6 . . PUNCT dpc-6646 284 1 15 15 NUM dpc-6646 284 2 . . PUNCT dpc-6646 284 3 gianfredi gianfredi PROPN dpc-6646 284 4 v v PROPN dpc-6646 284 5 , , PUNCT dpc-6646 284 6 casu casu PROPN dpc-6646 284 7 g g PROPN dpc-6646 284 8 , , PUNCT dpc-6646 284 9 bricchi bricchi PROPN dpc-6646 284 10 l l NOUN dpc-6646 284 11 , , PUNCT dpc-6646 284 12 kacerik kacerik ADJ dpc-6646 284 13 e e NOUN dpc-6646 284 14 , , PUNCT dpc-6646 284 15 rongioletti rongioletti PROPN dpc-6646 284 16 f f PROPN dpc-6646 284 17 , , PUNCT dpc-6646 284 18 signorelli signorelli PROPN dpc-6646 284 19 c. c. PROPN dpc-6646 284 20 epidemiology epidemiology NOUN dpc-6646 284 21 of of ADP dpc-6646 284 22 psoriasis psoriasis NOUN dpc-6646 284 23 in in ADP dpc-6646 284 24 italy italy PROPN dpc-6646 284 25 : : PUNCT dpc-6646 284 26 burden burden NOUN dpc-6646 284 27 , , PUNCT dpc-6646 284 28 cost cost NOUN dpc-6646 284 29 , , PUNCT dpc-6646 284 30 comorbidities comorbiditie NOUN dpc-6646 284 31 and and CCONJ dpc-6646 284 32 patients patient NOUN dpc-6646 284 33 ’ ' PUNCT dpc-6646 284 34 satisfaction satisfaction NOUN dpc-6646 284 35 . . PUNCT dpc-6646 285 1 a a DET dpc-6646 285 2 systematic systematic ADJ dpc-6646 285 3 review review NOUN dpc-6646 285 4 . . PUNCT dpc-6646 286 1 acta acta PROPN dpc-6646 286 2 biomedica biomedica PROPN dpc-6646 286 3 . . PUNCT dpc-6646 287 1 2022;93(6 2022;93(6 NUM dpc-6646 287 2 ) ) PUNCT dpc-6646 287 3 . . PUNCT dpc-6646 288 1 doi:10.23750 doi:10.23750 PROPN dpc-6646 288 2 / / SYM dpc-6646 288 3 abm.v93i6.13177 abm.v93i6.13177 PROPN dpc-6646 288 4 16 16 NUM dpc-6646 288 5 . . PUNCT dpc-6646 289 1 iskandar iskandar NOUN dpc-6646 289 2 r r PROPN dpc-6646 289 3 , , PUNCT dpc-6646 289 4 mulick mulick NOUN dpc-6646 289 5 a a NOUN dpc-6646 289 6 , , PUNCT dpc-6646 289 7 abuabara abuabara PROPN dpc-6646 289 8 k k PROPN dpc-6646 289 9 , , PUNCT dpc-6646 289 10 et et PROPN dpc-6646 289 11 al al PROPN dpc-6646 289 12 . . PROPN dpc-6646 289 13 p89 p89 PROPN dpc-6646 289 14 real real ADJ dpc-6646 289 15 - - PUNCT dpc-6646 289 16 world world NOUN dpc-6646 289 17 effectiveness effectiveness NOUN dpc-6646 289 18 of of ADP dpc-6646 289 19 guselkumab guselkumab NOUN dpc-6646 289 20 in in ADP dpc-6646 289 21 patients patient NOUN dpc-6646 289 22 with with ADP dpc-6646 289 23 psoriasis psoriasis NOUN dpc-6646 289 24 with with ADP dpc-6646 289 25 and and CCONJ dpc-6646 289 26 without without ADP dpc-6646 289 27 concomitant concomitant ADJ dpc-6646 289 28 psoriatic psoriatic ADJ dpc-6646 289 29 arthritis arthritis NOUN dpc-6646 289 30 : : PUNCT dpc-6646 289 31 retrospective retrospective ADJ dpc-6646 289 32 data datum NOUN dpc-6646 289 33 from from ADP dpc-6646 289 34 the the DET dpc-6646 289 35 british british PROPN dpc-6646 289 36 association association PROPN dpc-6646 289 37 of of ADP dpc-6646 289 38 dermatologists dermatologists PROPN dpc-6646 289 39 biologics biologic NOUN dpc-6646 289 40 and and CCONJ dpc-6646 289 41 immunomodulators immunomodulator NOUN dpc-6646 289 42 register register VERB dpc-6646 289 43 . . PUNCT dpc-6646 290 1 doi:10.1093 doi:10.1093 NOUN dpc-6646 290 2 / / SYM dpc-6646 290 3 bjd bjd PROPN dpc-6646 290 4 / / SYM dpc-6646 290 5 ljad113 ljad113 PROPN dpc-6646 290 6 . . PROPN dpc-6646 290 7 17 17 NUM dpc-6646 290 8 . . PUNCT dpc-6646 291 1 kim kim PROPN dpc-6646 291 2 bs bs PROPN dpc-6646 291 3 , , PUNCT dpc-6646 291 4 jo jo PROPN dpc-6646 291 5 sj sj PROPN dpc-6646 291 6 , , PUNCT dpc-6646 291 7 youn youn PROPN dpc-6646 291 8 sw sw PROPN dpc-6646 291 9 , , PUNCT dpc-6646 291 10 et et PROPN dpc-6646 291 11 al al PROPN dpc-6646 291 12 . . PROPN dpc-6646 291 13 five five NUM dpc-6646 291 14 - - PUNCT dpc-6646 291 15 year year NOUN dpc-6646 291 16 maintenance maintenance NOUN dpc-6646 291 17 of of ADP dpc-6646 291 18 clinical clinical ADJ dpc-6646 291 19 response response NOUN dpc-6646 291 20 and and CCONJ dpc-6646 291 21 consistent consistent ADJ dpc-6646 291 22 safety safety NOUN dpc-6646 291 23 profile profile NOUN dpc-6646 291 24 for for ADP dpc-6646 291 25 guselkumab guselkumab NOUN dpc-6646 291 26 in in ADP dpc-6646 291 27 asian asian ADJ dpc-6646 291 28 patients patient NOUN dpc-6646 291 29 with with ADP dpc-6646 291 30 psoriasis psoriasis NOUN dpc-6646 291 31 from from ADP dpc-6646 291 32 voyage voyage NOUN dpc-6646 291 33 1 1 NUM dpc-6646 291 34 and and CCONJ dpc-6646 291 35 voyage voyage NOUN dpc-6646 291 36 2 2 NUM dpc-6646 291 37 . . X dpc-6646 292 1 dermatol dermatol NOUN dpc-6646 292 2 ther ther ADV dpc-6646 292 3 ( ( PUNCT dpc-6646 292 4 heidelb heidelb NOUN dpc-6646 292 5 ) ) PUNCT dpc-6646 292 6 . . PUNCT dpc-6646 293 1 2023;13(11):2721 2023;13(11):2721 X dpc-6646 293 2 - - PUNCT dpc-6646 293 3 2737 2737 NUM dpc-6646 293 4 . . PUNCT dpc-6646 294 1 doi:10.1007 doi:10.1007 PROPN dpc-6646 294 2 /s13555 /s13555 PROPN dpc-6646 294 3 - - PUNCT dpc-6646 294 4 023 023 NUM dpc-6646 294 5 - - PUNCT dpc-6646 294 6 01026 01026 NUM dpc-6646 294 7 - - SYM dpc-6646 294 8 7 7 NUM dpc-6646 294 9 . . NOUN dpc-6646 294 10 18 18 NUM dpc-6646 294 11 . . PUNCT dpc-6646 295 1 dattola dattola PROPN dpc-6646 295 2 a a PRON dpc-6646 295 3 , , PUNCT dpc-6646 295 4 bernardini bernardini PROPN dpc-6646 295 5 n n CCONJ dpc-6646 295 6 , , PUNCT dpc-6646 295 7 anedda anedda PROPN dpc-6646 295 8 j j PROPN dpc-6646 295 9 , , PUNCT dpc-6646 295 10 et et PROPN dpc-6646 295 11 al al PROPN dpc-6646 295 12 . . PUNCT dpc-6646 296 1 the the DET dpc-6646 296 2 role role NOUN dpc-6646 296 3 of of ADP dpc-6646 296 4 guselkumab guselkumab NOUN dpc-6646 296 5 in in ADP dpc-6646 296 6 psoriatic psoriatic ADJ dpc-6646 296 7 artrithis artrithis NOUN dpc-6646 296 8 and and CCONJ dpc-6646 296 9 disease disease NOUN dpc-6646 296 10 progression progression NOUN dpc-6646 296 11 in in ADP dpc-6646 296 12 patients patient NOUN